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INTRODUCTION 
The scientific interest in gaseous molecules started in 1980 with the reports of endothelium-
dependent vasorelaxation,which led to the unequivocal identification of EDRF as nitric oxide 
{NO) [1-3]. Since the discovery that NO acts as a potent regulator of many processes, including 
vascular tone, neurotransmission, inflammation, intensive investigation has followed on the 
role(s) of NO in inducible gene regulation[4]. A major mechanism for NO-mediated signaling 
effects involves the activation of soluble guanylate cyclase (sGQ, leading to enhanced cGMP 
formation [S}.Strikingly however, it was known for a longer time, that cells can produce another 
endogenous gaseous molecule by an enzymatic reaction initially described by Tenhunen and 
Schmid in 1968: the catalytic breakdown of heme by the microsomal heme oxygenase (HO) 
enzyme system which releases carbon monoxide (CO) [6,7]. In the past decade, the interest 
in HO isozymes shifted from their metabolic function of heme degradation to another critical 
physiological function as a cytoprotective chaperone in numerous models of cellular stress [4, 
8]. Heme oxygenases catalyze the rate-limiting step in the metabolic conversion of heme to the 
bile pigments (i.e., biliverdin and bilirubin) and generate equimolar amounts of biliverdin, iron 
and carbon monoxide (CO). 
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The degradation products from HO-1 activity were for many years viewed as harmful waste 
products. 
HO catalyzesthefirstand rate-limiting step in the oxidativedegradation of heme (Fe-protoporphyrin-
IX) to form the open-chain tetrapyrrole biliverdin-JXa [6]. 
The reaction initiates with the NADPH-dependent reduction of the ferric heme-iron in the HO-heme 
complex, which binds02 to form an oxyferrous intermediate that in turn accepts a second electron 
from NADPH []].The resulting ferric hydroperoxide (Fe JII-DOH) intermediate hydroxylatesthe heme 
ring at the a-methene bridge carbon, forming a-hydroxy heme [4, 9]. Two further oxidation cycles 
involve the elimination of the a-methene bridge carbon as CO and the subsequent formation of a 
ferribiliverdin-IXcomplex (BV-Fe Ill) [1 O].lron released from HO enzymatic activity evokes pathways 
which activate the iron regulatory protein (IRP), leading to its sequestration. Biliverdin and bilirubin 
produced from HO activity potentially contribute to cellular defense against oxidative stress prior 
to their excretion [4]. 
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Besides the important anti-oxidative properties of the first two degradation products of heme 
catabolism, CO has been shown to possess multiple signaling properties which affect cellular 
functions including inflammation, cellular proliferation, and apoptotic cell death [11-13]. In this 
thesis we sougth to further define the signaling pathway of H0-1/CO in cardiovascular disease. 
Three genetically distinct isozymes of HO have been characterized:Thefirst one is heme oxygenase-1 
(H0-1), which expression is inducible by cellular stress, furthermore two more constitutively 
expressed forms have been identified, heme oxygenase-2 (H0-2) and heme-oxygenase-3 (H0-3) 
[14].H0-1 proteins (32 kDa) were first purified from the livers ofheme~induced rats and from porcine 
spleen [15, 16].The resulting H0~1 proteins bind heme in a 1:1 complex. The inducible form of heme 
oxygenase,HO~ l,occurs at a high level of expression in the spleen and othertissuesthatdegradered 
blood cells, including specialized reticuloendothelial cells of the liver and bone marrow. High levels 
of HO activity are detected in these tissues [6]. HO is present in hematopoietic stem cells of the bone 
marrow, where it may inhibit cellular differentiation by lowering the intracellular concentration of 
heme [17]. HO is also present in the liver parenchyma, which is the site of uptake and degradation 
of plasma heme, hemoglobin, and methemalbumin. Under conditions of hemolysis, HO activity 
dramatically increases in the liver parenchyma, kidney, and macrophages in response to increased 
levels of circulating hemoglobin [13]. 
Increased synthesis of the HO~ 1 protein occurs as a general response to cellular stress. This response 
depends on de novo synthesis of mRNA induced by transcriptional activation of the Hmox~ 1 gene. 
H0-1 belongs to a larger family of stress proteins whose transcriptional regulation also responds 
to adverse environmental and intracellular conditions. Of the known mammalian stress protein 
families, the expression of the heat shock proteins (HSPs) (20-30 kDa, 70-73 kDa, 90 kDa, 104-110 
kDa) constitutes a global cellular response to protein denaturation associated with hyperthermia. 
Hence H0-1 has sometimes been classified as a heat shock protein (Hsp32) due to its ability to be 
induced by hyperthermia. 
The substrate and catalytic cofactor of H0-1, heme (iron~protoporphyrin~IX), acts as an inducer 
of Hmox gene expression and activity [4, 3, 13].Several metalloporphyrins, including SnPPIX and 
ZnPPIX, can induce HO~ 1 transcription, while paradoxically acting as competitive inhibitors of HO 
activity both in vitro and in vivo.!n contrast,CoPPIX, which is a potent inhibitor in vitro, is a powerful 
inducer of HO activity in vivo [19]. 
Heme Oxygenase -2 (H0-2) is a constitutive expressed member of the heme oxygenase family. H0-
2,has been identified in the liver, spleen, the brain, and as well in the testes [20,21].H0~2 was initially 
purified from rat testes with a molecular mass of 36 kDa whereas human H0~2 displays an 88% 
amino acid homology to rat H0~2 (22]. HO~ 1 and H0-2 represent the products of distinct genes 
(Hmoxl, Hmox2) [23].The human, mouse, and rat Hmox~1 genes (14 kb) and the rat Hmox~2gene 
(12 kb) share similar organization into five exons and four introns [24]. 
McCoubrey and co~workers [25] isolated a eDNA (2.4 kb) encoding a third HO isozyme (HQ-3) in 
rat tissues. The predicted polypeptide has a high amino acid sequence homology to H0-2 (90%) 
and thus shares many common sequence motifs, including putative heme regulatory domains. 
H0-3 protein has very little heme degrading activity, and therefore, the function of this protein 
ln~rocuctlon 
still remains largely unknown.Jt was however speculated that this HO isotype was involved in the 
regulation of heme dependent cellular processes s'mce the H0-3 protein has two heme regulatory 
motifs that may be involved in heme binding. 
Biliverdin (BV), the first product of HO-catalyzed heme cleavage is under normal physiological 
conditions processed for rapid elimination. In cell culture studies the potential antioxidant capacity 
of the bile pigments was detected (26].A number of studies have recently explored the potential of 
BV as potential therapeutic agents in ischemia I reperfusion (1/R) stress models [27].Jn an isolated 
perfused heart model, heme preconditioning provided protection against myocardial infarction 
following 1/R injury, these effects were associated with increased H0-1 expression and bilirubin (BR) 
formation. In addition general anti-inflammatory effects of bilirubin due to ROS scavenging have 
been addressed [4]. 
Also CO reversibly binds to hemoglobin, to form carboxyhemoglobin (CO-Hb) (28]. The binding 
affinity of CO for the hemoglobin heme iron is 240 times that of 0 2 and thus CO competes 
against oxygen,which causes the intoxicating effects if large doses are inhaled. The association 
of endogenous CO production with a distinct enzymatic mechanism, HO, was first described by 
Tenhunen and colleagues [13]. 
Today multiple reports suggested that CO has profound effects on intracellular signaling processes, 
resulting in anti-inflammatory,antiproliferative, antiapoptotic effects. The physiological signaling 
effects of CO known to date involve relatively few defined mechanisms; the modulation of soluble 
guanylyl cyclase (sGC) activity and subsequent stimulation of cGMP production are the most 
described [13]. Like the classical agonist NO, CO binds directly to sGC, leading to stimulation of its 
enzymatic activity. The importance of CO in sGC activation likely increases in cells or tissues with 
low endogenous NO production. In the presence of NO, however, CO may even act as a partial 
antagonist of NO function by competing against NO binding to sGC [29]. 
Recent studies have described anti-inflammatory effects of both H0-1-derived CO and exogenous 
CO in cell culture models and animal models.The production of the anti-inflammatory cytokine IL-
l 0 has been shown to be augmented by the CO treatment [30].In the presence ofLPS,CO increased 
p38 MAPK activation without modulating ERK1/2and JNK activation. 
The cytostatic effects of CO were first examined by Morita and colleagues [31].CO exerted a general 
antiproliferativeeffect in hypoxic smooth muscle cells that could be reversed by chemical inhibitors 
of sGC. CO produced endogenously and released from vascular smooth muscle cells (SMQ as a 
consequence of hypoxia-inducible H0-1 expression, elevated the endogenous production of cGMP 
of endothelial cells in co-culture and was also associated with a cGMP-dependent downregulation 
of the expression of endothelial-derived mitogens such as PDGF and ET-1 [32].1n addition to that it 
was suggested that CO inhibited cell growth by influencing the expression and/or activation of cell 
cycle-related factors cyclin dependent kinases and eye! in complexes. Hmox-1 expression and CO 
treatment induced p21won/Cipl expression in SMC [33].The anti proliferative effect of CO was inhibited 
in SMC derived from the p21waf1/Cipl knockout mice (p21-1-).Although p21worl/Cipl is regulated by 
p53, the absence of the p53 gene in SMC derived from the p53-knockout mice did not affect the 
anti proliferative effect of CO (13]. 
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The importance of HO~ 1 in vascular biology was evident with the discovery of a patient with H0-1 
deficiency. In this HQ-1-deficiency subject, both intravascular hemolysis and endothelial cell injury 
were prominent. Importantly, oxidation of hemoglobin to methemoglobin occurred in the plasma, 
and Iron-induced oxidative modification of lipoproteins was cytotoxic and causes endothelial 
damage, leading to the development offatty streaks and fibrous plaques in the aorta. Endothelial 
cells in this case were susceptible to oxidative stress due to of heme-mediated oxidation of LDL [4, 
34]. 
Accumulating evidence suggests that H0-1 contributes to the balance of pro-oxidant and 
antioxidant factors in the vascular wall through multiple mechanisms. Endothelial dysfunction 
caused by reactive oxidant species (ROS) is a key step in the initiation of lesion formation. Previous 
studies have shown that increased expression of H0-1 attenuated R05-mediated cell growth and 
apoptosis of endothelial cells [35]. 
In this thesis we evaluated the effects of H0-1 against the background of cardiovascular disease 
with the purpose to obtain insight in the role ofH0-1 in cardiovascular pathology and the molecular 
mechanism by which H0-1 exerts its effects. 
We assessed the effects of H0-1 transgenesis on atherogenesis, transplantation atherosclerosis and 
allograft rejection and angiogenesis and we studied the effects of H0-1 on SMC migration. It is 
now generally believed that most of the stimuli which induce H0-1 modulate intracellular signal 
transduction pathways via protein kinase cascades. We have made an attempt to elucidate some 
of these signaling cascades initiated by H0-1 activity against the background of cardiovascular 
pathology. 
!n chapter 2 and 3 of this thesis we will focus on the effect of H0-1 on the development of 
atherosclerotic plaque and the transition of stable to vulnerable lesions. The expression of H0-1 
is induced by a number of pro-atherogenic stimuli, including hypertension, smoking, and oxidized 
lipids. In murine models, induction of H0-1 impeded the development of atherosclerotic lesions, 
whereas inhibition of H0-1 stimulated atherogenesis. Likewise, ApoE/Hmox-1 double knockout 
mice developed accelerated atherosclerosis compared to ApoE knockout mice when subjected 
to a high cholesterol diet [36]. Taken together, these anti-atherogenenic properties of H0-1 
expression suggest a prominent role for Hmox-1 in the genetic regulation in the development of 
atherosclerosis. 
CO may also cause a general down regulation of proinflammatory cytokine production through 
p38 MAPK-dependent pathways leading to anti-inflammatory tissue protection [13]. The potential 
physiological effects of CO also include inhibition of apoptosis,cellular proliferation,and thrombosis. 
In chapter 2 we assessed the role ofH0-1 on the development of atherosclerosis in a hyperlipidaemic 
mouse model, mainly focusing on the effects of the gaseous HQ-1 metabolite CO. 
In chapter 3 we postulate that H0-1 may be an important regulator of advanced atherosclerotic 
lesion progression and eventually plaque destabilization. !n this chapter, we sought to correlate 
H0-1 expression with phenotypes of atherosclerotic lesions in the carotid end atherectomy (CEA) 
material obtained from patients with documented cardiovascular disease. 
lr.~rocuctlor. 
Furthermore, we sought to validate the data obtained from human CEA material in a house-
developed murine model for vulnerable plaque which we combined with the systemic induction of 
H0-1 by cobalt-protoporphyrin (CoPPlX). 
Increasing survival rates in organ transplantation represent one of the successes of modern 
medicine. However, graft rejection limits its efficacy especially following transplantation. The 
frequency and severity of acute rejection episodes is a predominant risk for chronic graft rejection. 
Expression ofthe stress protein H0-1 in rodent allografts (kidney, heart, and liver) and xenografts 
(heart) correlated with long-term graft survival in several models of transplantation [33}.1n a rodent 
model of renal transplantation,H0-1 expression increased in the allograft in response to immune 
injury. The reduced expression of H0-1 in chronic rejection compared with acute rejection may 
represent an inadequate response to injury or a consequence of prior injury that sensitizes further 
tissue response to immune attack [37]. Considering the anti-oxidative and anti-apoptotic properties 
of H0-1 observed in allograft protection, in chapter 4 we sought to define the role of H0-1 in the 
genetic regulation of the al!oimmune response directed by the dendritic eel!. 
The signal transduction mechanism by which HQ-1 deficiency in dendritic cells regulates the 
a!loimmune response is further elucidated. H0-1 deletion was shown to preferentially initiate 
CDS+ T cell maturation and proliferation, furthermore it was shown that H0-1 regulated MHC class 
II expression in DC by an CTlla dependent pathway. 
In chapter 5 we investigated the effects of H0-1 expression in dendritic ce!ls (DC) in regard to 
their ability to initiate aT-helper 1 (Th1) vs.T-helper 2 (Th2) differentiation and subsequent immune 
responses of naive T cells stimulated by either H0-1 +/+or HO-1-/- dendritic cells in a murine model 
of asthma, in which mice develop an airway hyperresponsiveness similar to that seen in human 
asthma, when challenged with aerosolized ovalbumin (OV) after initial sensitization. This study 
provided us with novel and valuable insigths in the genetic regulation of the immune respons 
evoked by DC. 
Dysregulated growth and motility of vascular smooth muscle cells {VSMC) contributes to 
neointimal lesion development during the pathogenesis of vasculoproliferative disease, including 
atherosclerosis and restenosis. Previous studies have shown that overexpression of heme 
oxygenase-1 (H0-1) inhibits formation of neointima after vascular injury, an effect 
partly explained by inhibition ofVSMC proliferation. However, the effects of H0-1 on the regulation 
ofVSMC migration remain unclear. In chapter 6 we assessed the role of H0-1 in VSMC migration 
and the effect of H0-1 overexpression on focal adhesion formation and cellular polarity. 
In atherosclerosis, the complex biology of intralesional angiogenesis remains to be elucidated. 
lntra-lesional neovascularization is observed in atherosclerotic lesions in humans and in animal 
models, while modulators of angiogenesis have been reported to affect atherosclerotic plaque 
growth. In addition, intra-!esional neovascularization is associated with advanced atherosclerotic 
lesions {vulnerable plaques), which sustain a characteristic morphology that renders them 
vulnerable to rupture, causing cardiac infarction [38}. In chapter 7 we investigate the effects of 
17 
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HO-1 overexpression and silencing in an estabnshed in vitro model for angiogenesis. The results 
obtained from these experiments are further evaluated in a validated murine mode! for vulnerable 
plaque in order to investigate the role of H0-1 on neovascularization and in vulnerable plaque 
development. 
ln:roductlor, 
REFERENCES 
1. lgnarro, U., et al., Endothelium-derived relaxing factor and nitric oxide possess identical pharmacologic properties as relaxants of bovine arterial 
and venous smooth musde.J Pharmacal Exp Ther, 1988.246(1):p.218-26. 
2. lgnarro, U.,et ai.,Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties 
identical to those of nitric oxide radical. Ore Res, 1987.61 (6):p. 866-79, 
3. Furchgott, R.F. and D.Jothianandan, Endothelium-dependent and -independent vasodilation involving cyclic GMP: relaxation induced by nitric 
oxide, carbon monoxide and light Blood Vessels, 1991.28(1-3):p.52-61. 
4. Ryter, S.W.,J. Alam,and A.M. Choi, Heme oxygenase-1/carbon monoxide:from basic science to therapeutic applications, Physiol Rev, 2006,86(2): p. 
583-650. 
5. lgnarro,U.,R.E.Byms,and K.S.Wood,Endothelium-dependent modulation of cGMP levels and intrinsic smooth musdetone in isolate<! bovine 
intf'<lpulmonary artery and vein, Ore Res, 1 987, 60(1 ): p. 82-92. 
6. Ten hun en, R., H.S.Marver,and R.Schmid,Microsomal heme oxygenase, Characterization of the enzyme.J Bioi Chern, 1969. 244(23): p, 6388-94. 
7. Tenhunen,R.,etai.,Enzymatic def~radation ofheme.Oxygenativedeavage requiring cytochrome P-450.Biochemistry, 1972.11(9):p. 1716-20, 
8. Maines, M.D. and P.E. Gibbs, 30 some years of heme oxygenase: from aNmolecular wrecking ball" to aNmesmerizing"trigger of cellular events. 
Biochem Biophys Res Commun,2005.338(1 ): p.568-77. 
9. Chen,M., et al., Carbon monoxide prevents apoptosis induced by uropathogenic Escherichia coli toxins. Pediatr Nephrol,2006. 21 (3): p.382-9. 
10. Gong, P., A.L Cederbaum, and N. Nieto, Heme oxygenase-1 protects HepG2 cells against cytochrome P450 2E1-dependent toxicity. Free Radic Bioi 
Med,2004. 36(3): p.307-18. 
11. Ryter,S. W., D. Morse, and A.M. Choi,Carbon monoxide:to boldly go where NO has gone before. Sci STKE,2004. 2004(230): p. RE6. 
12. Yoshida, land CJ.Migita,Mechanism of heme degradation by heme oxygenase.) lnorg Biochem,2000.82(H):p.33-41. 
13. Yoshida,T.and G. Kikuchi,Sequence ofthe reaction of heme catabolism catalyzed by the microsomal heme oxygenase system. FEB$ Lett, 1974. 
48(2):p.256-61. 
14. Maines, M.D., Heme oxygenase: function, multiplidty,regulatory me<hanisms, and clinical applications. Faseb J, 1988.2(10): p. 2557-68, 
15. Yoshida, land G.Kikuchi,PurifiG!tion and properties of heme oxygenase from rat liver microsomes.J Bioi Chern, 1979.254(11):p.4487-91. 
16. Yoshida,T,and G. Kikuchi, Heme oxygenase purified to apparent homogeneity from pig spleen microsomes.J Biochem, 19n.S1(1):p.265-8. 
17, Brown, A.C.,et a I., Heme metabolism and in vitro erythropoiesis in anemia associated with hypochromic microcytosis. Am J Hematol, 1988.27(1 ): 
p.l-6. 
18. Pimstone, N.R., et al., Inducible heme oxygenase in the kidney: a model for the homeostatic control of hemoglobin catabolism.J Clin Invest, 1971. 
50(10):p.2042-50. 
19. Sardana,M.K.and G5. Drummond, Tryptophan pyrrolase in heme metabolism, Comparative actions oflnorganic tin and cobalt and their 
protoporphyrin chelates on tryptophan pyrrolase in liver,Biochem Pharmacal, 1986.35(3):p.473-8. 
20. Trakshel, G.M., R.K. Kutty, and M.D. Maines, Purification and characterization of the major constitutive form oftesticular heme oxygenase.The 
nonindudble isoform.J Bioi Chern, 1986.261(24):p.11131-7. 
21. Maines, M.D., G.M. Trakshel, and R.K. Kutty,Characterization of two constitutive forms of rat liver microsomal heme oxygenase. Only one molecular 
species of the enzyme is inducible.) Bioi Chern, 1986.261(1):p.411-9, 
22 McCoubrey, W.K.,Jr., TJ. Huang, and M.D. Maines, Heme oxygenase-2 is a hemoprotein and binds heme through heme regulatory motifs that are 
not involved in heme Ciltalysis.J Bioi Chern, 1997.272(19):p, 12568-74, 
23. Trakshel, G,M.,J.F. Ewing, and M.D. Maines, Heterogeneity of haem oxygenase 1 and 2 isoenzymes. Rat and primate transcripts for isoenzyme 2 
differ in number and size.BiochemJ, 1991.275 (Pt 1):p.159-64. 
24. Shibahara,$., eta!., Structural organization of the human heme oxygenase gene and the function of its promoter. Eur J Biochem, 1989.179(3): p. 
557-63. 
25. McCoubrey, W,K.,Jr,, TJ. Huang, and M.O.Maines, Isolation and characterization of a eDNA from the rat brain that encodes hemoprotein heme 
oxygenase-3.Eur 1 Biochem, 1997.247(2}:p.725-32. 
19 
20 lntrodL.;c:ion 
26. Tang, LM., et al., Exogenous biliverdin ameliorates ischemia-reperfusion injury in small-for-si~ rat liver grafts.T ransplant Proc,2007 .39(5): p. 
1338-44. 
27. Christiansen,J.,C.G.Douglas,and JS.Haldane,Theabsorption and dissociation of carbon dioxide by human blood.J Physiol, 1914.48(4):p.244-71. 
28. Hartsfield, C.L,J.Aiam,and A.M. Choi, Differential signaling pathways of H0-1 gene expression in pulmonary and systemic vascular cells. Am J 
Physiol, 1999.277(6 Pt 1):p.L1133-41. 
29. lee, TS. and L Y. Chau, Heme oxygenase-1 mediates the anti-inflammatory effect ofinterleukin-10 in mice. Nat M€<1,2002.8(3): p.240-6. 
30. Morita,T.,etai.,Smooth muscle cell-derive<! carbon monoxide is a regu!atorofvascularcGMP.Proc Natl Acad Sd USA, 1995.92(5):p. 147S..9. 
31. Morita, land S. Kourembanas, Endothelial Cl!ll expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived 
carbon monoxide.J Clin Invest, 199S.96{6):p.2676-82. 
32. Otterbein, LE.,et al., Carbon monoxide suppresses arteriosclerotic lesions associated with chroni< gli!ft rejection and with b<llloon injury. Nat Med, 
2003. 9(2): p. 183-90. 
33. Kawashima, A., et al., Heme oxygenase-1 deficiency:the first autopsy case. Hum Pathol,2002.33{1 ): p.125-30. 
34. Yet,S.F.,et a!., Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling. Faseb J,2003. 17{12):p.1759-61. 
35. Abraham,N.G.,etaL,Overexpression of human hemeoxygenase-1 attenuates endothelial cell sloughing in experimental diabetes.AmJ Physiol 
Heart Circ Physiol,2004. 287(6): p. H2468-77. 
36. Avihingsanon,Y.,etai.,Expression of protective genes in human renal allografts: a regulatory response to injury associated with graft rejection. 
Transplantation,2002.73[7}:p.1079-85. 
37. Ae'mer,M ., et al., Arter'1al neovascularization and 'mflammaf1on in vulnerable patients: early and late signs of symptomatic atherosclerosis. 
Circulation,2004, 11 0(18): p. 2843-50. 
HEME OXYGENASE-1/CARBON MONOXIDE 
SIGNALING INHIBITS ATHEROSCLEROSIS 
DEVELOPMENT IN APOE KNOCKOUT MICE 
M.M. Noordeloos 1, 5. Cardoso', C. Cheng 1, I. Pombo Gregoire', H.J. Duckers 1, 
M.P. Soares 2 
1 Molecular Cardiology Laboratory, Thoraxcenter, Rotterdam, The Netherlands, 21nstituto Gulbenkian de Cienca, 
Oeiras, Portugal. 
22 He:"".e oxygenJse-1/cJrbon ;nonoxide s:gnali'lg lrh:bits ~the:osclerosls development in ApoE knoc~ou: m'ce 
ABSTRACT 
Heme oxygenase-1 {H0-1) is a stress inducible enzyme that catalyzes the degradation of heme 
generating biliverdin, ferrous iron and carbon monoxide 
{CO) in the process. H0~1 and its degradation products have been shown to exert protective 
effects on the formation of atherosclerotic lesions in mice and cardiovascular patients. In this 
study the effects ofthe gaseous H0-1 metabolite CO on plaque formation in the ApoE knockout 
(ApoE+) receiving a high cholesterol diet (HCD) was assessed. Carbon monoxide inhalation 
starting either I week prior before or simultaneously with HCD suppressed the development of 
atherosclerotic lesions by 32-54% in aortas and in the supra valvular area and compared to air 
treated controls (P<O.OS, as determined by Students t-test). Furthermore, in ApoE I HQ-1 double 
knockout mice (ApoE-/- H0-1 -/-) deletion of HQ-1 promoted atherogenesis as compared to the 
ApoE-/- mice whereas no significant differences were observed in heterozygous mice (P=0.46 
and P=0.89 determined by Students t-test). 
Our data indicate that the heme oxygenase-1/ carbon monoxide signaling cascade attenuated 
atherogenesis in the ApoE-/- mouse and may function as a compensating mechanism in 
atherogenesis. Furthermore we showed that H0-1 deletion deteriorated lesion progression in 
the ApoE/H0-1 double knockout, which confirms the right genotype of this generated double 
knockout mice and makes them suitable for future experiments. One of these future options will 
be to assess whether CO administration would be successful to rescue the atherosclerotic lesion 
progression in ApoE/HQ-1 double knockout mice. These experiments would further contribute 
to the possibly therapeutical applicability of CO, which holds great promise for future strategies 
treating vasculoproliferative disease. 
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INTRODUCTION 
Heme oxygenase -1 (H0-1) is a stress responsive, ubiquitous enzyme that degrades heme, 
generating equimolar amounts of iron, biliverdin and carbon monoxide (C0)[3, 4]. Previous work 
has shown that induction of 
H0-1 and its metabolites counter vascular remodelling associated with the development of 
atherosclerotic lesions in mice[S, 6]. The vasculature in a human case of a documented deletion 
of the H0-1 locus contained fatty streaks and fibrous plaques, accompanied by high blood level 
of triglycerides.ln addition, deficiency of H0-1 led to increased iron deposition in liver and kidney 
with damage to the local vascular endothelium [7]. This endothelial cytotoxic effect was not only 
attributed to the direct cytotoxicity of heme, but also appeared to be caused by heme-associated 
LDL oxidation generating primarily lipid hydroperoxides which are toxic to endothelium. HO-1 is 
induced by oxidized LDL and is expressed in atherosclerotic plaques. In the LDL-receptor (LDL-R) 
knockout mice, H0-1 expression was detected in atherosclerotic plaques after dietary cholesterol 
feeding[8]. H0-1 degradation products, biliverdin and bilirubin, have been shown to contribute to 
the cellular antioxidant balance and ROS scavenging and thus protect vascular cells from oxidative 
stress injury [5,9] 
Indeed diminished expression or loss of H0-1 resulted in increased lipid uptake and foam cell 
formation and correlated with increased ROS generation and proinflammatorycytokine production. 
Also in ApoE-/-/H0-1-/- mice larger and more advanced lesions were formed as compared to 
ApoE knockout mice[6].Therefore, it has been suggested that H0-1 activation may represent the 
protective response mechanism against oxidative stress and inflammation during development 
of atherosclerosis. However, the molecular basis of H0-1 induced signalling pathways rendering 
atheroprotection remains incompletely understood. In this study, we focussed on the effects of 
carbon monoxide on atherosclerotic lesion development. CO is able to activate soluble guanylyl 
cyclase (sGC) leading to upregulation of cGMP. Further, CO is able to modulate the mitogen-
activated protein kinase pathway (MAP)(), including p38 MAPK, ERK, and JNK which will down 
regulate proinflammatory cytokine production [10]. 
In this study the role of heme oxygenase I carbon monoxide signaling in the development of 
atherosclerosis is assessed. 
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MATERIALS AND METHODS 
Lipid mediated atherosclerosis was induced in 12 week old female Apoliploprotein deficient mice 
(ApoE-/-) on a C57black6 background (Jackson Labs, USA) which were fed a high cholesterol (1 .25%) 
diet (HCD) which was continued for 8 weeks. CO inhalation (250 parts per million) was started 
before, during or after HCD. 
H0-1 and ApoE null mice were obtained by crossbreeding ApoE+ I (57 black6 background with 
H0-1-/-/ CS7black6 background in the Gulbenkian Institution, Oeiras,according to the guides and 
regulations of the Portuguese Animal Committee. 
ApoE + mice were randomly assigned to either the control group (7 weeks HFD and 8 weeks air 
·Inhalation) or one of the three experimenal groups (group CO-l ;treated with 8 weeks CO inhalation 
250ppm starting one week before and simultaneously with 7 weeks HFD,group CO-li; treated with 
7 weeks CO inhalation 250ppm simultaneously with 7 weeks HFD;and group C0-11!: in which mice 
received 7 weeks HFD and CO inhalation 250ppm during weeks 4,5,6 and 7 of the HFD (figure 1 a). 
After 8 weeks ofHCD mice were sacrificed and the aorta was harvested in total from the arch of the 
ascending aorta to the bifurcation of the ilio-femoral arteries and stained for lipid deposition with 
Oil-red-O. 
Lipid depositions were subsequently en face imaged and quantified by a computer assisted 
imaging analysis system (CLEMEX). 
Hearts from H0-1 +ApoE-/- mice were harvested after 8 weeks of HCD and whole mounted in 
paraffin. Continuous sections were made of the entire aortic valve area (S!Jm each). HE staining was 
performed and analysed every fifth section of the supra valvular area and lesion size was quantified 
with Clemex system. 
Adjacent sections were stained and quantified for presence of vascular smooth muscle cells (VSMC) 
(anti actin-Cy3, Sigma-Aldrich, The Netherlands). 
The percentages of the different plaque components were calculated as the percentage of surface 
area positive for each specific immunostaining relative to the total intimal surface area. Statistical 
analysis was performed using student's t-tests.Data are presented as mean± SEM.Pvalues less than 
0, OS were considered to be significant. 
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RESULTS 
CO inhalation starting either before or simultaneously with HCD suppressed the development of 
atherosclerotic lesions with 32 ~54%. Initiation of CO exposure starting 1 week prior to HFD reduced 
atherosclerotic lesion formation by 53% {?=0.004) whereas CO inhalation initiated either at onset 
or 3 weeks after HCD initiation resulted in resp. 32% and 34% lesion reduction compared to air 
treated controls (p<0.003 and p<0.0013 respectively figure 1 a,b.) Lesions quantified by computer 
ass'1sted '1mage analysis of oil red-O staining in the aortic arch showed lesion reduction in the 
CO -treated mice specifically at the aortic arch and the area of the internal and external carotid 
bifurcations (figure 1 c). Figure 1 d shows a representative cross-section of the aortic valve area of an 
ApoE-/- mouse treated with CO inhalation for 8 weeks versus an air-treated ApoE -/-control mouse 
indicating sustained plaque/valve size reduction at the supra valvular area. 
(Figure 1e. 33% P=0.026). Next ApoE -1- mice reveived either 12 weeks of HFD with CO inhalation 
250ppm started at week 7 orB weeks with justair inhalation with subsequent4 weeks of normal chow 
diet (figure 1f). Both groups displayed about 33% less atherosclerotic lesion formation compared 
to the air-HFD for 12 weeks control group (P< 0.0002 and P< 0.022 respectively) indicating that the 
effects of CO inhalation at this dosage are as potent as reduction of cholesterol levels suggesting 
that CO inhalation may be used therapeutically to arrest the progression of atherosclerosis. 
Neither CO treatment nor biliverdin administration modified total plasma cholesterol levels. 
In figure 2 data from a pilot we conducted in collaboration with the Gulbenkian Institute are shown. 
These data form a prerogative for a larger study in which we will assess the ability of CO to rescue 
the deteriorating effects on atherosclerotic lesion development in H0-1/ApoE double knockouts. 
Representative cross-sections are shown of the aortic valve area of ApoE -/-mice that were either 
wild type(+/+), heteroxygous (+/-) or nullizygous for HO-1 (-/-) after 8 weeks of high fat diet.The 
upper panel shows that deletion of H0-1 promotes atherogenesis (a trend is observed with p< 0.099 
at N=4 animals). No difference was observed in mice heterozygous for H0-1 expression compared 
to their wild type littermates (P< 0.46 and p<0.89 resp.) The lower pannel shows representaive 
cross-sections of the supra valvular area stained for a-actin. No significant difference was observed 
between the 3 experimental groups. These data confirm that in these home- generated H0-1/ 
ApoE1 double knockout mice we were able to reproduce an earlier finding [6] that H0-1 deletion 
promotes atherosclerotic lesion progression in the ApoE-1- mice. 
25 
26 Heme oxygen<Jse-1/c<Jrbor monoxide slgn<J:Ing inhibits ilt'1erosclcrosis develop~ent in A poE knockout mice 
.b c 
r-~---··-, 
---= : . 
- '0 a :§ :a ::;; !!!. 
• 
• ''K :'[ :-;:_ 
.!! 6 
. :--0) ~ ,.,.-t 
"'' 
4 
(Ill} 
'!lt• .. 2 
... 
0 
~. 
' " "' co 
d 
:l!J .. 6 : G : ~ PN 4 ;'[ 
ratio 3 .!!.. : 
2 l " 
' 0 
Ak CO(O 
g h 
'6 
w- ,. ···~~ ~~ 0 4 8 ,. g ,.,l ;l HFO 
.!! 
, 
Ak 
-= ~ • . .;-s 0 4 • , . • HFOJNF 
Ak 3 
0 
AJr eo AJ.r 
HF0HFO 
Figure 1 (I a) Outline of experimental groups: ApoE -/-mice were randomly assigned to either the control 
group (these mice were fed a HFD during 7 weeks while receiving normal air inhalation over the entire time 
course) or one of the three CO-inhalation groups (group CO-/ ;mice in this group were treated with 8 weeks CO 
inhalation at a concentration of 250ppm starting one week before and simultaneously with 7 weeks ofHFD, 
and group CQ-11; these mice were treated with 7'1reeks CO inhalation also at 250ppm simultaneously with 7 
weeks HFD;and group CO-Ill: in which mice received ?weeks HFD and CO inhalation 250ppm during weeks4, 
5, 6 and 7 of the HFD, N=-10 mice each group). (1 b) Graph shows atherosclerotic lesion reduction in the three 
experimental groups in which CO was inhaled during various time points of the HFD compared to air treated 
control mice. CO inhalation was effective in all three setups to sustain a significant lesion size reduction (CO-!: 
52% reduction,p<0.004 C0-11:32% reduction, p<0.03, COI/I: 34 %reduction p<0.0013) (I c) Oil-redO staining 
of representative whole mounted aorta's showing reduction in atherosclerotic lesion size at aortic arch end 
at side branch bifurcations. (ld) HE stained representative crosssections of aortic valve area of an air treated 
control mice and a mice receiving CO inhalation continuously for 8 weeks during HFD. (le) Valve area vs. 
Plaque area in }JM was significantly reduced after Co inhalation (p< 0.026). 
(1f) Outline of second set of experiments: Mice from control group were placed on a HFD over a time course 
of 12 weeks and inhaled normal air during these 12 weeks. The second group switched in week 7 from air to 
CO while continuing the HFD and the third group inhaled normal air while being fed HFD for 8 weeks and 
switched to NFD in week 8. lg: Both switching to a NFD and the inhalation of CO while continuing HFD for 4 
more weeks reduced atherosclerotic lesion formation with 30% compared to mice on HFD and air inhalation 
for 12 weeks. 
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Hmox1 
P = 0,099 wr versus H01 -/-
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Figure2 Representative cross-sections ore shown in the rigth panel of the supra aortic valve area of ApoE 
-1· mice that were either wild type(+!+) heteroxygous (+/·)or nullizygous for H0-1 (-1-) afterB weeks of high 
fat diet. The upper left panel depicts the effect of HO-I deletion on lesion formation in theApoE-1-H0-1 -/-mice 
(a trend is observed with p< 0.099 at N=4 animals.). No signif7canr difference was observed for the effect in 
mice that were heterozygous for H0-1 expression compared to wild type !itrermates (P= 0.46 and P=0.89 resp.) 
The lower rigth panel shows representative cross-sections of the valve area stained fora actin. No signif7cant 
difference 'ttas observed between the 3 groups. 
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DISCUSSION 
In the current study CO inhalation suppressed development of atherosclerotic lesions by 32-54% 
in ApoE knockout mice on a HFD when started either prior or simultaneously with compared to air 
treated controls. Furthermore, CO inhalation showed to be equally effective in attenuating plaque 
progression as reduction of cholesterol levels. In addition to that we show that the ApoE/H0-1 
double knockout mice generated respond as expected to high cholesterol feeding. 
H0-1 has been shown to have important antioxidant and anti-inflammatory properties that may 
result in vascular anti-atherogenic effects [11-15] 
Enhanced production of reactive oxygen species under pathophysiological conditions is integral 
in the development of cardiovascular diseases (CVD). These reactive oxygen species regulate 
various signaling pathways involved in vascular inflammation in atherogenesis but also mediate 
antioxidative and anti-apoptotic responses[14]. Accumulating evidence has shown that H0-1 
and its degradation products may function as adaptive molecules against oxidative insults. The 
proposed mechanisms by which H0-1 exerts its cytoprotective effects include its ability to degrade 
the pro-oxidative heme, and to release biliverdin which exerts a strong antioxidative action 
affecting intracellular redox signaling and reduces oxidized LDL accumulation. Carbon monoxide 
(CO) is a gaseous metabolite of heme oxygenase activity. Although long considered an insignificant 
and potentially toxic waste product of heme catabolism, CO is now recognized as a key signaling 
molecule that mediates several signaling cascades and has anti- proliferative and anti-inflammatory, 
as well as vasodi!atory properties [16] 
Interestingly, alterations in CO synthesis are associated with many cardiovascular disorders, 
including atherosclerosis, septic shock, hypertension, and ischemia-reperfusion injury [17-21] 
whereas restoration of physiologic CO levels exerted a beneficial effect in many of these conditions, 
suggesting a crucial role for CO in maintaining cardiovascular homeostasis[18,22].The observations 
in this study add to the belief that CO may act as the important signaling molecule that mitigates 
this anti-atherogenic action of H0-1. In addition we here report the finding that CO inhalation 
seems to be equally effective as lowering cholesterol levels in the inhibition of lesion progression 
in an APOE -/-model of atherosclerosis. These findings will contribute to the ongoing development 
of therapeutic strategies exploiting the antiatherogenic effects of H0-1/CO signaling. However 
there are some concerns that should be addressed before the use of CO as a therapeutic agent will 
become manifest. The therapeutic window of CO treatment in cardiovascular disease should be 
thoroughly explored. Alternatively generation of inducible or tissue specific viral vectors expressing 
H0-1 are a feasible option. In addition to that ongoing development of CO-releasing molecules will 
furthermore provide new strategies that make local or site specific delivery of CO possible while 
bypassing the dangers of systemic administration. We conclude with the prospect that CO therapy 
may hold great expectations for future treatment of atherosclerotic disease. 
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MATERIALS AND METHODS 
Analysis of the human atherosclerotic plaques in human carotid end 
atherectomy specimens 
Carotid end atherectomy (CEA) specimens were obtained from a biobank comprised of a collection 
of atherectomy-derived specimens of patients with symptomatic carotid artery disease (Athero 
Express biobank, Utrecht) [6]. The study was approved by an institutional review committee, and 
that the subjects gave informed consent. The collected specimens were routinely processed 
for immuno-histological analysis, as well as protein/RNA extraction, and were subsequently 
quantified by 2 blinded observers for presence of characteristics indicative for a vulnerable plaque 
morphology, as reported earlier [18]. Briefly, CEA specimens were harvested, embedded in paraffin, 
and immunohistochemically examined for the presence of macrophages, vascular smooth muscle 
cells (VSMCs),collagen and lipids. In addition,plaque thrombogenicity was assessed by the presence 
of intraluminal thrombus or intraplaque erythrocyte deposition, as defined by histomorphology 
in hematoxylin/eosin~stained sections. In addition, adjacent sections of the collected CEA 
atherosclerotic plaques were freshly frozen for protein analysis. Protein samples of 112 patients 
were randomly selected from the Athero Express biobank and analyzed. 
ELISA analysis of protein expression 
Proteins were extracted from atherosclerotic segments adjacent to the segments used for 
immunohistochemical analysis, byTri-Pure Isolation Reagent (Roche, The Netherlands).Total protein 
concentration was determined by a colorimetric protein assay, followed by optical spectroscopy 
(Biorad, The Netherlands). H0-1, IL6, and IL8 protein expression in lysates was assessed with a 
commercial quantitative sandwich ELISA assay (for H0-1; EKS-800 kit, Stressgen, USA, for IL6, ILS, 
MMP2 and MMP9; Sanquin, The Netherlands). The association between HO-1 protein expression 
and patient CEA characteristics was analyzed using a Kruskai-Wallis one-way analysis ofvariancefor 
ranks. Value of P<O,OSwas considered to indicate significance. 
Immunohistological analysis by confocal microscopy 
Paraffin embedded sections were stained with anti-human CD68 (Hycult, The Netherlands), CD1 63 
(done 1060, Sanbio, The Netherlands), a-Actin Cy3 (Dako, Belgium), and H0-1 (OSA-1 1 O,Stressgen, 
US), and with secondary antibodies labeled with Alexa Fluor (568nm, 488nm, Molecular Probes, 
Invitrogen Inc., The Netherlands). Processed sections were visualized by tile analysis on the confocal 
microscope and quantified using LSM software (LSM51 0 NLO/FCS,Zeiss,The Netherlands). 
Vulnerable plaque model in A poE-/- mice 
All experiments were performed in compliance with institutional (Erasmus University Medical 
Center, Rotterdam, The Netherlands) and national guidelines. 
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ApoE-/- mice on a C57BU6J background (age 12~1 Sweeks)wereobtainedfromJackson Laboratory 
(Bar Harbor, USA).The protocol for this animal study is described in figure 1. (A) Two weeks before 
surgery, all animals were placed on a Western type diet containing 15% (w/v) caeca butter and 
0,25% (w/v) cholesterol (diet W, Hope Farms, The Netherlands). (B) Two weeks later, animals were 
anaesthetized by isoflurane inhalation, and the right common carotid artery was dissected from 
circumferential connective tissues. The cast was placed around the right common carotid artery, 
after which the wounds were closed with vicryl sutures and the animals were allowed to recover. 
(C) Six weeks after cast placement, animals were randomized to either treatment with phosphate 
buffered saline (Cambrex, UK) (N::::1 O) or cobalt protoporhyrin (CoPPIX, Frontier Scientific Inc., 
Canada) treatment (N::::1 O) in order to induce endogenous H0~1 (ip injection,Smg/kg q2d, in 0,2M 
NaOH, ph 7,4).After 21 days of either PBS or CoP PIX treatment, animals were scarified and carotid 
arteries were harvested and processed for histological analysis. 
Tissue preparation and histological analysis 
Carotid arteries were embedded in OCf (Sakura Finetek,The Netherlands) and snap-frozen in liquid 
nitrogen. The abdominal aorta from each animal were excised and homogenized by sanification 
in NP40 lysis buffer on ice. 
Quantification of histological data was performed on 7 1-Jm cryosections, at 140 IJm intervals. 
In addition to standard hematoxylin/eosin (HIE) staining, immunohistochemical analysis was 
performed, including assessment of macro phages (anti~CD68 antibody, Santa Cruz Biotechnology 
Inc., The Netherlands), and smooth muscle cells (anti-a-actin antibody, Sigma, Zwijndrecht, 
The Netherlands). Upid and collagen deposition were visualized by Oil-red-0 and picosirus red 
stainings, respectively. Data analysis was performed using a commercial image analysis system 
(!mpak C, Clemex Technologies, Canada). Intima/media ratio and necrotic core/intima ratios were 
analyzed in sequential HIE-stained carotid sections. Necrotic area was defined as neointimal areas 
devoid of cellular tissue. Relative fibrous cap thickness was defined as the ratio of the average 
cap thickness at the shoulder and mid-plaque region divided by maximal intima cross-sectional 
thickness. The percentage of the different plaque components was calculated as the surface area 
positive for each specific indicative expressed as a percentage of the total intimal surface area. 
Statistical analysis was performed using student's T-test. Data are presented as mean ± SEM. P 
values less than 0,05 were considered to be significant. 
Western blot analysis 
Total protein concentration was determined using a colorimetric protein assay followed by optical 
spectroscopy (Biorad,The Netherlands).HO-1 prote"1n expression was analyzed by standard Western 
Blot analysis (Biorad, The Netherlands) and was subsequently visualized using a fluorescent 
detection system (Li-cor Biosciences,The Netherlands). 
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RESULTS 
H0-1 is specifically upregulated in human vulnerable atherosclerotic 
lesions 
Average H0-1 expression levels in the CEA material was 0,98 ± 0,12 pg/ml. CEA patients were 
divided into quartiles of H0-1 expression: the first quartile contained 28 patients (HO-1 expression: 
0,19 to 0,34 pg/ml), the second quartile contained 27 patients {H0-1 expression: 0,39 to 0,57 pg/ 
ml), the third quartile contained 29 patients (H0-1-expression: 0~8 to 1,01 pg/ml),and the fourth 
quartile contained 28 patients (H0-1 expression: 1,02 to 9,07 pg/mi).The baseline characteristics of 
these patients are shown in table 1. The distribution of CAD risk factors did not differ among the 
H0-1 quartiles. 
Increasing protein levels ofH0-1 were associated with a characteristic vulnerable plaque phenotype 
(P=0,004; figure 2a). More specifically, increasing percentages of lipids and macrophages in the 
carotid lesions correlated closely with H0-1 protein expression (P=0,006,and P=O,OOS;figure 2b, c), 
whereas increasing percentages of collagen and VSMCs in the lesions correlated significantly with 
decreasing levels of H0-1 (P=0,04 and P<O,OOOS;figure 1 d, e). Double labelling in imunohistlogical 
analysis suggested that H0-1 expression was mainly localized in the base of the intimal lesion 
(figure 3a), and co-localized with residing macrophages, whereas H0-1 expression in VSMCs was 
hardly detectable (figure 3b, c). 
H0-1 expression correlates with distinct molecular markers of plaque 
vulnerability in human CEA material 
Next, we assessed the relation between H0-1 levels, and protein expression of local matrix 
metalloproteinase (MMP), or various inflammatory cytokines, which previously were shown to 
promote plaque vulnerability. H0-1 expression levels in the carotid lesions correlated closely with 
MMP9 expression levels (P=0,02), whereas a trend was observed with MMP2 protein levels (P=0,06, 
figure 4a, b). Likewise, HQ-1 strongly predicted IL-6 and !L-8 protein levels (P<O,Ol, figure 4c, d). In 
contrast, no clear relation was detected with MMPS, and !L-10 (P=O, 13, and P=0,52, respectively, 
data not shown). 
H0-1 expression levels are associated with plaque thrombogenicity 
in human CEA material 
Luminal or intraplaque thrombus formation is an established characteristic sign of plaque 
vulnerability [20-22]. We therefore evaluated the relation between thrombus formation with the 
expression levels of H0-1. High intraplaque protein expression of H0-1 was correlated with the 
presence of thrombus in the assessed human carotid lesions (P=0,04;as shown in figure 5). 
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Table 1. Baseline patients' characteristics 
Risk factors Ntiles Hmox- Ntiles Hmox- Ntiles Hmox- Ntiles Hmox- P-Value 
N=112pts , , , , 
I II Ill IV 
28 27 29 28 
male 20/28 20/27 19/29 22/28 0,58 
(N:::Sl I 72,3%) 
--- -- --- ----- -·--~-- -----
Age 67,7 65,4 70,2 68,9 
{range) (63,5-72,0) (62,1-68,7) (66,8-73,6) (65,8-71,9) 0,25 
---------~--------------
-------- -·-·-·-·- -----------------
Hypertension 27/28 27/27 29/29 24/28 0,20 
(N=<107,95,5o/o) 
---------
-------,----------------
Diabetes 23/28 20/27 16/29 i 16/28 0,25 
(N=75,67,0%) 
Hypercholes- 4/28 6/27 1/29 6/28 0,07 
Terolemia 
(N=17, 15,.2%) 
Current smoker 14/28 18/27 16/29 14/28 0,24 
(N=62,55,4%) 
Previous smoker 4/28 7127 4/29 10/28 0,13 
(N=25,22,3%) 
Systolic tension 
mmHg 160,4 155,0 163,3 165,3 0,52 
(range) (149,3-171,5) (145,3-1 64,6) (150,5-176,0) (1 54,4-176,1) 
"' --·~--~-~-·----~~-------~ -· --· ·------~~--
Diastolic tension 
mmHg 82,4 83,2 79,8 86,7 0,28 
(range) (77,9-86,9) (78,5-87,9) (74,4-85,2) (82,3-91,1) 
----~----~-~---
Total cholesterol 
mmol/1 5,0 4,8 4,3 5,1 0,22 
(range) (4,3-5,8) (3,6-5,8) (3,7-4,8) (4,5-5,6) 
-----~--- ---------
--· -----·-·--------------
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T =- 2 weeks T= 0 weeks. T= 6weeks T=9weeks 
ApoE-1- ApoE-· 
+ + A B 
c ApoE-· 
-
CoPPIX injections. 
start 
high fat diet 
cast implantation 
Figure 1 Schematic overview of the experimental animal model. (A) C57bl/6 ApoE -/- mice were fed a 
cholesterol rich, high fat diet starting from 2 weeks before cast implantation (T=-2 weeks). (B) The cast device 
v·vas implanted into the right carotid artery (T= 0 v;eeks). (C) CoPPIX was injected i.p. three times a '.Neek 
starting from ·vveek 6 (T = 6 weeks). The animals were sacrificed 9 weeks post cast-imp!antation,and the carotid 
artery segments were harvested for immunohistological analysis. Two groups were included in the study:(!) 
The control group ·.,Nos injected with saline from T= 6 vreeks. (II) The Hmox-1 induced group was inJected with 
CoPPIX from T = 6 'Neeks. 
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Figure 2 Intraplaque Hmox-7 levels correlated strongly to the characteristic parameters of vulnerable 
plaque. (A) A correlation between Hmox-7 expression and plaque vulnerability was observed in the human 
CEA samples (P=0,004 based on correlations found bet'Neen Hmox-1 expression and characteristic vulnerable 
plaque parameters: including a linear correlation ofHmox-1 with (8) intima/lipid deposition,(() macrophages 
(P=0,006, and P=O,OOS respectively), and an inverse correlation of Hmox-1 ·,;.;ith (D) intimal collagen and (E) 
VSMCs (P=0,04and P<O,OOOS,respective/y),divided into four quartiles ranging from 0.5 (representing the group 
of patients with the lowest percentage) to 2 (representing the group of patients with the highest percentage) on 
they-axes. On the x-axes, Hmox-1 protein expression levels are shown, divided into four quartiles of expression 
ranging from 1 (representing the group of patients with the IO'II'rest percentage) to4 (representing the group of 
patients with the highest percentage). 
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Figure 3 Hmox-1 expression is mainly co-localized with macrophages inf71troting in human atherosclerotic 
lesions. Representative pictures from paraffin cross-sections of human CEA material are shO'Im. Hmox-1 
expression was mainly focalized in the base of the intimal lesion, close to the media and the adventitia (A). 
Hmox-1 is defined by a green fluorescent signal, while the red fluorescent signal det7nes the elastic laminas of 
the media. Hmox-1 expression was co-localized with mocrophages residing in the intima (8). The middle panel 
depicts Hmox-1 expression, the upper panel shows CD68+ cells, and the lower panel shO'NS the combined 
images. Hmox-7 expression in VSMCs rich area was hardly detectable (C). The middle panel depicts Hmox-1 
expression, the upper pane! shows a-actin+ VSMCs, whereas the lower pane! shO'NS the integrated images. 
(magnirication 200X), 
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Figure 4 Hmox-1 expression correlates with biomarkers of advanced atherosc!erosis. Hmox-1 expression 
levels in the carotid lesions correlated with !L6,1L8,ond MMP9 expression levels in the vulnerable atherosclerotic 
plaque. For MMP2, a trend was obsen;ed. The graphs show the expression levels in mmoflml for (A) MMP9 
(P=0,02), (8) MMP2 (P=0,06), (C) IL -6 (P<O,O I), and (D) IL -8 (P<O,O I) on the y-o xes. On the x-axes,Hmox-1 protein 
expression levels are shO'Nn, divided into four quarti!es ranging from 1 (representing the group of patients with 
the lowest intra plaque !eve!) to4 (representing the group of patients with the highest intraplaque level). 
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Figure 5 Hmox-1 expression correlates with lesion 
thrombogenecity. 
Hmox-1 expression levels in the carotid lesions 
correlated with thrombus formation and erythrocyte 
extravasation in the human carotid vulnerable 
plaque lesions (P=0,04). They-axes show the degree 
of accumulation of erythrocytes/blood plasma in 
CEA lesions divided into four quartiles ranging from 
0,5 (representing the group of patients 'l'rith minor 
deposition) to 2 (representing the group of patients 
with the most severe deposition). The x-axes shovv 
Hmox-1 expression levels divided into four quortj/es 
ranging from 1 (representing low expression level) to 4 
(representing high expression level). 
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H0-1 induction inhibits vulnerable plaque development in ApoE-/- mice 
without modulating lesion size. 
The observations in the human carotidectomy materia I suggestthat HO-1 expression is compensatory 
upregulated in advanced atherosclerotic plaques with a vulnerable phenotype. Induction of H0-1 
expression could therefore aid to the stabilization of the atheromatous plaque. In order to study 
this, H0-1 expression was induced by cobalt protoporhyrin (CoPPIX) treatment in a mouse model 
for vulnerable atherosclerotic plaqueformation.ApoE knockout mice were fed on a high cholesterol 
diet and implanted with an carotid cast as previouslydescribed.This flow-modifying device induces 
atherosclerotic lesions with a vulnerable phenotype in the proximal segment, whereas downstream 
from the device stable atherosclerotic lesions are formed. The murine proximal vulnerable lesions 
typically comprise a low content of plaque-stabilizing components, including collagen and VSMCs, 
and high percentages of plaque-destabilizing components, including lipids and macrophages, 
which taken together composes a lesion phenotype typically seen in human vulnerable plaques 
described byVirmani [23,24]. 
Endogenous H0-1 mRNA expression was increased in the proxima! lesions with the vulnerable 
phenotype, but not in the distal lesions with stable phenotype or in the contralateral naTve carotid 
arteries (figure 6a) at 9 weeks post implantation. 
CoPPIX treatment to induce H0-1 expression was initiated at 8 weeks ofWestern diet (6 weeks post 
cast implantation), when the early lesions in the carotids do not yet show the histomorphological 
characteristics of vulnerable plaque development. Histomorphologica! analysis was performed after 
3 weeks of CoPPIX treatment and 9 weeks of cast placement. H0-1 protein levels were increased in 
vascular segments of CoPP!X-treated mice, as compared to the saline-treated group by 20-fold as 
measured by western blot analysis of aorta segments. H0-1 expression levels were elevated as early 
as 2 days after initiation of CoPPlX injections (figure 6b). 
Although H0-1 overexpression did not affect neointima/media ratio of advanced vulnerable lesions 
(2,97 ± 1,32 versus 3,40 ± 0,71, control versus CoPPIX, figure 7a), induction of H0-1 reversed the 
vulnerable plaque into a stable lesion, with an increase of relative fibrous cap thickness by 333% 
(0,067 ± 0,019 mm versus 0,29 ± 0,077 mm,control versus CoPPIX, P<0,05, figure 7b),and a significant 
decrease of necrotic core/intima (N/1) ratio by 49% (34,9 ± 2,3% versus 17,8 ± 2,2%, P<0,05, figure 
7c). In addition, H0-1 overexpression was associated with a diminished lipid deposition in the 
vulnerable atherosclerotic lesions by 40% (19,2 ± 2,8% versus 11,5 ± 1,4%, control versus CoPPIX, 
P<O,Ol, figure 7d). H0-1 expression also was associated with the induction of plaques reminiscent 
of stable lesions, indicated by an increase in VSMCs residing in the intima by 66% (11,0 ± 0,27% 
versus 18,3 ± 2,6%, control versus CoPPIX, P<0,05, figure 7e). Interestingly, H0-1 overexpression 
did not affect intimal collagen formation in the atherosclerotic lesions (15,0 ± 0,6% versus 15,6 ± 
0,62%, control versus CoPPlX, figure 7f).A trend towards reduction was observed in intimal CD68+ 
macrophage infiltration by 37% (23,7 ± 6,5% versus 14,9 ± 6,7%,.control versus CoP PIX, figure 7g). 
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Figure6 Hmox-7 expression in murine vulnerable 
A 0.8 plaques and stable atherosclerotic lesions. 
*# 
0.6 (A) QPCR analysis indicated that endogenous Hmox-1 
::> 
mRNA level was increased in lesions with the vulnerable 
"' 
0.4 phenotype, compared to the contralateral nai've 
0.2 carotid arteries and the stable plaques. (8) Western 
blot analysis show Hmox-1 protein levels in pooled 
0.0 aortas of CoPPIX treated ApoE-1- mice compared to 
control :table vulneroble the saline-treated group after 2 days and 3 'll'reeks of 
eo.rotid plaque plaque 
CoPP!X injections. * P<O,OS versus control . # P<O.OS 
B • CoPP!X + CoPPIX versus stable lesion. 
-
32KO 
2d"Y' 32KO 
Figure 7 Hmox-7 induaion stabifizes the progression of advanced lesions into vulnerable plaque. 
Morphometric and immuno-histological analysis of vulnerable plaques in CoPPIX-treated and control ApoE 
-1- mice. In the right column, representative cross-sections are shown. In the left column, bar-graphs show 
the effects of Hmox-1 induction on (A) intima/media (1/!v!) ratio, (8) relative cop thickness (i.e. mean cop 
thickness at plaque shoulders and midregion/maximal intimal thickness), (C) necrotic core/intima (Nil) ratio, 
(0) %intima/lipids, (E) %intimal VSMCs, (F) %intimal collagen, and (G) %intimal CD68+ mocrophages in 
vulnerable plaque lesions.~ P<O,OS versus control. 
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Figure 7 Hmox~ 1 induction stabilizes the progression of advanced lesions into vufnerable plaque. 
Morphometric and immuno+histological analysis of vulnerable plaques in CoPPIX-treoted and conrrol ApoE 
-1- mice. In the right column, representative cross-sections are shown. In the left column, bar-graphs show 
the effects of Hmox-1 induction on (A) intima/media (JIM) ratio, (B) relative cop thickness (i.e. mean cap 
thickness at plaque shoulders and mid region/ maximal intima/thickness), (C) necrotic core/intima (Nil) ratio, 
(D) %intima/lipids, (E) %intimal VSMCs, (F) %intimal collagen, and (G) %intimal CD68+ macrophoges in 
vulnerable plaque lesions.* P<0,05 versus control, 
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DISCUSSION 
The current data in human carotid end atherecthomy atherosclerotic plaques and in murine 
vulnerable lesions suggest that H0-1 expression is strongly associated with a vulnerable plaque 
morphology: H0-1 protein expression was specifically upregulated in human vulnerable 
atherosclerotic lesions with lipid and macrophage accumulation and low collagen and VSMCs 
content. These lesions typically express high levels of proteolytic factors (MMP9 and MMP2) and 
pro-atherogenic cytokines (!L6,!L8), and show increased plaque thrombogen·1city. HO-1 expression 
level correlated closely with the extend of these vulnerable plaque characteristics. Further on, in 
a well-validated murine vulnerable plaque model, HO-1 expression prevented vulnerable plaques 
formation and lead to the development of lesions with a more stable phenotype: HO-1 induction 
diminished the necrotic core and increased fibrous cap thickness, without affecting lesion size, 
whereas H0-1 induction reduced lipid and increased VSMCs accumulation in the intima. 
H0-1 was designated as a protein involved in heme protein degradation, but more recently 
was suggested to play a more versatile role, as the heme catabolic products were shown to be 
cytoprotective. H0-1 has been associated with early atherogenesis by previous clinical studies. 
Kaneda and coworkers showed in a study with 554 patients that short (GT)(n) repeats in the H0-1 
gene promoter with elevated H0-1 expression was predictive of a positive outcome in coronary 
atherosclerotic disease (CAD) progression, on angiographic follow-up [25]. Likewise, the ability of 
blood-derived mononuclear cells to express HO-1 correlated with short (GT)n promoter repeats, 
suggested that high HO-1 expression levels protects against the initiation of atherosclerosis [26]. 
Previously, increased H0-1 expression was also detected in advanced atherosclerotic lesions [7, 
27]. However, data regarding the genetic regulation of advanced atherosclerotic lesions and the 
progression into vulnerable plaque are Jacking. 
In the current study, we soug htto define the role of HO-1 in the genetic regulation ofvu lnera b le plaque 
formation. Intra-plaque H0-1 expression in CAD patients was correlated with plaquevulnerabi!ity,as 
assessed by intimal distribution of destabilizing components (lipids and macrophagesLand plaque 
stabilizing components (VSMCs and collagen). These observations are corroborated by correlations 
with pro-atherogenic cytokines IL6 and IL8, and with the matrix metallo-proteases MMP9 and 
MMP2, previously shown to be involved in collagen breakdown that weakens the atherosclerotic 
cap and add to the vulnerability of the advanced atherosclerotic lesion. 
Increased HO-llevels in lesions with an atheromatous/vulnerable plaque phenotype suggested that 
H0-1 could be upregulated to modulate plaque morphology and stability. In line with this finding, 
H0-1 was expressed in endothelial cells (ECs) overlying advanced atherosclerotic lesions, whereas 
ECs derived from early lesions did not express H0-1 in a small group of patients [28]. Immuno-
histological analysis of these human atherosclerotic lesions by others and in the current study 
showed that H0-1 was mainly expressed by the macrophages/foam cells residing or infiltrating in 
the neointima. 
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In addition, atherosclerotic vulnerable lesions are characterized by an increase in frequency and 
extend of intraplaque haemorrhages, due to intimal neovascularization, increased permeability of 
the vasa vasorum,orextravasation of hemoglobin due to small ruptures. Clearance and degradation 
of haemoglobin by infiltrated (0163+ macrophages again induces H0-1 expression. Schaer and 
coworkers described colocalization of H0-1 and macrophages that express the hemoglobin 
scavenger receptor, CD163, in human atherosclerotic lesions. In vitro, H0-1 expression indeed was 
induced by CD163 internalization after haemoglobin binding in macrophages [27]. !n the current 
analysis of human carotid vulnerable plaque, HOH 1 was speci1ically upregulated in vulnerable 
lesions with the highestthrombogenecity,suggesting that intimal haemorrhages indeed stimulate 
H0-1 expression in this type of lesions, presumably as a compensatory mechanism. 
The induction ofH0-1 that occurs in the vulnerable plaque strongly suggests a role for this enzyme 
in the regulation of plaque destabilization and stabilization. To study the role of H0-1 in the 
progression of plaque destabilization, a murine model for vulnerable plaque was used. This model 
permits the comparison of stable versus vulnerable plaque in a single ApoE-/- mouse. Endogenous 
H0-1 expression was indeed increased in the vulnerable plaque region, as compared to the 
downstream stable plaque region in this animal model. Previously it was shown that adenoviral 
gene transfer of H0-1 inhibites initiation of atherogenesis, as suggested by a reduction in intimal 
size of lesions located in the aortic root and aortic arch in ApoE -/-mice [29]. Induction of H0-1 by 
hemin injections also decreased the lesion size in LDL-receptor-/- mice, whereas H0-1 inhibition by 
Sn-protoporhyrin IX promoted only lesion development as compared to the saline-treated control 
animals (8].1n H0-1/ApoE double knockout mice, accelerated atherosclerotic lesion formation was 
observed, whereas the ApoE knockout control mice developed lesions with the characteristics of 
a fatty streak after 8 weeks of Western diet. However, the role of H0-1 in the molecular regulation 
of plaque progression into an advanced complex lesion with plaque vulnerability remains poorly 
understood. 
The function of H0-1 in the progression of early atherosclerotic lesions into advanced vulnerable 
plaques was therefore investigated in an established vulnerable plaque model developed in the 
mouse using a shear stress modifying device placed around the carotid arteries of ApoE knockout 
mice [30]. Cast placement has been shown to induce low shear stress proximal, and oscillatory 
shear stress, distal to the device [30], which w·ilr induce atherosclerotic les·1ons that are h·lstologically 
reminiscent to human vulnerable plaques in the proximal region, and stable plaques distal to the 
cast [23, 24]. H0-1 induction by CoPPIX injections was initiated at 6 weeks after cast placement. 
Previous studies have indicated that at this timepoint, in the proximal segments, lesions are already 
developed with an advanced phenotype with VSMCs in1iltration and cap-formation, although 
a necrotic core is still absent. Although late H0-1 induction had no effect on lesion size, further 
progression of the vulnerable plaque phenotype was prevented in the H0-1 expression group, 
indicated by a decrease in the necrotic content by49o/o,and reduced lipid deposition by40o/o in the 
vulnerable lesions compared to control. !n line with this 'finding, H0-1 de1iciency was associated 
with increased oxLDL uptake by macrophages, and lipid accumulation in foam cells in vitro [31]. 
Accumulation and apoptosis of foam cells in the atherosclerotic lesion leads to extracellular lipid 
deposition and the formation of the necrotic core characteristic of a vulnerable plaque. The observed 
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decrease in intimal lipids in response to HO~ 1 expression could have aided in plaque stabilization 
by limiting the necrotic core area. In addition, H0-1 expression was associated with a significant 
increase in the percentage of intimal VSMCs, and the relative cap thickness of a more stabilized 
atherosclerotic lesion. H0-1 expression might prevent cap thickening by inhibition of VSMC 
proliferation.H0-1 expression inhibited progression of wire or balloon injury induced restenosis by 
VSMC cell-cycle arrest via its catabolic end-products [32,33].However, Yet and coworkers showed in 
an autologous vein graft transplantation model that neointimal VSMCs in H0-1 -/-vein grafts were 
severely reduced by increased VSMC death as detected by a TUNEL assay [15]. In addition, H0-1 
deletion significantly decreased viability ofVSMCs following oxidative stress stimulation in vitro and 
in vivo associated with hemodynamic pressure in the vein graft model [15]. Taken together, these 
data support the idea that H0-1 expression may protect VSMCs from oxidative stress-induced cell 
death. Due to the distinct morphology of the vulnerable plaque, the VSMC rich fibrous cap is indeed 
exposed to high vascular strain and apoptosis during the cardiac cycle. This renders the lesion 
prone to rupture by sheer mechanical force [1], but also weakens the cap by inducing apoptos'1s 
in the residing VSMCs. In our study, intimal VSMC accumulation was significantly preserved in 
the arteries with H0-1 induction. This finding suggested that H0-1 prolongs VSMC survival in the 
fibrous cap and in the neointima by protecting the cells against oxidative stress damage, surpassing 
the cytostatic effect of H0-1. 
In conclusion, the current study provides first evidence that H0-1 expression defines progression of 
an advanced atherosclerotic lesion into a vulnerable plaque, both in human carotid atherosclerotic 
lesions (in 112 patients) and in a hyperlipidaemic vulnerable plaque mouse modei.H0-1 expression 
in vulnerable plaques is enhanced as a compensatory atheroprotective response, in which 
H0-1 prevents plaque instability by ·Impeding lipid deposition and necrotic core groiNth, and by 
prolonging VSMCs survival in the fibrous cap. Genetic or pharmaceutical enhancement of H0-1 
levels could protect this type of lesion from rupture, thereby reducing the risks on subsequent 
acute coronary events. 
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ABSTRACT 
Heme oxygenase-1 (Hmox1) is an important modulator of physiological function with vascular 
cytoprotective properties. Here we show that Hmoxl also plays a crucial role in the molecular 
regulation of the dendritic cell {00 function that governs the alloimmune response leading to 
the development of transplantation associated vasculopathy. 
SiRNA Hmox1~knockdown and Hmox1~knockout DCs showed increased expression of MHC 
class II in culture. MHC class II upregulation was induced by STAT1 phosphorylation with 
subsequent CIITA-driven activation of MHC II genes transcription. As a result, increased MHC 
class II expression and alloantigen presentation by Hmox1-/- DCs directed the primary T-cell 
response preferentially towards a CD4+ T-cell, rather than a CDS+ T-cell response. In a murine 
model for transplantation atherosclerosis, presentisization by transfer of alloantigen-primed 
recipient syngeneic DCs accelerated development of allograft vasculopathy. More importantly, 
adoptive transfer of Hmox1-/- DCs prior to allograft transplantation was indeed associated 
with pronounced CD4+ T-cell accumulation, with attenuated CDS+ T-cell and macrophage 
infiltration, compared to wildtype DCs pretreated recipients, which is suggestive of an 
advanced chronic phase in vasculopathy, whereas animals presensitized with wildtype DCs 
showed an early phenotype phase. Hence, deletion of Hmox1 in DCs promoted the alloimmune 
response delegated by dendritic cells and resulted in an aggravated development of transplant 
atherogenesis, by increased intima hyperplasia and medial thickening in the arterial allograft. 
These findings imply that HQ-1 plays an important role in the genetic regulation of the vascular 
ailoimmune response elicited by DCs. 
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INTRODUCTION 
Transplant atherosclerosis subsequent to transplantation continues to impede long-term allograft 
survival [1]. Transplant atherosclerosis is thought to be initiated by alloimmune-mediated injury 
to graft endothelial cells lining the vascular bed as a response to ischemia/reperfusion injury 
concominant to the transplantation procedure which induces the generation of reactive oxygen 
species. This subsequently leads to Toll-Like Receptor (TLR)-mediated maturation of resident 
dendritic cells (DCs), as well as infiltration of recipient-derived DCs into the graft. Alloantigen 
presentation by these mature DCs initiates the development of an alloantigen-specific adaptive 
immune response against the allograft [1], resulting in endothelial cell activation, and dysfunction, 
and perivascular infiltration of lymphocytes.lntimal vascular smooth muscle cells respond through 
activation, consequent migration into the intima of the vessel, and cell proliferation, which results in 
progressive intimal hyperplasia with impediment of allograft perfusion, and eventual graft failure. 
Although involvement of DCs in allograft rejection is presumed, the direct function of DCs in the 
pathogenesis of transplantation atherosclerosis still remains to be elucidated. 
Allograft vasculopathy in humans, as well as in rodent experimental models, is associated with 
expression of a series of cytoprotective genes in the graft including the ll 10 and the anti-apoptotic 
gene A20,as well as Heme oxygenase-1 [2,3].The latter has previously been associated with increased 
recipient adaptation to the graft and improved survival of the vascular allograft in rat models in 
response to induction of heme oxygenase-1 by cobalt-protoporphyrin [3, 4]. Heme oxygenase-1 
is a stress-inducible enzyme that degrades heme proteins into free iron, carbon monoxide (CO), 
and biliverdin, which is then rapidly converted into bilirubin. These catabolic end products exert 
anti-oxidant, and potentially anti-apoptotic properties, rendering the overall function of Hmoxl 
to be cytoprotective. Indeed, H0-1 upregulation by induction or transgenic expression has been 
shown to protect allografts from oxidative stress mediated-ischemia/reperfusion injury [5-7], to 
reduce restenosis after arterial injury [8], and to attenuate development of atherosclerotic lesions 
in LDL-receptor-deficient mice [9]. Conversely, loss of Hmoxl aggravated atherogenesis in ApoE-
KO mice, and augmented vein graft stenosis [1 0], which were attributed to the anti-proliferative 
properties of H0-1 and its metabolites. The enzyme and its catalytic products may also exert 
vascular protection by virtue of its immune-modulating actions. Hmox1 overexpression and CO, as 
its downstream effector, reduced the response of macrophages to LPS,shifting cytokine production 
from pro-inflammatoryTNF-a, towards the anti-inflammatory cytokine, ll-1 0 [11], whereas Hmox1-
deletion enhanced the pro-inflammatory response in atherosclerosis by stimulating MCP1 and IL-6 
production in macrophages [12]. 
Considering the anti-oxidative and anti-apoptotic properties of H0-1 observed in vascular 
disease and allograft protection, and the potential role of DCs in allograft rejection, we sought 
to define the role of HO-1 in the genetic regulation of the alloimmune response directed by DCs 
in transplantation atherosclerosis. The current study demonstrates that H0-1 in DCs, beside its 
catabolic and anti-oxidative properties, may also function as a regulator of the alloimmune response 
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targeted against the vascular grafts. Here, we found that Hmoxl deletion in DCs accelerated 
transplantation atherosclerosis by eliciting an alloimmune CD4+ T-cell driven response against the 
allograft, eventually leading to allograft failure. This process is mediated through induction of MHC 
class II expression by MHC class II transactivator (CIITA)-driven transcriptional initiation, which was 
associated with increased STAT1 phosphorylation. Taken together, these data indicate that Hmoxl 
plays a crucial role in DC activation of the CD4+ T cell alloimmune response during development of 
transplantation atherosclerosis. 
0 
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MATERIALS AND METHODS 
Dendritic cell culture 
Bone marrow was isolated by crushing femur bones from 12~week old, wild type or Hmox1~/­
C57BU6 mice. Myeloid dendritic cells {mDC) were subsequently cultured according to the Lutz 
protocol(13) in RPM I medium (Cambrex, The Netherlands) containing 10% FBS, gentamycin and 
-mercaptoethanol after stimulation with GMCSF for 9 days (10ng/mi).At day 9, mDC cultures were 
pulsed for 24 hours with allogeneic splenocyte lysate der"1ved from BALB/c mice in a ratio of 1:10. 
Lysates were obtained by 5 repetitive freeze-thaw cycles of homogenized spleen tissue. After 24 
hours, mDC were collected and washed three times in fresh RPM! medium. 
Mixed lymphocyte response assay and flow cytometry analysis 
In the mixed lymphocyte response assay (MLR), na'ive T-cells obtained from C57BU6 spleens were 
co-cultured with mDCs, previously stimulated with alloantigens. The number of CDS+ T-cells and 
CD4+ T-cells were assessed at day 4 (MLR4) and day 7 (MLR?).Cell suspensions were stained for cell 
surface markers (0,2 IJ9 antibody/300.000 cells) and were analyzed by flow cytometry (FACSCanto, 
BD Bioscience, USA). Fluorescence-labeled antibodies directed against CD8,CD4,MHC class li,CD80, 
CD40, CD86 and CD11 c antibodies were all obtained from eBioscience (San Diego,CA, USA). 
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RNA and protein expression analysis 
CIITA expression in cultured mDCs was assessed by quantitative PCR (QPCR). Total RNA was 
isolated using the RNAeasy kit (Qiagen, Germany) and reverse transcribed into eDNA using random 
hexamers.QPCR reactions were performed using cybergreen incorporation and real time detection 
in the iCyder iQ Detection system (Biorad,The Netherlands).Target gene mRNA levels were assessed 
relative to the housekeeping gene hypoxanthine guanine phosphoribosyl transferase (HPRT). 
Statistical analysis was performed by use of Student's t-test analysis. Data are presented as mean 
±SEM unless stated otherwise. (14)P values <0,05 were considered statistically significant. 
Western blot analysis was performed using antibodies against STAT1 and phosphoTyr701 STAT1 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), and anti rabbit-lgG or goat-JgG antibodies (JRdye 
680 CW, fRdye 800 CW, Licor Bioscience, USA) using an Odyssey infrared imaging system (Ucor 
Bioscience, USA). 
siRNA knockdown of Hmoxl in bone marrow derived mDCs 
Selective silencing of Hmox1 was achieved bytransfection of C57BU6 bone marrow derived mDCs 
at day 7 of the Lutz protocol [1 3]. Transfection was carried out in Dharmafect transfection agent, 
using a pool of 4 different HO-1 mRNA targeting siRNAs, whereas control cultures weretransfected 
with a pool of4 different scrambled siRNAs,according to the protocol provided by the manufacturer 
(Dharmacon, USA). For silencing of CIITA, a similar combination of 4 CIITA mRNA targeting siRNA 
sequences was used (Dharmacon, USA) 
Mouse vascular allograft model 
All animal experiments were performed according to protocols approved by the national and local 
committees for use and care of laboratory animals. 
For a schematicoverviewoftheexperimental setup,seefigure 1.Ten days before arterial allografting, 
12-week old C57BU6 mice were injected intraperitoneally with either saline (n=6, group 1), or 
2x1 06 C57BU6-derived, wild type (n=6, group 2) or Hmox1-/- mDC (n=6, group 3) (figure 1c). The 
mDCs cultured from (57BU6 bone marrow (figure 1 a) were presensitized with BALB/c alloantigens 
derived from freeze-thawed, BALB/c spleen lysate (in a ratio of 1:10, between DCs and spleen cells) 
at day 9,24 hours prior to ·mjection (figure 1 b). 
Aortic allograft transplantation of 12-week old BALB/c mice into the right carotid artery position 
of age-matched C57BU6 mice, was performed as described previously [1 5]. Briefly, isoflurane-
anesthetized, C57BU6 mice were intubated and the right common carotid artery was ligated 
and cut. The proximal and distal portions of the carotid artery were passed through nylon cuffs 
(Portex ltd. Smiths medical international, UK) and fixed using aneurysm clips (Yasargil gold, B-braun 
medical, The Netherlands). The extending carotid artery segment was inverted over the cuff 
followed by ligation. The arterial segments derived from BALB/c donor mice were implanted by 
placing the arterial segment over the cuff followed by ligation with sutures (figure 1 d). At 14 days 
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post transplantation, mice were sacrificed and perfused with 0,9% saline via a cardiac puncture. 
Vascular grafts were embedded in OTC med'1um (Sakura,The Netherlands), frozen in liquid nitrogen 
and subsequently processed for immunohistological analysis. 
lmmuno~histological and morphometric analysis 
Contineous serial sections (6 j.Jm) were cut with a cryotome from one cuff end to the other. 
Cryosections were stained for every 51h section with Hematoxilin/Eosin (HE) in order to gain an 
avera!! histological overview. Evaluation started in each graft, SO 1-1m after one cuff end, towards 80 
1-Jm before the opposite cuff end. For quantification of cellular infiltration in the media, the media 
was divided into two areas; the luminal side of the media was defined as the area confined by 
the three inner medial elastic lamina adjacent to the neointima. The adventitial side of the media 
was defined as the area confined to the outer medial elastic laminae adjacent to the adventitia. 
For immuno-histological evaluation, every 1 Qth cross-sections was stained for immuno-histological 
analysis. Sections were analyzed by (confocal) microscopy using primary antibodies against !L -6 
(done 20F3, Genzyme, USA; 1:1 00), CDS, (YTS1 69, B'1oceros, USA; 1:1 SO), CD1 1 c (APC conjugated, 
Ebioscience, USA; 1 :50) CD4 (Ebiosciences,USA; 1:1 OO),and a-actin antibody {Cy3-conjugated;Sigma, 
The Netherlands; 1 :200) followed by DAP-PO or AEC incubation according to the manufacturer's 
protocol. Apotosis was analyzed using a TUNEL assay (Roche Diagnostics, The Netherlands). Blind 
data analysis was performed, using a commercial, quantitative image analysis system and an 
adjusted color threshold routine {Ciemex Vision Image Analysis System, Clemex Technologies). 
Areas of specific cell staining were expressed as the percentage of medial or intimal surface area. 
Statistical analysis was performed by Student's t-test analysis. Data are presented as mean ±SEM. P 
values <0,05 were considered statistically significant. 
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RESULTS 
Pretreatment with alloantigen stimulated mDCs accelerates transplant 
atherosclerosis in the vascular allograft. 
In order to asses the effect of Hmoxl expression specifically in mDCs in adoptive transfer in allograft 
vasculopathy, three groups of C57BU6 mice received aortic allografts from BALB/c donor mice 
(N=6 in all groups). The first group of age-matched control animals underwent vascular allograft 
transplantation without any prior treatment. In the two other groups, C578U6 recipient mice 
received an intraperitoneal injection of bone~marrow derived mDCs cultivated from Hmoxl +/+or 
Hmoxl-/- C578U6 mice, 10 days prior to allograft transplantation. These mDCs were pulsed with 
BALB/c mice-derived spleen lysate (alloantigen) and LPS prior to adoptive transfer into the C57BU6 
recipients (See figure 1 for overview of the protocol). 
Treatment with mDC cells prior to implantation of the vascular graft led to a pronounced increase 
of transplant atherosclerosis by 915,4% at day 14 post transplantation, as compared to control mice 
that received PBS injections (Intima area; 38428 ± 265461Jm2 versus 4198 ± 2963 1Jm2 respectively, 
P<0,05; figure 2b). Presensitization of BALB/c alloantigen stimulated mDCs therefore appears to 
accelerate the alloimmune response and substantiates the involvement of mDCs in the initiation of 
allotransplant-associated atherosclerosis. 
Deletion of Hmoxl in mDCs significantly promotes the development of trans-
plantation atherosclerosis in vascular allografts following adaptive transfer. 
loss of Hmox1 in al!oantigen-stimulated DCs used for adoptive transfer prior to allografting 
increased transplant atherosclerosis function by 2686,9%,as compared to control animals (116995 
± 27041Jm2 versus 4198 ± 2963 1Jm2. respectively, P<0,05;figure 2b). 
Pretreatment with Hmoxl-/- mDC significantly stimulated neointimal hyperplasia in vascular 
allografts, as compared to pretreatment with wild type mDC by 204,7% (116995 ± 27041Jm2 versus 
38428 ± 26546 )..lm2 respectively, P<0,05; figure 2b). The upper panel shows representative cross-
sections of the allografts derived from the various groups (figure 2a). 
Loss of Hmox1 in mDCs used for presensitization prior to allografting 
facilitates vascular infiltration-
The medial surface area of grafts in mice pretreated with Hmoxl-/- mDC was increased by 32,4%, 
as compared to WT mDC-pretreated recipients (15936 ± 1060 J..lm2 versus 12034 ± 698 1Jm2, P<0,05; 
figure 3a).Furthermore, the grafts in Hmoxl-/- mDC-treated recipients contained 66,1% !essVSMCs, 
as compared to the wild type mDC-pretreated group (46,0 ± 11,1% versus 76,4 ± 5,3% of total graft 
area, P<0,05;figure 3b and c). Therefore the observed increase in medial thickness did not appear to 
be associated with increased VSMCs proliferation, but could potentially be explained by pronounced 
vascular graft infiltration from the luminal or adventitial sides. Administration of Hmoxl-/- mDC 
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Figure 1 Flow cytometr; analysis of mDC maturation markers. Hmoxl deletion did not affect dendritic 
cell maturation. Expression of CD40, COSO, and CD86 dendritic cell maturation markers 'Nere present on 
unstimulated (blanco) cultured dendritic cells, and were increased in response to alloantigen stimulation 
(LPSIBALB/c spleen lysate) as shown by flow cyrometry analysis. However, no difference was observed in 
the expression of these maturation markers between the Hmox1-deficient and WT mDCs. Red histographs 
represent the isorypic control, green histographs represent the Hmoxi-silenced mDCs and blue represent the 
mDCs treated ·,.rith scrambled siRNA. 
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Figure 1 Schematic overview of the experimental allograft model. (A) Dendritic cells were cultured 
from bone marrO'II derived from Hmoxl ~1~ and INT C578U6 mice. (B) Dendritic cells were presensitized with 
al/oantigen derived from BALB/c spleen lysate. (C) The presensitized VVT (Hmoxl +I+) or Hmoxl-defkient 
(Hmox I -I-) DCs were injected introperitoneaf/y in C57BU6 mice, 1 Odays before aortic allograft transplantation. 
(0} Aortic allografts derived from BALB/c mice were transplanted into the right carotid artery position of these 
pretreated C57BU6 recipients. Mice were sacrificed 14 days post transplantation, and the allografts were 
harvested for immunohistological analysis. Three groups vrere included in the study:(!) The control group 
without adoptive transfer of dendritic cells. (II) A second group received adoptive transfer of ol/oantigen 
stimulated C51BU6 mDCs at day -10 prior to aortic allograft transplantation from BALB/c mice. (Ill) A third 
group received adoptive transfer of Hmox1-deficient C57BU6 mDCs at day -10, prior to implantation of the 
aortic allograft. 
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Figure 2 Histological analysis of arterial allografts at day 14 after transplantation. Representative images 
from regions in the middle section ofthegraftore shown. (A) Images of control (no additional treatment), and 
Hmoxl+l+ mDC or Hmoxl-/~ mDC presensitized recipients are shown. (8) The bar-graph shows the mean 
surface area of the neointima, as measured by computer-assisted image analysis of the intimal and medial 
surface area of the grafts. (data shown in JJm 2, # P<0.05 Hmoxl-1- versus Hmoxl +I+ mDC-treated group. 
~P<0,05 Hmox1+1+ mDC and Hmoxl -/- mDC-treared group versus the control group as defined by the 
Student's t-tests, mean± sem.) 
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Figure 3 (A) Mean medial surface area in allografts. Cross-sections ·vvere analyzed throughout the allografts 
at equal distance of both cuffed ends by confocal microscopy after staining with -actin-Cy3. Media/surface 
area v•tas defined as the difference in total surface area between the inner and outer lamina elastica in J..lm 2• 
(B) Percentage of medial VSMC content per j..lm 2 medial surface area. (~P<0,05 Hmoxl-1- versus Hmoxl +I+ 
mDC-treated, mean ± sem.) (C) Representative confocal images of allografts from Hmoxl +li- and Hmoxl 
-/- mDC-pretreated recipients (magnit7cation: 100X). 
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indeed resulted in accumulation of cells at the luminal side of the media by 98,7% (461 ±58 cells 
versus 232 ± 81 cells,Hmox1-/- mDCs versus WT mDCs pretreated group respectively,P<O,OS,figure 
4a).Since a difference in total medial surface area between both groups was observed, the number 
of infiltrating cells on the luminal side was corrected for differences in surface area in this particular 
region, by calculating the number of cells per f.Jm 2 medial surface area. A trend towards an increase 
in the number of cells per ]..lm 2 medial surface area by 51,2% was observed (1 9,5 ± 1,5 cells/ 1Jm2 for 
the Hmox1+ mDC versus 12,9 ± 4,0 ce!ls/1Jm2 in the WT mDC pretreated group, P=O,OS, figure 4b). 
In contrast, at the adventitial side of the media, the absolute number of infiltrating cells and relative 
cell accumulaf1on d.1d not differ between groups (489 ± 74 cells in Hmoxl-/- mDC versus 514 ± 144 
cells in the WT mDC group, P=0,44, and percentage of infiltrating cells; 20,8 ± 3,9 cells/ 1Jm2 in the 
Hmoxl-/- mDC versus 20,9 ± 5,2 cells/ 1Jm2 in the WT mDC-pretreated group, respectively). Figure4c 
depicts examples of HE-stained cross-sections of arterial allografts derived from the WT mDC and the 
Hmox1-/- mDC-pretreated group,2 weeks after allograft transplantation. Perivascular infiltration of 
blood-derived cells is characteristic of the early vascular allograft response and precedes neotimal 
formation [15]. In both groups, accumulation of infiltrating cells at the luminal side of the media 
was mostly observed in the areas with no or limited nee-intima formation (Indicated ·m the figure 
by black arrows). 
Hmox1 deletion in mDCs used for adoptive transfer prior to allografting is 
associated with pronounced CD4+ T-cell infiltration and lgG accumulation, 
whereas CDS+ T -cell and CD68+ macrophage infiltration is attenuated. 
In both WT and Hmoxl-/- mDC-treated mice, mDCs were detected in the vascular allografts. No 
significant differences between mDC accumulation were detected in the groups (2,3 ± 0,3% versus 
1,9 ± 0,7%, in the Hmox1-/- mDC versus WT mDC-treated group, respectively). However, treatment 
with Hmoxl-/- mDC prior to the transplantation procedure was associated with extensive CD4+ 
T-cell infiltration in the intima, media and the adventitia of the allograft by 4650% (9,5 ± 4,5% in the 
Hmoxl-/- mDC-pretreated group versus 0,2 ± 0,1% in the WT mDC-pretreated group, P<O,OS;figure 
Sa}. This specific CD4+ T -cell infiltration was accompanied by a decrease in CDS+ T-cell infiltration 
of 76,5% (8,1 ± 1,0% versus 14,3 ± 1,6% in the Hmoxl-/- mDC versus WT mDC-pretreated group, 
P<O,OS;figure Sb). 
However, Hmox1 deletion in mDC did change locai!L-61evels (17756 ± 12647 f.lm2 versus 11854 ± 
4824 ]..Jm2 surface of !L-6+ staining area in Hmoxl-/- mDC versus WT mDC-treated mice, P=0,34; 5,2 
± 2,4% versus 2,3 ± 0,7% Hmoxl-/- mDC versus WT mDC-pretreated mice, P=0,26). A TUNEL assay 
indicated that the CDS+ T-cell response in the allograft was not associated with increased apoptosis 
of graft ECs and VSMCs. Apoptosis was rarely detected in vascular allografts (figure 6), whereas no 
difference was observed between the WT and Hmoxl-/- mDC-pretreated m·1ce. 
The acute phase of the vascular alloimmune response is characterized by infiltration of CD68+ 
macrophagesand CDS+ T cells into the allograft, as early as 2 weeks post transplantation. In contrast, 
the chronic phase of the alloimmune response is defined by lgG deposition, and perivascular CD4+ 
T cell infiltration [15]. Concomitant to the significant CD4+ T cell accumulation, Hmox1 deletion in 
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Figure 4 Number of cells inf71trating the media. (A) The number of inf7/trating cells into the luminal side of 
the media 'NOS increased. (~P<O,OS Hmoxl·l· versus Hmoxl +I+ mDC·treated, mean ± sem.) (B) Number of 
inf71trating cells per f..im 2 medial surface area at the luminal side (P<O,OB: Hmoxl·l· versus Hmoxl +I+ mDC-
treated group as def7ned by the Student's t·tests). (C) Representative sections of arterial allografts shovv ~elf 
inf7!tration at the luminal side of the media (magnif7cation: IOOX). 
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Figure 5 (A) CD4+ T-ee!! graft 
inf71tration (8) and CDS+ T ~ell 
int71trotion into the allograft. 
Number of CD4+ or CDS+ 
cells was corrected for the 
total allograft surface area 
(mm 2), and is presented as a 
percentage of total surface 
area. (C) Representative sections 
of arterial allografts obtained 
from !NT and Hmoxl·l- mDCs-
pretreated groups are shown 
(magnif7cation: IOOX ~· P<O,OS 
Hmox7·1· versus Hmox/+1+ 
mDC-treated group, Student's 
t-tests, mean±sem). 
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Figure 8 F!ovv cytometr; analysis of CDS-:- and CD4+ T-ee!! populations in alloontigen-primed mixed 
leukocyte reaction (MLR) cultures. (A) Knockdm•m of Hmoxl RNA expression by Hmox1-targeting siRNA 
decreased Hmoxl mRNA expression by 80% as compared to DCs transfected with non-targeting siRNA. (8) 
Flow cytometr; analysis of CDS+ T-ee/Is and CD4-':- T-ee/Is, and the CD4+/CD8+ T-ce/1 ratio in MLR cultures at 
4 (MLR4), and 7 days (MLR7) and4 days after restimulation with a!!oonrigen (R(4)) (C) In Hmoxl-silenced mDC 
MLR culrures, the %CDS.,.. T-ee/Is vvere decreased (Quarter 1 ), while the %(04+ T-ee !Is simultaneously increased 
after MLR restimulotion with o/loontigen (0uarter4). (0) This resulted in a significant increase in CD4+!CD8+ 
T-ee!/ ratio in Hmox7 silenced mDC co-culrures. (* P<O,OS scrambled versus Hmoxl-siRNA knockdovvn MLR, 
paired t-tests per culture, N=4, mean± sem.) 
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mDCs cultures, no difference in these maturation markers was observed betv.~een the two groups 
(see supplemental data). This indicated that Hmox1 knockdown did not interfere with mDC 
maturation in vitro in response to al!oantigen. 
However, ·m previous microarray analysis, Hmox1 deletion in DC cells was associated with a 
predominant increase in MHC class II expression (crucial for CD4+ T -cell priming), while MHC class 
I (crucial for CDS+ T-cell priming) remained unaffected (data not shown). SiRNA-mediated Hmox1 
silencing in cultured mDCs indeed upregulated MHC class II but not MHC class I expression levels, 
as verified by flow cytometry. In the CD11 c+ mDC subset, the percentage of MHC class II +cells 
was significantly increased following Hmoxl silencing either in non-stimulated, LPS-stimulated, 
or alloantigen-stimulated culture conditions (figure 9a and b).ln addition, the average MHC class 
II expression level in the CD11 c+/MHC class II+ population was significantly increased upon 
Hmoxl siRNA knockdown in mDCs, as indicated by the two-fold induction in the mean intensity of 
fluorescence (figure 9c).ln contrast, no effect was observed in MHC class I expression levels in the 
CD11 c+/MHC class ll+ Hmoxl silenced mDCs under all tested conditions (data not shown). 
MHC class I! transactivator (CIITA) is a co-transcription factor that is involved the regulation of 
MHC II expression in antigen presenting cells [1 6]. Knockdown of Hmoxl was associated with a 
significantly increase ofCIITA expression in non-stimulated, or alloantigen-stimulated mDCs (figure 
9d). CIITA gene expression is regulated by STATl, which is activated by phosphorylation atTyr701. 
SiRNA knockdown of Hmoxl led to STATl (Tyr701) phosphorylation, without affecting STAT1 total 
protein levels (figure 9e en f). Subsequent siRNA-mediated silencing of the CI!TA expression upon 
Hmox1 knockdown rescued the MHC class II upregulation, suggesting that loss of H0-1 induced 
MHC class II cell surface expression via CIITA transcriptional regulation (figure 9g-i). 
Taken together, these data indicate that Hmoxl silencing in mDCs promotes STAT1 Tyr?Ol 
phosphorylation, and subsequent gene expression of the co-transcription factor CIITA, thereby 
increasing the level of MHC class !I on mDCs. Increased expression of MHC class II in Hmox1 
knockdown mDCs facilitated the preferential priming of CD4+ T~cells (as opposed to CDS+ T~cells), 
thereby acce!erat'1ng transplantation atherosclerosis formation. 
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Figure 9 (A) MHC class II levels on mOCs cultured in non~stimulated, LPS-stimulated and a/loantigen-
stimulated conditions, and analyzed by flow cyrometry. Red depicts the isorypic control, while blue depicts 
the MHC class II signal. (8) Hmox1-silencing increased the percentage of MHC class II+ cells in the COlle+ 
mDC population (C) and augmented the mean intensity of fluoresence (MIF) of the CD11c+/MHC class II+ 
cells, in all three different conditions compared to non-targeting-siRNA tronsfected mDCs. (0) C!ITA mRNA 
expression levels in mDCs cultured in non-stimulated, LPS-stimu!ated, and a!!oantigen/LPS-stimuloted 
conditions, analyzed by QPCR. Hmoxl deletion augmented the expression levels ofCIITA in mDCs in all three 
conditions. (E) Western blot analysis shows increased phosphorylated (Tyr701)-5TATI protein levels in Hmoxl 
knockdown mDCs, (F) whereas no difference in total STAT/ protein levels was observed. Right panel shovvs 
western blot analysis of phospho(Tyr701)-STATi, total STAT/, and i3 actin loading control. (G) MHC class II 
levels on alloanrigen-activated mDCs, analyzed by fiowcytometry.Red depicts the isotypic control, while blue 
depicts the MHC class II signal. (H) Hmox1-silencing increased the percentage of MHC class II+ cells in the 
mDC population. This effect was rescued by subsequent knockdown ofC!ITA. (!) Hmoxl-silencing augmented 
the MIF of the CD11c+IMHC class II+ population, v1hereas transfection with Hmoxi/C/!TA targeting siRNA 
down regulated the average cell surface expression ofMHC class II on mDCs, as indicated by a decrease in MIF. 
(* P<O,OS Hmoxl siRNA knockdown mDCs versus scrambled-siRNA treated (control) mDCs, f P<O,OS Hmoxl/ 
CI!TA knockdown mDCs versus Hmoxl siRNA knockdown mDCs,paired t-tests per culture, N=4, mean± sem.) 
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Figure 10 Proposed mechanism by 'Nhich Hmoxl deletion in mDCs promotes the C04+ T-cel/ response. (A) 
Hmox1 deletion in mDCs promotes phosphorylation ofSTATI.Activation ofSTATI induces CI!TA upregu/otion, 
which functions as a co-transcription foetor dnVing the expression of MHC class II genes in the mDCs. (8) 
Increased MHC class II eel/surface availability on Hmoxl -1- mDCs induces preferential CD4+ T-ee/! activation. 
(C) Increase in CD4+ T-ee!/ proliferation shifts the al/oimmune response towards a (04-;- T-ee// mediated 
reaction, and promotes neointimal hyperplasia in transplantation atherosclerosis 'l'lith a phenotype consistent 
'Nith the chronic phose ofo!!oimmune response. 
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DISCUSSION 
We were able to show that: (!) Previous adoptive transfer of alloantigen-presensitized myeloid 
dendritic cells accelerates transplantation atherosclerosis. (II) Loss of Hmox1 function induces 
STAT1 phosphorylation and subsequent CJITA expression, which leads to a rise in MHC class II in DCs 
without modulation in MHCclass I expression.(lll) Hmox1 deletion in mDCs is associated with a MHC 
class 11-mediated, preferential CD4+ T-cell alloimmune response in DOT-cell co-cultures (VI) loss 
of Hmoxl ·m DCs in vivo promotes transplant associated vasculopathy with increased perivascular 
infiltration of CD4+ T -cell and lgG deposition, suggestive of a chronic phase in the disease. (V) As a 
result, alloreactive Hmox1 -/- mDCs stimulates increased intimal hyperplasia formation in vascular 
allografts compared to WT mDCs-pretreatment. Taken together, these data indicate that mDCs 
play a key regulatory role in the initiation and progression of transplantation atherosclerosis, and 
provide evidence that Hmox1 is an important genetic regulator of dendritic cell function. 
Progressive transplant atherosclerosis is the leading cause of late graft fa i I u rein he a rttra nspla ntati on, 
responsible for 23% to 36% of deaths among patients that survive > 1 year after surgery (17), 
whereas substantial clinical manifestations of transplant atherosclerosis is observed in 50% of heart 
transplant recipients within five years after transplantation [18, 19].The vascular lesion pattern is 
diffuse, and involves the entire vascular bed of the transplanted organ, which limits the options for 
further revascularization based on conventional surgical or percutaneous medical intervention. 
In the early phase of transplantation atherosclerosis, the endothelial layer is disrupted and activated 
by invading blood-cells, and loss of medial VSMCs is induced by the host-derived inflammatory 
reaction. In the sequence of events, intimal hyperplasia is observed predominantly in the late 
phase of the disease, with intimal inflammatory cell infiltration, followed by intimal VSMCs 
migration and proliferation [20]. In the rat abdominal aortic allograft model, arterial transplants 
show limited hyperplasia up to 2-3 weeks [20, 21]. Our results in the mouse transplantation model 
adapted from Dietrich eta! [15]. confirmed these findings, as transplantation of the BALB/c aortic 
allograft into na'lve recipients initially induced modest intimal lesions within the first 14 days post 
transplantation. The crucial event in the priming mechanism is the interaction between (al!o) 
antigen-presenting cells (APCs) and na'ive recipientT-cells, which results in the activation of various 
T-cell subsets and subsequent production of antibodies directed against the allograft (the allogenic 
humoral response). Pre-activatedT -cells and memory 8-cells that react specifically to donor-derived 
al!oantigens are responsible for accelerated graft rejection at the time of recurrent exposure (i.e. the 
transplantation). 
DCs are professional APCs, which have been suggested to initiate the allogenic humoral reaction 
directed against vascular al!ografts:AIIoantigen injection to prime autogenous DCs in rat recipients 
prior a I log rafting promoted intima I lesion size [20], and adoptive transfer of a I loantigen-presensitized 
DCs in rats with renal allografts induced hyper acute rejection, characterized by acute kidney failure 
and tissue damage of the grafts [22].1n contrast, inhibition of recipient DC function by Sanglifehrin 
A suppressed acute and chronic cardiac allograft rejection [23]. Our study provide supportive data 
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that mDCs play a crucial role in transplant atherosclerosis, as adoptive transfer of alloantigen-
primed mDCs severely accelerated the disease progression, and subsequently promoted lesion size 
in the mouse aortic allograft model. The data also suggest that Hmox1 is a key regulator of mDC 
function during the a!loimmune response in transplantation atherosclerosis. Deletion of Hmoxl 
in alloantigen-activated mDCs used for adoptive transfer further promoted lesion growth, as well 
as changed the phenotype of the transplant lesions compared to wi!dtype alloantigen-activated 
mDCs pretreated recipients. Progression oftransplantation atherosclerosis can generally be divided 
into an acute "cell~mediated phase" and a chronic"humoral response phase" [20]. The acute phase 
is characterized by activation and infiltration of predominantly macrophages and CDS+ T~cells into 
the media of the allograft, which contribute to the early assault of the graft ECs and VSMCs(24). 
Immunohistological evaluation of the lesions in the wi!dtype alloantigen~activated mDCs~ 
pretreated group depicted limited transplantation atherosclerosis with CDS+ T~cell infiltration and 
CD6S+ macrophage accumulation, reminiscent of an early cell~mediated alloimmune response. 
In contrast, Hmoxl deletion in alloantigen~activated DCs stimulated neointimal hyperplasia with 
predominant (04+ T-cell infiltration, with limited CDS+ T~cell and macrophages, consistent with 
a humoral chronic alloimmune response. This hypothesis is corroborated by the accumulation of 
lgG antibodies in the allografts of the Hmoxl-/~ mOC~treated group. Indeed, the chronic phase of 
transplant atherosclerosis is associated with lgG antibodies sequestered by the residing cells in the 
allograft before Cl complex formation and activation of the complement cascade [25]. Therefore, 
the general pathological phenotype of the lesions suggests that Hmoxl~deletion in alloantigen~ 
activated mDCs expedites progression of transplantation atherosclerosis towards the chronic, 
humoral response. 
During progression of allograft vascu!opathy, the medial area becomes devoid ofVSMCs [26] and 
infiltrated by inflammatory cells [15].1n alloreactive Hmoxl + mDC primed animals, a predominant 
luminal infiltration of the media was observed, while VSMC content of this segment was indeed 
decreased. Previously, it was postulated that VSMC cell death may be induced by antibody~ and 
comp!ement~dependent cytotoxicity directed towards medial cells, as deposition of lgG antibodies 
and complement were observed in the media of arterial allografts [20, 25], and administration 
of alloantibodies initiated cytoxicity of graft vascular cells in vitro [25, 27]. Consistent with these 
observations, in ourstudy,Hmoxl deletion in mDCsaggravated lgGaccumu!ation in the media of the 
allografts of the Hmox1 ~/~ mOC primed group and was associated with a decrease of medial VSMCs. 
However, apoptosis was not prevalent at 14 days post transplantation. Complement-dependent 
cytotoxity may sti!! play a role in graft VSMCs survival in a later phase in chronic vascu!opathy, 
as apoptotic VSMCs were predominantly identified as late as 2 months post-transplantation in 
unprimed recipients [20,25]. 
Hmox1 deletion did not impede DC maturation, as expression of maturation markers CD40, COSO, 
CD86 did not differ between wild type and Hmoxl knockout mDCs. Conform to our findings, CD40, 
COSO, CDS6 cell surface expression in (011 c+ DCs was unaffected by CoPPJX induction of Hmox1 
[28]. More importantly, the !eve! of MHC class II, but not class I, was increased on Hmoxl~deficient 
mDCs under basal and stimulated conditions. Preferential C04+ T~cell activation by Hmoxl~ 
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deficient mDCs in vitro and in vivo could therefore be the result of this constitutive induction 
of MHC class II. MHC class II transactivator (CIITA) regulates the expression of MHC II in APCs. 
Macrophages or dendritic cells derived from CIITA -/-mice were unable to induce MHC Jl J-A and 1-E 
expression (1 6), whereas Chora and co-workers found downregulation of MHC class Jl expression 
in COl 1 c+ DCs located in lymphoid tissues after Hmoxl induction in an EAE mouse model(28). 
Our results demonstrate that Hmoxl-targeting siRNA increased MHC class II expression in DCs by 
STAT1 phoshorylation, which is involved in the transcriptional regulation of CJITA expression. More 
importantly, subsequent silencing of CI!TA in Hmoxl-knockdown mDCs impeded Hmoxl silencing 
induced upregulation of MHC class II.This demonstrates that cell surface availability of MHC class II 
forCD4+ T-cell activation was affected by H0-1 levelsspecifical!yvia CJITA transcriptional regulation. 
The increase in CI!TA transcription by Hmoxl silencing could be mediated by CO, as CO stimulation 
of CD11 c+ DCs down regulated CJITA mRNA expression in response to JFN-y stimulation in vitro 
[28].These findings suggest that increase in MHC class II cell surface availability in Hmox1-defident 
mDCs is mediated by activation of the STATl/C!ITA pathway (figure 1 0). 
!n conclusion, we here demonstrate the central role of Hmoxl as a genetic regulator of mDC 
function and subsequent T-ceJJ priming in the alia-immune response associated with transplant 
atherosclerosis. Adoptive transfer of myeloid DCs accelerated the alia-immune response that 
amounted into an increase in neointimal hyperplasia. Hmox1 deletion in mDCs accelerated T-cell 
priming and progression into a CD4+ T eel! mediated response, giving rise to a more chronic 
phenotype of transplant atherosclerosis with CD4+ T-cell infiltration and JgG deposition, and 
attenuation of CDS+ T-cell and CD68+ macrophage accumulation. Dendritic cell function in the 
alloimmune response is regulated by Hmoxl via a P(tyr701 )-STAT1/CIITA/MHC II mediated pathway. 
Therefore, we speculate that Hmoxl could play a key role in the design of therapies to prolong 
allograft function, based on the potent alloimmunity modulating capacity of this enzyme. 
Study limitations 
lschemia/reperfusion injury of the allograft provides the initial trigger for pathogenesis oftransplantation 
vasculopathy, and could determine the phenotypical outcome of the lesion. Therefore, great care was 
taken during the procedure to keep the ischemic time to which each transplant was exposed constant 
(1 0 minutes) and to a bare minimum. 
Donor DCs residing in the allograft could have contributed to the observed alloimmune response via the 
direct pathway of alloantigen recognition (i.e. the direct interaction of recipientT-cells with complexes 
of intact allogenic MHC molecules bound to the surface of donor APCs) [1 ]. However, since the three 
different experimental groups rece'.ved the same type of aortic transplants derived from BALB/c mice, 
this process could not be accounted for the detected effects between the Hmox1-deficient mDC and 
the Hmox1 wildtype mDCs presensitized group. 
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ABSTRACT 
Heme oxygenase~1 (H0~1) has been shown to be a mediator in various immune responses, 
including the graft-versus~host alloresponse, in which H0-1 seems to play a protective role. 
Here, we report that H0-1 gene expression in dendritic cells {DC) is crucial in the induction of 
na"ive CD4+ T cells towards Th2 differentiation. Ovalbumin presentation by H0-1 null myeloid 
DCs (mDCs) to Ova Transgenic (OT2) (04+ T cells impeded the Th2 response, characterized by 
an attenuated production oftheTh2-specific cytokines, including IL4,1L5,1L 10,and IL 13,without 
affecting the production of typical Th1 cytokines, including INF~. This effect was independent 
of DC maturation, as expression levels of CD40, CD80, and CD86 remain unaffected. In a 
murine model for asthma, governed by a Th2 dominant response, adoptive transfer of pulsed 
HO~ 1 null mDCs failed to elicit the typical TH2 response in vivo as indicated by the absence 
of peribronchial and perivascular infiltration of eosinophilic inflammatory cells, diminished 
globlet cell hyperplasia, and a significant reduction in total cell number and eosinophils in the 
bronchoalveolar lavage fluid {BAL). T-cells harvested from mediastinal lymph nodes (MLNs) in 
this model showed an alike decrease in production ofTh2 associated cytokines, whereas the 
level of INF--y was not affected. Taken together, the current study suggests a novel function of 
H0-1 signaling in the genetic regulation of dendritic cell induced T-cell priming towards a Th2 
response. 
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INTRODUCTION 
H0-1 is the key enzyme in the degradation of hemoproteins. Degradation products of this 
catabolic reaction including ferritin, biliverdin and carbon monoxide {CO) have been shown to 
play a key role in cardiovascular signaling cascades. Three distinct HO-1 isozymes have thus far 
been identified; H0-1,-2 and -3. H0-1 is inducible by various inflammatory stimuli, as well as by 
oxidative stress. HO-1 -/-mice were shown to be susceptible to chronic inflammation, manifested 
by enlarged lymph nodes and spleen,leukocytosis,and heme depositions in the kidney and r1ver [1, 
2].1nterestingly,primary splenocytes derived from H0-1 -/-mice produce a Th1-associated cytokine 
profile following LPS stimulation, indicative of a possible correlation between H0-1 deficiency and 
alteredT cell function [2].Recent studies have also identified a role for H0-1 in allograft survival and 
organ transplantation associated vasculopathy, in which T cell activation plays a crucial role [3-5]. 
In an allograft model for transplantation atherosclerosis H0-1 deletion increased the capacity of 
myeloid dendritic cells to elicit a specific CD4+ T cell response. This CD4+ T-cell allograft response 
was mediated through induction of MHC class I! expression by MHC class I! transactivator (CIITA)-
driven transcription and could be rescued by C!ITA knockdown. Myeloid dendritic cells (mDCs) are 
potent professional antigen-presenting cells that direct the adaptive immune immunity in response 
to antigen stimulation. Dendritic cells are able to initiate the activation of naTve CD4+ T cells, and 
are able to directT-cell polarization into distinct lineages (e.g.Th1, Th2,Th17 and regulatoryT cells) 
[6].The mechanism by which mDCs initiate this lineage differentiation remains poorly understood. 
It has been implied that differential expression of co-stimulatory surface molecules could affect 
the polarization process. Costimulation via CD86, CD40, and OX40l favors the development of a 
Th2 response [7-1 O].ln addition, cytokine stimulation during naTve CD4+ T cell priming could also 
determine the CD4+ T cell polarization.Th1 induction via mDC depends largely on IL 12 stimulation, 
whereas IL4 and IL6 promotes a Th2 driven reaction [10-15]. However, the precise mechanisms 
of action of H0-1 in the regulation of DC function in CD4+ T cell polarization remains to be 
elucidated. 
In the current study, the effects of H0-1 on mDC function are further explored, to elicit a dominant 
CD4+ T cell response. Here, we were able to demonstrate in both H0-1 nullizygous and H0-1 
silenced mDCs that maturation of mDCs is largely independent of H0-1, as cell membrane 
expression levels ofCD40,CD80,and CD86 are unaffected. Loss of H0-1 function however impeded 
the Th2 response elicited by mDC-CD4+ T cell interaction as characterized by in vitro T -cell and Th2 
cytokine responses and in vivo in an adoptive transfer model of bronchial inflammation elicited 
by OVA-primed H0-1 null DC in OTII transgenic mice. Therefore, these studies suggest that H0-1 
is involved in the genetic regulation of DC-governed Th2 response, and may provide a molecular 
basis for the immune-modulatory effects of H0-1 expression in immune-mediated cardiovascular 
diseases, including transplant atherosclerosis and vulnerable plaque formation. 
79 
so Heme oxygt>n<Jse-1 i1volveme'1t In the dendritic cell ·nduced skewing tow~~d~ Th2 immune respo1sc> 
MATERIALS AND METHODS 
Animals 
HO-1 knockout mice (H0-1-/- I C57b!ack6) were obtained from Arthur M.E. Lee (Harvard Medical 
school, Boston, MA, US) and CS?b!/6 OVA-TCR transgenic mice (0011.10) were cross bred at the 
Erasmus Medical Center. All experiments were performed according to the institutional guidelines 
of the animal ethics committee at the Erasmus MC. 
Generation and antigen pulsing of bone marrow DCs 
DCs were cultured as previously described [16]. Briefly, bone marrow cells were obtained from 
femurs and tibiae of wildtype or H0-1 -/- CS?bl/6 mice, and cultured at a density of 2x1 06 per 10 
em diameter petri dish in 10 ml cell-culture medium {TCM) consisting of RPM! 1640 (Invitrogen, UK) 
supplemented with gentamicin {60]-Jg/ml), 2~mercaptoethanol (5 x 1 o-s moi!L), 5%fetal calf serum 
(Biocell Laboratories, UK) and GM-CSF (200 IU/ml) (kindly provided by Prof. B.Lambrecht). At day 3, 
10 m!TCM was added to the cultures. At days 6 and 8,ha!fofthe medium was collected, centrifuged, 
and the pellet was resuspended in TCM and added back to the cultures. 
At day 9, DCs were pulsed overnight with 100 ]Jg/m! of OVAJLPS (LPS contamination of 2.9 ng/mg 
protein; Worthington) per 1x 106 cells/ml.Theviability of the DCs after treatment with OVAJLPS was 
>99% as assessed by trypan blue exclusion. 
The DC phenotype was validated by staining for 30 minutes at RTwith anti~CD11c~APC,anti~MHCII~ 
FITC, in combination with anti~CD40~PE, anti-CD80-PE, and anti-CD86-PE (BD Biosciences, The 
Netherlands) dissolved in PBS containing 0.5% bovine serum albumin and 0.01% sodium azide.DCs 
were subsequently washed and analyzed by flow cytometry on a FACS canto (BD Bioscience, The 
Netherlands). 
Murine asthma model 
At day O,C57bl/65 mice were anesthetized with avertin (2% v/v in PBS) and received 80 ]JI of the cell 
suspension (1 x 1 06 0VAJLPS pulsed wild type or H0-1 + DCs) via an intratracheal injection through 
the opening of the vocal cords. 
From days 10 to 13,micewere exposed to OVA aerosols (Grade III,Sigma,The Netherlands) delivered 
from a jet nebulizer delivering 1% OVA in PBS for 30 min. Mice were sacrificed 24 hours after the last 
aerosol challenge. Bronchoalveolar lavage (SAL) was performed with 1 ml of Ca2+- and Mg2+-free 
HBSS (Invitrogen) supplemented with 0.1 mmoi/L of sodium ethylenediaminetetraaceticacid. The 
BAL fluid was centrifuged;the cel!s were resuspended in HBSS,and enumerated in a hemocytometer. 
After washing, cells were stained for 30 minutes with anti-t-Ad/t-Ed FITC (macrophages),anti-CCR3 
PE (eosinophils), anti-CD3 cy-chrome, anti-8220 cy-chrome (T and B cells, respectively), and anti-
COl 1 c APC (macrophages) (BD Biosciences,The Netherlands), in PBS containing 0.5% bovine serum 
albumin and 0.01% sodium azide. 
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After SAL was performed, 1 ml of fixative (4% PFA/PBS) was gently infused through the catheter. The 
lungs were dissected and embedded in paraffin. Five-1-1m sections were stained with hematoxylin-
eosin and assessed by brightfield microscopy. 
Cytokine measurement in MLNs in a secondary response 
MLNs were removed, homogenized, and resuspended in RPM I 1640containing 5% fetal calf serum 
before enumeration. Ex vivo production of cytokines by T cells collected from the MLNs was 
measured after restimulation of2 x 106 tota! cel!s/ml with 10 j.Jg/ml of OVA/LPS for 4 days. 
T cell proliferation assay 
For fluorescent cell labeling, T cells were washed twice with serum~free medium, labeled with 5 
1-1M CFSE (Molecular Probes, Oss, The Netherlands) in serum~free medium for 10 min at 37°C. For 
quantification of cell division based on serial halving of CFSE intensity, algorithms provided by 
FlowJo software (Treestar,San Carlos, US) were used as earlier described [17]. 
Real-time quantitative RT -PCR 
H0-1 and Foxp3 expression in cultured mDCs was assessed by quantitative PCR (QPCR). Total RNA 
was isolated using the RNAeasy kit (Qiagen, Germany) and reversed transcribed into eDNA using 
random hexamers. QPCR reactions were performed using cyber green incorporation and real~ time 
detection in the iCycler iQ Detection system (Biorad, The Netherlands). Target gene mRNA levels 
were assessed relative to the household gene hypoxanthine~guanine phosphoribosyltransferase 
(HPRT). 
Elisa analysis 
Cytokines levels (murine IL4,!LS,IL 1 O,IL6,1L 13,1L 12P70,and !FN) were determined using commercial 
quantitative ELISA assays according to the instructions of the manufacturer (Bender Medsystems, 
The Netherlands). 
siRNA transfection of DC 
siRNA transfection with H0-1-/~ targeting siRNA or scrambled sham siRNA was performed using 
Dharmacon smartpool siRNA (a commercial mix of four different sequences per target gene) 
according to the instructions of the manufacturer (Dharmacon, Thermoscientific,The Netherlands). 
siRNA transfection was initiated at day 7 of the DC culture protocol, and efficient knock down of 
H0-1 was validated by qPCR analysis at day 10 (1 day after stimulation with OVNLPS) (Figure 1 a). 
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RESULTS 
H0-1 deficiency partially influences dendritic cell maturation 
Bone marrow (BM) derived mDCs of H0-1 +/+and -1- mice (CS7bl/6 background) were cultured 
according to the lutz-protocol and used in the various assays (figure 1 a).ln addition, knockdown of 
H0-1 mRNA by gene targeting siRNA substantially decreased H0-1 mRNA expression in BM derived 
mDCs compared to non-targeting siRNA (sham) transfected mDCs (figure 1 b). H0-1 deletion or 
knockdown in mDCs did not alter cell surface expression of the mDC maturation markers CD40, 
COSO, and CD86 on the COl 1 c+ mDC population compared to the controls (BM derived mDCs from 
wildtype littermates). However, HO-1 deficiency in mDCs was associated with significantly increase 
in MHC class II surface expression (Figure 2d). 
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Figure 1 H0-1 expression in transgenic and transduced mDCs. 
(A) H0-1 mRNA expression is diminished in mDCs derived from bone morrow of H0-1 ·I· C57bl/6 mice 
compared to wild type and heterozygous !ittermotes. Representative result of 3 independent experiments 
is shown. (8) Tronsfection of vvi!dtype bone morrow derived mDCs with HO-I-targeting siRNA significantly 
decreased H0-1 mRNA expression compared to non-targeting siRNA (si-shom) treated mDCs. N=S, *P<O.OS 
'Nifdtype versus H0-7 -/- mDC as defined by the Student's t-test, mean ± sem. 
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Figure 2 Phenotype ofWT and H0-1 -/-DC. 
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DCs cultured from bone marro·N of wi/dtype and H0-1 -/- CSlb/16 mice were stimulated 'Nith OVNLPS 
for 24 hours. Cell surface expression of DC specific maturation markers were analyzed by flow cyrometr;. 
Representative FACS profiles of 5 independent experiments ore sho.tm, red prof7/e indicates the isotypic-control, 
blue profile indicates the CD40, CDBO, CD86, and MHCI! signal (/eft panel). The percentages ofCD40+, COSO+, 
CD86+, and MHCII+ cells in the COlle+ cell population of each group are shmvn (right panei)(A-0). N=S, 
*P<O.OS wi/dtype versus HO-I -1- mDC as defined by the Student's Hest, mean± sem. 
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H0~1 deletion in dendritic cells impedes Th2~polarization without affecting 
the T cell proliferation capacity 
Next, the effect of HO~ 1 deletion on the capacity of mDCs to activate na"ive CD4+ T cells in an in 
vitro mixed lymphocyte response (MLR) assay was assessed. Murine wild type and HO~l-/- mDCs 
were pulsed for 24h with Ovalbumin (OVA) with trace amounts of LPS.CD4+ T cell priming capacity 
of these OVA pulsed mDCs was tested by co-culture with CFSE labeled OVA specifier cells purified 
from the spleens of OT2 C57b!/6 mice (ratio 1:10, mDCs versus CD4+ T cells respectively). Loss of 
H0-1 in mDCs did not affect CD4+ T cell proliferation in response to mDC priming (figure 3). 
However, H0-1 defidency in mDCs extensively affected the Th1ffh2-cytok'lne profile of the effector 
CD4+ T cells. Cytokine levels were assessed in the supernatant of wild-type and H0-1 mDC MLR 
cultures after 4 days of stimulation. Secretion ofTh2-cytokines IL4, ILS, !L 10, and !L 13 by H0-1 -/-
A 
B 
Figure 3 Tcell response to \NT and H0-7-1- DC. 
H0-1 deficiency in mDCs decreased DC function to induce cytokine secretion by responsive CD4+ T cells 
without effecting DC capacity to induce CD4+ T cell proliferation. (A) CD4+ T cells isolated from the spleen of 
OT2 C57bl/6 mice were labeled with CFSE and co-cultured with OVNLPS pulsed H0-1 -1- mOCs and wildrype 
mDCs (MLR ratio 10:1) for 4 days. Shown are representative FACS profiles of 3 independent experiments. (8) 
ELISA analysis of cytokine production in stimufatedT cells showing the levels /L 4, ILS, IL 7 0, IL 13, and IFN-y in the 
supernatant derived from the MLR co-cultures of OT2 CD4+ T cells with OVNLPS pulsed H0-1 -/- or wi!dtype 
mDCs. N=S, ~P<O.OS wi!dtypeversus H0-1 -1-mDC as defined by the Student's t-test,mean ±sem. 
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mDC primed CD4+ T cells was markedly diminished compared to the CD4+ T cells primed by wild 
type mDCs (figure 3b).ln contrast, the production of the Thl ~cytokine, IFN-y, remained unaffected 
(figure 3b). These in vitro data suggest that H0-1 deficiency in mDCs impedes Th2 polarization of 
naYve CD4+ T cells without affecting T cell proliferation. 
H0~1-/- mDCs are incapable of induction of a Th2 response in a mouse model 
for asthma. 
The inability of H0-1-/- mDCs to induce a Th2 serological response was further assessed in a well 
established Th2 driven murine model of asthma. CS?bl/6 OVA-TCR transgenic mice received OVA 
pulsed mDCs by intratracheal injection and were subsequently challenged with OVA aerosols 
10 day later, for 3 consecutive days. This treatment typically leads to production ofTh2 cytokines 
in the draining mediastinal lymph nodes of the lung and goblet cell hyperplasia, peribronchial 
inflammation, and eosinophilia in the broncho-alveolar lavage (BAL) fluid, all characteristic of 
asthma. Histological analysis revealed that OVA-pulsed wild type mDCs induced the accumulation 
of inflammatory cells, which consisted mainly of granulocytes that were located around the 
brionchioles and lung vasculature (figure 4a). In addition, the number of goblet cells in the airway 
epithelium increased and mucus thickening was observed (B). In contrast, in mice that received OVA 
pulsed H0-1-/- mDCs, peribrionchial and perivascular infiltration was virtually absent, whereas no 
goblet cell hyperplasia or hyperaccumulation of mucus were observed (figure 4a, b). 
Likewise, C57bl/6 mice treated with H0-1 -/- mDCs showed a significant decrease in the total cell 
number in the BAL fluid compared to the wild type mDC treated animals. Eosinophilia was also 
diminished in H0-1 -/- mDC presensitized mice, including a decrease in percentage and absolute 
number of eosinophils in the bronchoalveolar compartment.ln addition, lymphocyte accumulation 
in the BAL fluid was also attenuated (figure 6).Assessment of the Th2 cytokine profile of the T cells 
obtained from the draining mediastinal lymph nodes (MLNs) indicated that the Th2 dominant 
serological response was impeded by H0-1 deletion in mDCs. The in vivo production of Th2 
cytokines IL4, ILS, ll10, and IL13 were all diminished in the H0-1-/- mDCs treated C57bl!6 mice 
compared to the with wildtype mDCs treated animals. In contrast, INF-y levels by MLN derived cells 
were not significantly affected (figure 5). Recent studies have implied that H0-1 suppresses the 
pathophysiology of asthma by inducing high levels of CD4+ CD25+ Treg cells. The mRNA level of 
Foxp3, a specific marker of CD4+ CD2.5+ T reg cells, was therefore assessed in the lungs by QPCR. 
Animals treated with H0-1 -/- mDCs showed reduced pulmonary mRNA levels of Foxp3 compared 
to animals treated with wildtype mDCs (figure 1 ,supplemental data). 
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Figure 4 Murine model of asthma using \IVT and HO~ 1-/- mDC. 
Wi!dtype C57bl/6 mice received intratracheal injections of OVA pulsed wildtype or H0-1 -1- mDCs at day 0, 
fol/ovved by intratracheal challenges with OVA aeroso!es at day 7 0 and 13. Animals vvere sacrificed at day 7 4 
for analysis. Respresentative photomicrogophs of haematoxy!in-eosin stained cross-sections of the lungs of 
wildtype and HO-I-/- mDC treated mice. (A) OVA challenge in wildtype mDC treated mice induced o marked 
peribronchial and perivascular infiltration of inflammatory cells (indicated by black arrows), 'Nhereos HO-I 
mDC presensitized mice failed to induce a marked peribronchial inflammation. (8) hyperplasia of g!oblet 
cells in the ainvay epithelium and mucus accumulation (indicated by black arrows) '!'las clearly present in 
'ltildtype mDC treated mice, but was absent in H0-1 mDC treated animals. (C) FACS analysis of SAL fluids 
showing the total number of cells, the percentage of eosinophils, the numberofeosinophils, and the number 
of macrophages, neurophi!s, and lymphocytes, in SAL fluid of wildtype mDC compared to HO-I -1- mDC 
treated animals. N=70 per group, *P<O.OS wildtype versus H0-1 -1- mDC as defined by the Student's t-test, 
mean :tsem. 
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Figure 5 Cytokine prof7/e of MLN derived T cells obtained from wildtype or H0-1 -1- mDC treated C57bl/6 
mice. Cytokine levels of1L4, ILS, /L IO,IL 13, and !NF-"{ are shown. N=IO per group, ·'P<O.OS wildtype versus H0-1 
-/- mDC as defined by the Student's t-test, mean :.':sem. 
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Figure 6 Supplemented data Figure 7: Foxp3 mRNA expression in the lungs of wild type or H0-7. 
-1- mOC treated C57bl/6 mice. N=IO per group, ''P<O.OS 'Nildtype versus H0-7 -1- mDC as def7ned by the 
Student's t-test,meon ±sem. 
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DISCUSSION 
The current study demonstrated that Joss of H0-1 in mDC resulted in the inability of mDCs to 
elicit a CD4+ predominant T-cell response, and polarization towards a Th2 serological response 
was inhibited, as shown by MLR assays in vitro and in a passive transfer model of bronchial hyper 
reactivity in vivo. 
HO-1 has been identified as a cytoprotective enzyme which function relies on the degradation 
of hemoproteins into its bioactive metabolites carbon monoxide, iron and biliverdin. Studies of 
graft-versus-host disease, and tolerance induction have suggested that H0-1 may impede the T-ce!J 
mediated adaptive immune response [18, 19, 20]. H0-1 deficient mice show a proinflammatory 
phenotype,characterized by splenomegaly, related to an increase in the total numberoflymphocytes 
[21]. Furthermore, H0-1 was induced after activation of CD4+ T -cells by CD3 and CD28 signaling 
[22]. Also, H0-1 upregulation in activated CD4+ effector T-cells protected against Fas-mediated 
apoptosis [22,23], but inhibited cell division by carbon monoxide mediated down regulation of the 
production of the mitogenic cytokine IL2 [24].1n addition, H0-1 has been implicated to play a role 
in the immune suppressive function of CD25+/CD4+ regulatory T-cells (Treg ce!ls). However, the 
exact contribution ofH0-1 in the regulation of DC function and the subsequent differentiation and 
activity ofT lymphocyte subsets is sti!J debated. Systemic H0-1 induction by cobalt protoporphyrin 
(CoPP) suppressed the characteristic features of allergic airway inflammation in a murine model for 
asthma mediated by a Th2-type response, and correlated with an increased numberofCD4+/CD25+ 
Treg cells [25]./n vitro, isolatedTreg cells overexpressing H0-1 displayed increased expression of the 
specific Treg marker, Foxp3, and in addition, enhanced secretion of the Th2 cytokine lL 10 [26]. In 
contrast, in vivo studies in wildtype and H0-1 deficient mice showed similar numbers of CD4+/ 
CD25+ Treg cells with equal capacities to induce effector CD4+ T-cell proliferation in vitro [21]. 
Recently, George and coworkers have shown that Joss of H0-1 in myeloid derived DCs abolished 
the suppressive capacity ofTreg cells on effector CD4+ T cells (27], indicating that H0-1 function 
in antigen presenting dendritic cells may play an important role in the polarization of the general 
T-cell response towardsTh1,Th2 orTreg differentiation. 
Although initial H0-1 levels in immature DCs are high, HO-1 is downregulated during the 
maturation process. CoPP induction of H0-1 in vitro inhibited DC maturation characterized by 
attenuated cell surface expression of the maturation markers MHCJJ,CDSO,and CD86 [28]. However, 
a more recent study suggested that CoPP may induce this refractory effect on DC maturation is 
dependent on STAT3 phosphorylation and independent of HO-1 activity [29].1n this study, mDCs 
derived from the BM of H0-1-/- mice enhanced MHC!l cell surface expression in response to OVN 
LPS stimulation compared to wildtype mDCs, but no significant difference in the expression levels 
of CD40, CD80, or CD86 could be observed. Knockdown of H0-1 by targeting siRNA in mDCs, also 
significantly upregulated MHC!l levels in response to LPS stimulation compared to scrambled 
siRNA transfected control mDCs. Consistent to these findings, recent studies from Soares and 
co-workers have demonstrated a marked decrease in MHC!I expression in mDCs exposed to CO, 
whereas the progression of experimental allergic encephalomyelitis was shown to be attenuated 
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by H0-1 expression and CO inhalation, both associated with dampened expression of MHC class 
II expression in DC. [30,31] Both expression of MHCI! and co-stimulatory molecules, as well as the 
cytokine environment define CD4+ T cell activation and differentiation. Here, we have been able to 
demonstrate that H0-1 deficient DCs had an impaired capacity to induce Th2-polarization in mixed 
lymphocyte reaction (MLR) assays in vitro, indicated by the reduction in the secretion ofll4,1LS,IL 10, 
and IL 13 characteristic for the cytokine profile ofTh2 effector cells. Conversely, !NF-y production by 
effector T cells in response to priming by H0-1 deficient DCs seemed to be unaffected, indicative 
that the capacity to induce Th1 differentiation was sustained. This effect was validated in vivo in 
a well-defined murine model for asthma. Presensitization with HO-1 deficient mDCs dampened 
the Th2-dominant allergic response to the allergen ovalbumin (OVA), with failure to induce the 
histomorphological manifestation and immune activation characteristic to the model. The cytokine 
profile derived from mediastinal lymphnodes derived T-cells of H0-1-deficient mDC-treated 
animals also failed to express the associated cytokines involving IL4, ILS, IL 10, and !L 13 compared 
to wildtype mDC-treated animals. Together, these in vitro and in vivo data suggest that H0-1 in DCs 
is involved in the regulation ofTh2-response, essential to various pathogenesis including asthma, 
transplantation atherosclerosis (chapter 4) and vulnerable plaque development (Chapter 3). 
Previously systemic HO-1 induction by CoPP attenuated the induction ofTh2 driven asthma in this 
murine model, and this was associated with increased levels of CD4+/CD25+ T-reg cells and FoxP3 
[26]. Consistent with these findings, our current study showed that animals treated with H0-1 -/-
mDCs had decreased levels ofFoxP3 in the lungs,suggesting that CD4+/CD25+ T-reg cells presence 
was impeded. 
ln addition,Choi and co-workers demonstrated that Foxp3 is able to induce H0-1 expression whereas 
the expression of Foxp3 and H0-1 in peripheral CD4+CD2S+ Treg and suppress'1ve funct'1on of these 
Treg cells are attenuated by inhibition of H0-1 activity. Therefore, it seems that H0-1 deficiency 
in mDCs does not counteract the Th2 response in the current model of asthma via induction of 
T-reg cell subtype, but rather inhibits the disease process by directly regulating the onset of the Th2 
dominant response. 
In conclusion, this study provides evidence that H0-1 is a crucial factor in mDC priming of priming of 
na'lve CD4+ T cells towards a Th2 response. Dysregulation of the adaptive immune response which 
results in the imbalance of the Th 1 !Th2 response ·Is strongly assodated with a w'1de range ofimmune 
disorders, including allergic asthma and EAE.The regulation of the Th11Th2 cell response by mDCs is 
crucial in this process. The current new observations in our study could aid in the understanding of 
the pathophysiology of these Th2 dominant diseases including allergic asthma. 
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ABSTRACT 
Dysregulated growth and motility of vascular smooth muscle cells (VSMC) contribute to 
neointimal lesion development during the pathogenesis of vascular disease, including 
atherosclerosis and restenosis.lnhibition of this process is associated with reduced neointimal 
thickening in the setting of balloon angioplasty and chronic graft vessel disease. Previous 
studies have shown that overexpression of heme oxygenase-1 {H0-1) inhibits formation of 
neointima after vascular injury, an effect partly explained by inhibition of VSMC proliferation. 
However, the effects of H0-1 on the regulation of directed VSMC migration remain to be further 
elucidated. Directional cell migration requires the assembly of focal adhesions, a process 
which is orchestrated by focal adhesion kinase (FAK). In addition, directional cell migration is 
determined by cell polarity, regulated by both assembly and disassembly of microtubules (MT), 
and reorientation of the Microtubule Organization Centre (MTOC). 
Previously, studies from our group showed that H0-1 overexpression inhibited cell cycle progression 
by p21<1P upregulation. This p21<1P was associated with inhibition ofVSMC migration in a modifled 
Boyden's chamber assay (Duckers, Tashiro, unpublished data). Here we explored the effect of H0-1 
expression on VSMC migration and studied the effect of H0-1 on focal adhesion assembly and cell 
polarization as a possible molecular basis for these effects. 
In the current studies migration of porcine VSMC was significantly impeded by adenoviral H0-1 
overexpression in vitro in a standard scratch assay, in a modified Boyden chamber assay, and a 
barrier migration assay. Inhibition of cyclic GMP or the guanylate cyclase pathway led to the reversal 
of H0-1 induced anti-migratory effects. Overexpression of H0-1 in VSMC resulted in decreased 
FAK protein expression which was associated with increased Erk1 phosphorylation, but not with 
Erk2 phosphorylation. These effects could be reversed upon co-incubation with the H0-1 inhibitor 
ZnPPlX, but not with a NOS inhibitor, suggesting that the observed antimigratory effects were 
independent of nitric oxide synthase signaling.lmmunofluoresence showed increased expression 
of focal contact sites concomitant to FAKdownregulation in cells overexpressing H0-1 ,as compared 
to control VSMC. 24 hour time lapse imaging in a barrier assay showed a reduction of the absolute 
migration distance of H0-1 overexpressing VSMC vs. sham controls (absolute distance; 12.27)Jm ± 
3.22)Jm vs.13.60 )Jm ±3.01)Jm p<O.OS;effective distance;7.5 ±2.9)Jm vs 5.6 )Jm± 2.5)Jm.p=0.11). 
Immunofluorescent staining of both acetylated and -tubu!in showed an increase in stable 
microtubule formation and significant reduction in MTOC orientation and cell polarization in VSMC 
overexpressing H0-1 (38% vs.65% p< 0.05). 
This difference in cell polarity was accompanied by a significant increase in glycogen synthase 
kinase 3 beta (GSK3[3) phosphorylation, which previously was associated w'1th FAK assembly and 
MT-stabilization. 
This study hypothesizes that H0-1 overexpression inhibits directional migration of VSMC by 
interfering with turnover of focal adhesions and MTOC reorientation by modulation of FAK protein 
expression. 
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INTRODUCTION 
In cardiovascular disease, pathological neointima formation which occurs after vascular injury 
requires directional vascular smooth muscle cell (VSMC) migration from the media to the intima[1, 
2]. Dysregulated groVIIth and motility of VSMCs contributes to neointimal lesion development 
during the pathogenesis of vascular obstructive disease, including atherosc!erosis,restenosis, and 
bypass graft stenosis [1,2].1nhibition ofVSMC migration was associated with reduced neointimal 
thickening in animal models of balloon angioplasty and chronic graft vessel disease[3,4].Aithough 
intracellular changes underlying directional cell migration are studied extensively [5~8], the exact 
molecular signaling pathways in VSMC migration still remain to be elucidated. Previous studies 
have shown that directed cellular migration requires co-localization of the golgi apparatus with 
the microtubule organizing center (MTOC) [9}.The exact mechanism and cellular signaling cascade 
ultimately leading to cellular polarization appears to be complex, and multiple signaling cascades 
were proposed to contribute to this process. 
A study from Gomes and co-workers suggested that MTOC reorientation occurred by a major rearward 
movement of the nucleus, while the MTOC remained immobile. Nuclear movement was in this study 
was found to be driven by actin retrograde flow and was myosin !! dependent. Cdc42 was found to 
mediate both this nuclear movement and myosin phosphorylation. Myotonic dystrophy kinase-related 
Cdc42 binding kinase (MRCK) was identified as a downstream Cdc42 effector [10} that stimulates 
myosin phosphorylation and activation of rearward nuclear movement. In addition a previous report 
suggested that FAK phosphorylation may be important in the regulation of the centrosome~associated 
microtubule structure to promote nuclear translocation by prevention of the accumulation of FAK at 
the centrosome [11]. Evidence has been accumulated to show that glycogen synthase kinase 3 (GSK-
3) is involved in the regulation of microtubule turnover and stabilization. Results from recent studies 
suggested that GSK-3beta may function in transporting centrosomal proteins to the MTOC resulting in 
the regulation of a focused/polarized microtubule organization [12, 13]. 
The heme oxygenase system catalyzes heme degradation into its metabolites biliverdin (BV) 
bilirubin (BR), iron and carbon monoxide (CO) [14]. The generated CO is thought to function as a 
second messenger in various signal transduction pathways. CO activates intracellular signaling 
pathways that involve activation of soluble guanylate cyclase and generation of cyclic GMP,as well 
as p38 mitogen~activated protein kinase activation and subsequent downstream phosphorylation 
of several rho GTPases including CDC42 [15]. Previous studies have shown that HO~ 1 inhibitsVSMC 
proliferation by causing a cell cycle arrest at the Gl/S phase [16].Howeverthe effects ofHO~ 1 on the 
regulation of directed VSMC migration are still poorly understood. 
To define the biological function of HO·l in VSMC migration, we assessed the effect of H0-1 
overexpression on directional VSMC migration, mediated by focal adhesion assembly and MTOC 
polarization. The current study suggests that H0-1 inhibits directional migration of VSMC by 
interfering with turnover of focal adhesion complexes through modulation of FAK expression 
and GSK-38 phosphor!ation. Insight in the mechanism that drives VSMC migration in vascular 
proliferative disease including atherosclerosis and restenosis could contribute to the development 
of useful therapeutic remedies. 
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RESULTS 
In order to assess the effects of H0-1 expression on the migration ofVSMC H0-1 overexpression 
was 'mduced by adenoviral transfection in these different '1n vitro migration assays. 
H0-1 inhibited VSMC migration in vitro both in a modified Boyden's Cell chamber assay and in 
a standard scratch assay under PDGF and FCS chemotactic stimulation (Scratch assay figure 1 a, 
b,c,: 10% FCS: control; 3.051-JM +1- 0.20~-JM, ElA; 2.81JM +/- 0.33 IJM, AdH0-1;0.875 1-JM +/-0.02 1-JM 
vs. 20% FCS: control; 3.81JM +/- 0.081-JM, El A; 3.47 IJM +/- 0.1 1 J-IM, AdH0-1; 1 .61JM +/-0.08 fJM vs. 
PDGF10 ng/ml: control; 3.7~M +1- 033~M. E1A; 3.65~M +1- 0.12 ~M. AdH0-1; 0.1.40 ~M +/-0.08 
!JM and modified Boyden chamber assay (figure lg:%change to normal; ElA 100%+/-9.3%,H0-1 
56.9%+/-4.8%). These anti-migratory effects were attenuated by a specific inhibitor of sGC (figlg; 
H0-1/0DQ 61%+/-6.8%) but not by NOS inhibition (figure 1g; H0-1/LNAME43.05% +/- 0.8), which 
indicates that the effect of H0-1 on VSMC migration is med'1ated by sGC activat'1on independent of 
NOS stimulation. 
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Figure 1 In vitro primary VSMC migration assays. 
HO-I inhibited VSMC migration in vitro both in a modified Boyden's Cell chamber assay and in a standard 
scratch ossa under PDGF and FCS chemotactic stimulation (Scratch assay figure /a, b ,c,: 10% FCS: control; 
3.05pM +/- 0.20pM, EIA; 2.8 pM +/- 0.33 pM, AdH0-1;0.875 pM +1-0.02 pM vs. 20% FCS: control; 3.8pM +1-
0.0BpM, El A; 3.47 pM +I- 0.11 pM, AdH0-1; 1.6pM +1-0.08 pM vs. POGFI 0 ng!ml: control; 3.7pM +I- 0.33pM, 
E1A;3.65!-IM +1- 0.12!-IM,AdH0-1; 0.1.40 }JM +1-0.08 }JM and Boyden chamber figure lg:%change to normal; 
E1A 100%+1-9.8%, H0-1 56.9%+1-4.8%).These ami-migratory effects were attenuated by specific inhibitor of 
sGC (lg; H0-1/0DQ 61%+1- 6.8%) but not by NOS inhibition (1g; H0-1/LNAME 43.05% +1- 0.8).24 hour time 
lapse imaging in a barrier migration assay shovved significant reduction in absolute migratory distance in 
VSMC overexpressing HO-I vs. sham controls (figure 1 h,i: Absolute distance; 12.27{Jm ± 3.22}Jm vs./3.60 I-'m 
±3.0/{Jm p<O.OS; Effective distance; 7.5 ±2.9{Jm vs 5.6 j)m±2.5!-'m.p=0.11). 
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Subsequently, we aimed to evaluate the effect of H0-1 expression on VSMC migration using time-
lapse imaging. H0-1 overexpression in VSMC impeded the absolute migration distance (defined -as 
the-absolute, non-lineairdistance in ]..lm that each individual cell migrated from the starting position 
over 4 hours as analyzed by computer assisted cell tracking) compared to sham virus transfected 
cells. No difference was observed in effective migration distance. 
(Defined as the lineair distance between the end and starting point after 4 hours migration analyzed 
with computer-assisted cell tracking) (figure 1 h,i: absolute distance; 12.27]..lm ± 3.22]..lm vs.13.60 J..lm 
±3.01 ]..lm p<0.05;effective distance; 7.5 ±2.9]..lm vs 5.6 ]..lm± 2.5J..lm. P=0.11). 
H0-1 adenovira! overexpression enhanced cGMP levels in VSMC in vitro as compared to control 
VSMC. Co-incubation with a NOS inhibitor L-NAME (1 J..lM lane 3) or cGMP-inhibitor; Rp8Br-GMPs 
(30J..1M lane 5) did not reverse cGMP levels, whereas inhibition of H0-1 (ZNPPIX 20]..lM lane 2) and 
sGC {ODQ,3J..1M; Lane 4) reduced cGMP to controllevels.(figure 2:%change to controllevei:Ad-H01 
228+/-26,+ZnPPIX 1 13+/-S,+L-NAME 293+/-53, ODQ1 1 0+/-6, Rp8Br-GMP 21 8+/-18). 
The decrease in migration in VSMC overexpressing H0-1 was associated with a prominent 
reduction in focal adhesion kinase pp125 (FAKpp125) protein expression (figure 3a.) Loss of FAK 
protein expression closely coincided with H0-1 protein expression in a close time dependent 
manner, suggesting a direct interaction between H0-1 and FAK (figure 3a,b). In addition, H0-1 
overexpression was associated with Erkl MAPKdephosphorylation,whiletotal Erk1 and Erk2 protein 
levels remained unaffected (figure 4b,e).No differences in SRC phosphorylation were observed. 
+ Rp-cGMP 
Figure 2 Steady state cGMP fevefs adenoviraf infected VSMC. 
HO-I adenoviral expression enhanced steady statecGMP levels in 'v'SMC in vitro compared 'Nith control VSMC. 
Inhibition of NOS by L -NANIE (I pM lane 3) or inhibition of cGMP(RPBBr-GMP 30pM lane 5) did not affect 
cG!viP levels, whereas inhibition of HO-I (ZnPPIX 20/)M lane 2) and sGC(ODQ, 3{JM; Lane 4) reduced cGMP 
levels to baseline values (%change to control level: Ad-HOI 228-"-/-26, -+-ZnPPIX 113+1-5, +L -NAME 293+/-53, 
ODQ 11 0+1-6, Rp8Br-GMP 218+1-18) 
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Figure 3 FAK (pp 725) protein expression in H0-7 expressing cells. 
HO- 7 was associated with a decrease in FAKpp 125 expression (figure 3a) Effects of HO- 7 protein expression 
associated with FAK protein expression in a time dependent manner suggesting a direct relation. (figure 3o, b) 
Confocal microscopyofvinculin (F!TC),phalloidin (TR!TC) and the nucleus (DAPI) in (1) control VSMC (2),H01 
transfected VSMC (MOl 1000) and (3) after co-incubation with ZnPPIX 
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Figure 4. Western blot shO'Ning that H0-7 overexpression was associated with Erk1 MAPK 
dephosphorylation, but not Erk2. These effects could be reversed upon co- incubation with the H0-1 inhibitor 
ZNPPIX No differences in SRC or PtP protein expression were observed. 
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H0~1 overexpression in VSMCs increased focal adhesion formation, indicated by confocal 
microscopical imaging of VSMC stained for vinculin and phalloidin which suggests decreased 
turnover of focal contact-sites by down regulated FAK (figure 3c). Cellular polarity of VSMC was 
assessed in the barrier ring assay. Immunofluorescent staining of acetylated and -tubulin showed 
an increase in stable MT formation (preliminary data not shown) and significant reduction in 
MTOC polarization directed towards the barrier area in VSMC overexpressing H0-1, two hours after 
removal of the barrier VSMC (38% vs. 65% p< O.OS).(figure Sa,) This reduction in cell polarity was 
accompanied by significant increase in GSK313 phosphorylation as determined by Western blot 
analysis (ratio GSK313P/total GSK;0.69JOD vs.0.49 IOD; H0-1 vs.sham) as well as with an increase in 
MRCKmRNA expression in H0-1 overexpressingVSMC compared to controls (Figure6supplemental 
data). 
ccn polarJsatjon Barner mlarntl<m .:JSsay Sham vs. 
H0-1 moJ t~OB 
Figure 5 MTOC orientation in H0-1 overexpressing cells. 
Figure Sa: V911C transfected with sham (right pane!) or H0-1 adenovirus (left panel) 24 hours post transfection 
and subsequently after migration for 2 hours in barrier ring setup. Cells were fixed and stained for -tubulin to 
visualize centrosome position.Arrows indicate direction of migration towards the cell free area after the barrier 
has been removed prior to migration. Figure Sb: Analysis of centrosome position from 4separateexperiments 
of each 12 'v'.rel/s indicating significantly more polarized cells in sham transfected group vs. H0-1 rransfected 
pVSMC two hours after migration. 
Figure 6 Effects of H0-1 overexpression on GSK-3 protein phosphorylation. 
HO-I overexpression leads to increased GSK-313 protein phosphorylation as quantified 'l'lith Odyssey/Liquor 
western blot imaging. Ratio GSK3i3Pitota! GSK;0.69 100 vs. 0.49100; H0-1 vs.Shom 
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DISCUSSION 
The heme oxygenase system is responsible for the initial step of heme degradation into its 
metabolites biliverdin, iron and carbon monoxide (CO) [14}.The generated CO, that may function as 
a gaseous signal transduction messenger, has been demonstrated to share many properties with 
NO, including signal transduction via activation of guanylyl cyclase [1 5]. Most of the effects of CO 
signaling are indeed mediated by the stimulation of the CO-sensitive GC (guanylate cyclase) and 
the subsequent increase in cyclic guanosine monophophate (cGMP) formation. 
Previous studies have shown that CO generated by H0-1 activity triggers cytoprotective signaling 
pathways rendering tissue specific anti-proliferative, anti-apoptotic, and anti-migratory effects [18, 
19]. 
Moreover, in previous studies it was found that HQ-1 inhibited VSMC proliferation by upregulation 
of p21 CIP [16] and ·mduced G 1/GO cell cycle arrest in the context of vascular injury[16] concomitant 
to an anti migratory effect. 
However the effects of H0-1 solely on the directed migration ofVSMC remain mainly unclear. 
In the current study, H0-1 inhibited VSMC migration in vitro in different migration assays. These 
effects were diminished by specific inhibition of H0-1 (ZnPP!X) or guanylyl cyclase, but not by NOS 
inhibit"1on, suggesting that these anti migratory effects occurred independently of NO and were 
mediated by a cGMP-dependent pathway. 
Interestingly, these anti-migratory effects of H0-1 overexpression were associated with a decrease 
in focal adhesion kinase pp125 (FAKpp125) protein expression, and activation of the Erk1/MAPK 
pathway and GSK-313 phosphorylation. H0-1 expression on VSMC was in addition associated with 
attenuation of cell polarity and MTOC reorientat"1on as compared to sham transfected controls. 
This cyclical regulation of focal complex formation and disassembly is critical in the control of cell 
movement. Several cytoplasmic protein tyrosine kinases, and phosphatases, including Src,PTP, and 
focal adhesion kinase (FAK),are present in focal complexes [20]. FAK phosphorylates focal adhesion 
components which leads to focal adhesion disassembly and turnover [21]. The heme oxygenase/ 
carbon monoxide pathway may alter FAK expression and phosphorylation by cGMP generation. 
The relationship between cGMP and FAK already has been suggested in previous work. In rat 
pancreatic acini, exogenous NO increased tyrosine phosphorylation of pp125FAK which was 
dependent on cGMP act"1vation [22].Activation of cyclic Guanylyl Kinase1 (cGK I) by increased levels 
of cGMP led to inhibition of HUVEC migration through the modulation offocat adhesion assembly. 
Indeed cGMP-cGK J phosphorylation resulted in Joss of the structural components VASP and zyxin 
from focal adhesions, which led to focal adhesion disassembly [22]. 
Though cGMP induced by CO may modify FAK pp125 phosphorylation, in our studies heme 
oxygenase-1 expression led to downregulation of FAK protein expression rather than 
dephosphorylation. Possibly, supra-physiological H0-1 levels following adenoviral transfection may 
induce a negative feedback loop between the generated CO and cGMP signaling. 
0 
0 
A similar feedback loop was described previously for NO-induced cGMP signaling. For NO-induced 
cGMP signaling not only depends on cGMP formation, but is also critically determined by the 
activity of cGMP degradation enzyme phosphodiesterase 5 (PDES)[23]. Likewise sustained H0-1 
overexpression may induce both significant cGMP production and PDES activation, which may lead 
to desensitization within CO/cGMP signaling and alterations in FAK phosphorylation,as observed 
in our assay. 
In addition a tendency in H01 overexpressing VSMCto loose orientation of MTOC may also account 
for an attenuated directional migration capacity due to Joss of polarization. 
MTOC reorientation occurs by a relative movement of the nucleus away from the leading edge of 
the migrating cell. This complex process of nuclear movement is initiated by myotonic dystrophy 
kinase-related Cdc42 binding kinase (MRCK) regulated actin-myosin retrograde flow that moves the 
nucleus in the direction of the leading edge of the cell and par6-PKCS regulated dynein centration 
which prevents the MTOC from being swept rearward with the nucleus [24]. In a number of cell 
types, microtubules (MT) have been shown to selectively stabilize in the migration direction which 
facilitates polarization of the cell. 
The kinase glycogen synthase kinase-3 (GSK-313) was first described in a glycogen metabolic pathway 
[2S].Evidence accumulated to suggest the involvement of GSK-3!3 in both MTOC orientation, fAK 
signaling and the regulation of microtubule stabilization during directional migration[26-28]. 
These findings challenged us to explore whether the observed alterations in FAK phosphorylation 
and MTOC reorientation after H0-1 overexpression related to GSK-3!3. Previous work indicated a 
mechanism for regulation of FAK activity during cell spreading and migration, modulated through 
the competing actions of GSK3B [29]. Furthermore, reduction of GSK-3!3 by RNAi impaired the 
disassembly of paxillin from focal adhesions [30-31].The phosphorylation of proteins by GSK-3!3 at 
focal adhesions may thus be required to mediate dissembly and assembly. The substrates ofGSK-3B 
that regulate FAK and MT activity remain to be identified further. 
This study demonstrates for the first time that H0-1 in VSMC inhibits directional migration and we 
propose a signaling cascade in which CO interferes with FAKpp125 expression and phosphorylation 
by a cGMP dependent signaling pathway. FAKdownregulation results in diminished focal adhesion 
turnover and increased cellular attachment. 
Moreover,an increase in GSK-3!3 phosphorylation and MRCKexpression following H0-1 upregulation 
may lead to microtubule stabilization, and altered patterns of MTOC orientation. These findings 
provide insight in the biology of H0-1/CO signaling in vascular disease and may provide new 
strategies to prevent the formation of neointima in the context of vascular injury. 
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ABSTRACT 
Hemoproteins are catabolized by the heme oxygenase family (HO) to yield biliverdin, iron and 
carbon monoxide (CO). These metabolites have been recently suggested to function as second 
messengers in multiple signal transduction pathways by modulating redox signaling, heavy-
metal-response driven gene transcription or by generating cGMP. Recent reports have shown that 
H0-1 directly protects endothelial cells from apoptosis, and is involved in blood-vessel relaxation 
regulating vascular tone,and attenuation of the inflammatory response ·In the vessel wall. Recent 
studies have suggested that H0-1 may facilitate neoangiogeneis in HUVEC primary cell culture, 
however, the exact role of H0-1 in angiogenesis and vascu!ogenesis remains to be elucidated. 
Recently we were able to perform a genome-wide microarray analysis to specify the genetic 
regulation of vasculogenesis by angioblasts during murine embryonic development. Among the 
candidate genes that may be involved in embryonic vasculogenesis was heme oxygenase-1.To 
extend our studies to define the biological function of heme oxygenase-1 in adult vessel formation 
and atherosclerotic plaque neovascularization H0-1 transgene expression was studied in in v·rtro 
assay for angiogenic sprouting and in vivo in a murine model for vulnerable atherosclerotic plaque 
formation. 
H0-1 promoted angiogenic sprouting and tube formation of HUVEC in an in vitro matrigel 
assay whereas systemic induction of H0-1 by cobalt-protoporphyrin (CoPPIX) in a murine 
atherosclerosis model promoted neovascularization in atherosclerotic plaques, suggestive of 
plaque destabilization. 
We hypothesize that H0-1 facilitates noninflammatory angiogenesis, as well as in embryonic vessel 
development as well as in vessel formation in atherosclerotic plaques. 
0 
Efftoct of H0-1 toxprtosslon on a'1glogtor.esls and p.aque neovascularlzation 
INTRODUCTION 
Neovascularization is the generation of new blood vessels, either by vasculogenesis (defined as de 
novo vessel synthesis from progenitor cells) or angiogenesis (defined as new vessel formation from 
sprouting of pre-existing vasculature). This process is required for embryonic development and 
plays an important role in the pathogenesis of a variety of adult human diseases[1] including cancer 
and rheumatoid arthritis, and diabetes mellitus[2].ln atherosclerosis, the role of neovascularization 
remains controversial and incompletely understood. Atherosclerosis is regarded as an inflammatory 
disease of the arterial wall in response to intra-vessel lipid deposition. Angiogenesis is a complex 
multi-step process, where, in response to angiogenic stimuli, new vessels are created from the 
existing vasculature. These steps include: degradation of the basement membrane, proliferation 
and migration (sprouting) of endothelial cells {EQ into the extracellular matrix, alignment of EC 
into cords, branching, lumen formation,anastomosis,and formation of a new basement membrane. 
lntra-lesional neovascularization is observed in advanced atherosclerotic lesions exceeding a 
certain thickness in humans and in animal models including the murine ApoE-/- model[3]. 
Growing evidence suggested an association between intra-lesional angiogenesis with 
atherosclerosis progression and plaque destabilization [4,5]. 
In large mammalian arteries, the main function of the microvasculature in the adventitial layer 
(vasa vasorum) is to supply nutrients to the vessel wall. Due to the increase in intimal area during 
atherosclerosis progression, limitations to the diffusion efficiency from both the luminal and 
adventitial side create hypoxic zones in the atherosclerotic lesion. 
A genome-wide microarray analysis for the genetic expression pattern in angioblasts during 
embryonic vessel development previously identified potential genetic regulators ofvasculogenesis. 
The specificvascularexpression and functionality of these genes were validated by gene knockdown 
studies (morpholino injections) and whole mount in situ hybridization in the zebrafishmodel. 
Among the candidate genes identified in this screen was heme oxygenase-1 (H0-1) [6] 
The heme oxygenase family consists of three H0-1 isoenzymes of which H0-1 and H0-2 are 
catalysts of heme protein degradation.The generated metabolites from heme degradation; carbon 
monoxide (CO) iron and biliverdin gained interest over the past years because of their potential 
role in the cellular stress defense, as important antioxidant, anti apoptotic and anti-inflammatory 
mediators. H0-1 in the vascular bed was shown to protect endothelial cells from apoptosis, to 
regulate vasomotor tone [7), and attenuate the local inflammatory response in the vascular wall. 
Preliminary data suggest that H0-1 may facilitate blood vessel formation by angiogenesis [8]. 
The latter function links H0-1 expression inevitably to cardiovascular ischemia but also to many 
other conditions that are dependent on neovascularization, including the vascular repair response, 
embryological development, metastasis and solid tumor formation. 
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H0-1 is indeed induced rapidly during hypoxia, ischemia/reperfusion,hyperthermia and during 
inflammation [9].The importance of this is demonstrated by the severe endothelial damage 
observed in human H0-1 deficiency [1 0] and in gene targeted mice deficient of H0-1 [ll].ln 
addition to its role in vascular cytoprotection during ischemia and inflammation, Preliminary data 
suggest that HQ-1 may play a role in angiogenesis as expression of H0-1 increases endothelial 
VEGF synthesis and endothelial cell proliferation and formation of capillary like structures. 
We aimed at understanding the role of H0-1 in the generation of new blood vessels in a well~ 
de"fined angiogenesis tube formation assay in vitro and in vivo to assess neovascu!arization within 
atherosderotic vu!nerab!e lesions. 
0 
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MATERIALS AND METHODS 
Cell culture and tube formation assay 
HUVEC's (ATCC) were cultured for 24 hours in fresh EGM-2 (Cionetics, Lanza Walkersville, USA) on 
0.1% gelatin coated 10 em Nunc polyethylene cell culture dishes before transfection. 
Ad-H0-1 and control Ad-b-ElA vectors were constructed by homologous recombination in 293 cells 
as earlier described (Duckers et.al. Nature,2001) purified and viral titer was determined by optical 
densimetry. Cells were infected by adenoviral vectors for 2 hours under low serum conditions, 
incubated for another 22 hours after serum suppletion and detached from their matrix with 
Accutase (Ebioscience) and harvested. 
siRNA for HO-1 and sham controls were obtained from Dharmacon RNAi technologies (Lafayette, 
CO, USA) and used according to manufacturers instructions. H0-1 siRNA mix contained: 
sense,S'-UGCUGAGUUCAUGAGGAACUU3'; 
antisense,S'GUUCCUCAUGAACUCAGCAUU-3' 
and sense, S'CAUUGCCAGUGCCACCAAGUU-3'; 
antisense, S'CUUGGUGGCACUGGCAAUGUU-3' 
Corresponding negative control sequences were also purchased from Dharmacon RNAitechnologies 
(Lafayette, CO, USA).HUVECs were plated at4 x 105 cells per well in six-well plates in Endothelial Cell 
Basal Medium (EBM2) (Cambrex BioScience,Wokingham,UK) without antibiotics and were cultured 
to obtain 50% confluency. Test and control siRNA (1 0-50 nM) was transfected into HUVECs using 
lipid-siRNA complex-based transfection. 
ECs were cultured for 4S h in EBM2 and analyzed for target gene expression by quantitative real-
time PCR 
After transfection cells were counted and transferred to the Biocoat Angiogenesis System tube 
formation assay according to manufacturer's instructions in a seeding density 4 x 105 cells/mi. 
Cells in the tube formation assay were closely monitored at different time points and were 
photographed after staining with Calceine Am® to increase tube resolution for imaging with 
fluorescent microscope (Zeiss) 
In vivo vulnerable plaque model: 
All experiments were performed in compliance with institutional (Erasmus University Medical 
Center, Rotterdam, The Netherlands) and national guidelines. 
ApoE-/-mice on a C57BU6J background (age 12-15 weeks) were obtained from Jackson Laboratory 
(Bar Harbor, USA). The protocol for this animal study is described in figure 1. (A) Two weeks before 
surgery, all animals were placed on a Western type diet containing 15% (w/v) caeca butter and 
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0,25% (w/v) cholesterol (diet W, Hope Farms, The Netherlands). (B) Two weeks later, animals were 
anaesthetized by isoflurane inhalation, and the right common carotid artery was dissected from 
circumferential connective tissues. The cast was placed around the right common carotid artery, 
after which the wounds were closed with vicryl sutures and the animals were allowed to recover. 
(C) Six weeks after cast placement, animals were randomized to either treatment with phosphate 
buffered saline (Cambrex, UK) (N=l O) or cobalt protoporhyrin (CoPPIX, Frontier Scientific Inc., 
Canada) treatment (N=l 0) in order to induce endogenous Hmox-1 (ip injection, Smg/kg q2d, in 
0,2M NaOH, ph 7, 4). After 21 days of either PBS or CoPPIX treatment, animals were scariiied and 
carotid arteries were harvested and processed for histological analysis. 
Tissue preparation and histological analysis 
Carotid arteries were embedded in 00 (Sakura Finetek, The Netherlands) and snap~frozen in liquid 
nitrogen. Quantification ofhistological data was performed on 7 J.Jm cryosections,at 140 ].Jm intervals. 
In order to evaluate the effect of HO~ 1 induction on neovascularization driven atherosclerotic 
lesion growth sections were stained with an antibody against PECAM; CD31 +conjugated to Cy~S 
(Biomol) to assess vascular ingrowth in the plaque. The percentage of neovascularisation in the 
atherosclerotic area was calculated as the surface area positive for CD31 expressed as a percentage 
of the total intimal surface area. Statistical analysis was performed using student's T~test. Data are 
presented as mean± SEM. P values less than 0, OS were considered to be significant. 
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RESULTS 
The effect of HO~ 1 adenoviral overexpression on the formation of angiogenic sprouts, the first stage 
in angiogenesis after basement membrane degradation was assessed in vitro in a 2- dimensional 
matrigel. 
7 hours after onset of the tube formation assay HUVEC's over expressing H0-1 initially had formed 
more sprouts compared to HUVEC's transfected with sham vector. However, the shape and thickness 
of the sprouts formed by the HUVEC expressing H0-1 were slightly deteriorated, sprouts were 
thinner and there seem to have formed an increased number of side branches in the assay with 
the H0-1 transfected HUVEC's compared to the sham controls. In contrast sprouts formed by the 
HUVEC's in the sham transfected group tend to have a more dense shape. 
In the left panel of figure 2 (a) four representative examples of each group is depicted at 7 hours 
after onset of incubation. The right panel (2b) shows the network of angiogenic sprouts at 23 
hours after seeding of the HUVEC. The neocapillary network of H0-1 expressing cells contained 
gaps whereas sprouts are thin and irregularly shaped. The sham transfected HUVEC tend to form 
a more dense type of sprouts. In figure 2c the preliminary results from the effect of silencing H0-1 
gene expression with siRNA are shown. Silencing of H0-1 in HUVEC resulted in a decrease in sprout 
formation at 24 hours following initiation of the 20 matrigel culture compared to empty-particle 
siRNA transfected control HUVEC. 
Figure 1 
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Figure 2 Four representative examples of each group is depicted at 7 hours after onset of incubation. The 
righr panel (2b) shows the network of angiogenic sprouts at 23 hours after seeding of the HUVEC frgure 2c 
shows preliminar; results from the effect of silencing H0-1 gene expression with siRNA are. Silencing ofH0-1 
in HUVEC resulted in a decrease in sprout formation at 24 hours following initiation of the 20 matrigel culture 
compared to empry-particle siRNA transfected control HUIEC. 
The brigth 1ield microscopical analysis of H0-1 overexpression or silencing on lumen formation of 
HUVEC are shown in figure 3. 
Eventhough it needs to be addressed that further experiments are necessary to draw valid 
conclusions these preliminary data suggest that loss of HO-1 gene expression in HUVECs did not 
affect lumen formation as compared to untransfected HUVEC. 
Next, we assessed the effects of HO-1 gene expression on HUVEC to migration in vitro in matrigel. 
Figure 4 shows that at 4 hours after the incubation of an in vitro transwell assay overexpression of 
H0-1 significantly inhibits migration of HUVEC compared to sham transfected HUVEC and control. 
Future experiments will have to be carried out in different animal models for angiogenesis to further 
specify the effect of H0-1 in angiogenesis formation in vivo. 
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Figure 3 Analysis of H0-1 overexpression or silencing on lumen formation of HUVEC are shovm.loss of 
HO-I gene expression in HUVECs did not affect lumen formation as compared to untransfected HUVEC. 
(preliminary data). 
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Figure 4 4 hours after the incubation of an in vitro transwel/ assay overexpression of H0-1 significantly 
inhibits migration ofHUVEC compared to sham transfected HUVEC and control. 
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Finally, the effect of HO~ 1 gene expression was assessed on atherosclerotic plaque (de)stabilization 
and intraplaque neovascularisation (Figure S).ln a previous study of human carotid atherectomy 
material, we showed that high protein levels of H0-1 strongly correlated to a vulnerable 
atherosclerotic plaque phenotype. High levels of HO-1 were found in lesions with high content of 
lipids and macrophages,and low abundance of collagen andVSMCs.ln a well defined in vivo model 
for vulnerable plaque development, systemic induction of H0-1 by cobalt-protoporphyrin (CoPPIX) 
significantly promoted neovascular"1zation in the vulnerable plaque although no plaque rupture 
was observed. 
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Figure 5 Systemic induction ofH0-1 by cobalt-protoporphyrin (CoPPix) tend to increase neovascularization 
as indicated by increased CD31 staining (Sa) in the vulnerable plaque. (Preliminary data P=O.IO 
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DISCUSSION 
In this study gain-of-function and loss-of-function modifications ofH0-1 have been used, including 
siRNA-targetting Hmox-1 and recombinant viral vector mediated HO-1 overexpression, to 
develop understanding of the role of H0-1 in angiogenesis in vitro and the effect on intraplaque 
neovascularization in vivo. It should be emphasized that the results presented here are unfortunately 
preliminarly. Additional studies are needed to clarify the molecular basis of H0-1 more detailed in 
promoting neovascularization in atherosclerotic disease in vivo. 
H0-1 was initially identidied as a catabolic enzyme that degrades hemoproteins, but was more 
recently shown to posses cytoprotective properties against oxidative stress, inflammatory damage 
and apoptotosis. The role of H0-1 in angiogenesis appears to be a complex one [12]. Studies 
supporting a role for H0-1 in angiogenesis have shown that several proangiogenic activate H0-1 
expression in endothelial cells in vitro[12]. Furthermore, local H0-1 inhibition with competitive 
inhibitors including ZnPPIX or siRNA blocked tumor angiogenesis in vivo [1 3].Recent in vivo studies 
reported that vascular endothelial growth factor (VEGF) was able to upregulate H0-1 expression 
and activity in vascular endothelial cells whereas inhibition of H0-1 abrogated VEGF-induced 
endothelial activation and neocapillary formation. 
Remarkably H0-1 induction was also associated with VEGF-induced monocyte recruitment and 
inflammatory angiogenesis [14, 15]. Finally H0-1 may also regulate the synthesis and activity 
of VEGF, resulting in a positive-feedback loop[14]. Indeed, H0-1 activity likewise attenuated 
(lipopolysaccharide-driven) inflammatory angiogenesis. 
Our in vitro experiments corroborate in part the results from earlier reports [16-18] suggesting 
that H0-1 promotes angiogenic sprouting and tube formation. However, sprouts formed by H0-1 
expressing HUVEC in our assays deteriorated over time,suggestive of a possible cytopathic effect 
following adenoviral transfection. Alternatively, an imbalance between cell growth and capillary 
network differentiation may underlie these in vitro effects. To further specify these results additional 
experiments are currently being performed. 
Neovascularization assures perfusion of nutrients into the growing lesional area, thereby increasing 
cell proliferation, and accounts for an additional delivery route for lipoproteins and inflammatory 
cells wich promotes lesion growth [6, 19]. 
Recent studies in animal models have indicated that pro-angiogenic factors (including VEGF 
and PDGF) were able to promote angiogenesis in ischemic cardiac tissues and partially recover 
heart function, but concom'1tantly promoted atherosclerosis development. In contrast, treatment 
of atherosclerosis with inhibitors of angiogenesis (angiostatin, VEGF receptor inhibitors) reduced 
plaque growth [20-22].Piaque instabilitydueto intra-lesional neovascularization is more prominent 
in advanced atherosclerotic plaques [23].These so-called vulnerable plaques consist of a large, lipid-
enriched necrotic core, surrounded by activated macrophages, and a thin fibrous cap of vascular 
smooth muscle cells (VSMCs). Due to their morphology, they are more likely to rupture and cause 
117 
118 Ef'cct of H0-1 expression on ~nglosenesls i:lnd p:Jq-Je r.eovJscJIJ,iZJtlon 
acute thrombotic occlusion. In humans, intra-lesional neovascularization is strongly correlated with 
both the incidence and the location of vulnerable plaque rupture[24]. However, the mechanism by 
which intra-plaque angiogenesis could affect plaque stability remains unclear. Based on correlation 
studies, it was postulated that haemorrhages from the frail neovasculature could trap inflammatory 
cells in the lesion, secreting pro-inflammatory factors that amplify the general immune response, 
and contribute to the morphological change of the lesion into a vulnerable plaque [25, 26]. In 
addition, progressive migration of endothelial cells (ECs) and inflammatory cells increase breakdown 
of the extra cellular matrix, thereby weakening the collagen based cap, which renders the lesion 
more likely to rupture [27,28]. Our results in the murine cast model show that systemic induction 
of HQ-1 by cobalt-protoporphyrin (CoPPIX) increased neovascularization in the vulnerable plaque. 
However, this occured simultaneously with a stabilizing effect on lesion morphology (Chapter 3), 
with increased VSMC and collagen content of atherosclerotic plaque. We hypothesize that HO-1 
induction during atherosclerotic lesion formation has multiple roles, primarily an anti-inflammatory 
response inhibiting leukocyte infiltration into the atherosclerotic lesion,as well as a pro-angiogenic 
response, which protects against hypoxia-induced cell death and benefits tissue repair. 
Considering the evidence supporting a role of plaque neovascularization to stimulate atherogenesis 
and plaque vulnerability, it is crucial to achieve a better understanding of the molecular mechanisms 
that drive H0-1 induced proangiogenic effects, before attempting to apply pro-angiogenic factors 
in cardiovascular therapy in general. 
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DISCUSSION AND FUTURE PERSPECTIVES 
Heme oxygenases are enzymes involved in the breakdown ofhemecontaining proteins.Physiological 
heme degradation is catalyzed by the two functional isoenzymes, H0-1 and H0-2, yielding carbon 
monoxide,(CO) iron and biliverdin in this process [l].For many years, these degradation products of 
heme catabolism were considered to be cellular waste products with even toxic implications. 
The free radical scavenging and anti-oxidative properties of bilirubin and the ability of CO as 
an important gaseous second messenger and activator of soluble guanylate cydase (sGQ [2, 3] 
evoked attention to the role of these metabolites as second messengers to mediate cytoprotective 
properties. Today, the anti-inflammatory, antiapoptotic, and anti-oxidant properties of HO and 
its metabolites to maintain vascular homeostasis and cellular protection have been described 
in multiple reports [4-1 1]. However, the exact molecular background of HO-1 signaling remains 
incompletely understood. 
In this thesis, we sought to understand the role of HO-1 gene expression in cardiovascular related 
disease and attempt to elucidate the molecular signaling pathways by which these effects are 
exerted. 
Cardiovascular related diseases are the leading cause of mortality in western Society.Atherosclerotic 
lesion progression into plaque rupture with subsequent acute thrombus formation, and coronary 
artery occlusion is the main mechanism in the pathogenesis of myocardial infarction and sudden 
coronary death [12-14]. 
In chapter 2 and 3 the role of H0-1 gene expression in the development and destabilization of 
atherosclerotic lesions was assessed. In progressive atherosclerotic lesions, endogenous HO-1 
expression is localized in endothelial cells, macrophages and foam cells [15, 16]. In animal models, 
induction of H0-1 has been shown to abrogate the development of atherosclerotic lesions, whereas 
systemic inhibition of HO-1 gene expression by Zinc protoporphyrin !X stimulated atherogenesis 
[16, 17]. Likewise, ApoE/H0-1 double knockout mice subjected to a high cholesterol diet (HCD) 
developed accelerated atherosclerosis as compared to ApoE knockout mice on HCD [18]. One 
explanation for the antiatherogenic property of HO-1 may be that the induction of H0-1 promotes 
heme degradation and subsequent inactivation of heme proteins, including NADPH, a major 
source of reactive oxygen species (ROS) in the vascular cells [19]. Biliverdin and ferritin have been 
shown to posses potent antioxidant activity capable of inhibiting LDL-oxidation and reducing ROS 
underlying atherogenesis [20,21]. 
ln addition, HO-1 may inhibit atherosclerosis by activation of specific immune-modulatory signaling 
pathways. Carbon monoxide, the gaseous metabolite from HO-1 activity has been described earlier 
to induce a cGMP/p38MAPK dependent signalling cascade leading to a general down regulation of 
pro-inflammatory cytokines and release of anti inflammatory cytokines as IL 10 [22]. 
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The potential physiologic effects of H0-1/CO signaling that could contribute to inhibition of 
atherosclerotic lesion progression include further tissue specific ·Inhibition of apoptosis [23-26], 
promotion of cell cycle arrest and inhibition ofVSMC proliferation by induction of p21c1P1[27,28J. 
Taken together, we hypothesized that specific H0-1/CO signaling, while affecting regulation of 
atherosclerotic lesion progression, may play an important role in the deterioration from stable to 
vulnerable lesion types as well. 
In collaboration with a research group from the Gulbenkian Institute in Portugal 
(prof. M. Soares) we assessed the effects of H0-1/CO inhalation on progression of atherosclerotic 
lesions in ApoE-/- mice. In this study described in chapter 2, we observed that CO inhalation starting 
either before or simultaneously with high cholesterol diet (HCD) suppressed the development of 
atherosclerotic lesions in the aorta and in the supra valvular area significantly with 32 -54% as 
compared to control mice. An equipotent inhibition of lesion formation was observed when CO 
inhalation was initiated 4 weeks after onset of HCD.This would suggest that the H0-1/CO mediated 
anti-atherogenic effects could is also effective late during lesion development. These data indicate 
that there may be therapeutical options for the use of CO 'mhalation to arrest the progression of 
atherosclerosis development. 
Inhalation of CO has already been demonstrated to be effective in models of inflammation, 
hypertension, and organ transplantation [29-31}. Because of the potential toxic effects of CO 
inhalation, finding a window of opportunity for safe CO inhalation would be a prerequisite. In a 
recent reportWistar rats were exposed to either CO inhalation at a dose comparable to the dose we 
used in our setups, for 20 h/day or air for 72 weeks [32]. 
It was shown that carboxy-haemoglobin concentration was 14.7+/-0.3% in CO exposed animals 
and 0.3+/-0.1% in control animals. In the lungs, no signs of pathology were observed between the 
groups after these 72 days of exposure. However chronic CO inhalation was also associated with a 
20% weight increase of the right ventricle and a 14% weight increase of the !eft ventricle indicating 
that the effects of long term CO inhalation on the cardiovascular system seem to involve myocardial 
hypertrophy 
Human trials have to place a verdict of whether H0-1/CO signaling can be used as therapeutic 
strategy for atherosclerosis in the future [33]. The pharmacological administration of CO to tissues 
using for instance carbon monoxide releasing molecules (CO-RM) may present an acceptable 
alternative to the inhalation of gas. However safety, tissue site specificity and optimal dosage 
of these compounds for human delivery remain to be further explored [34]. In the future, the 
development of improved versions of CO-RM, as well as the ongoing development of other effective 
methods utilizing the cytoprotective properties of the HO/CO signaling system will inevitably lead 
to discovery of novel therapeutic strateg·Jes. 
In chapter 3 ofthisthesis the role of H0-1 on atherosclerotic plaque destabilization was assessed in 
human carotid endatherectomy specimen as well as in a murine model for vulnerable atherosclerotic 
plaque formation. 
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In human carotid endatherecthomy material H0-1 protein expression was strongly correlated with 
a vulnerable plaque morphology:HO~ 1 protein expression was shown to be specificallyupregulated 
in vulnerable type atherosclerotic lesions with high lipid depositions and macrophage accumulation 
and conversely low collagen and VSMCs content. Furthermore, these lesions expressed high levels 
of pro-atherogenic cytokines including IL-6 and IL-8 as well as proteolytic factors like MMP9 and 
MMP2.The oxidative stress associated with progression of atherosclerosis may involve upregulation 
of H0-1 expression. On the other hand, we hypothesize that endogenous upregulation of H0-1 
expression may function as a compensatory and cytoprotective response resulting in modulation 
of plaque morphology to a stable phenotype. 
To address these questions we used a well validated murine vulnerable plaque model to elucidate 
whether the expression of HO~ 1 in this human vulnerable lesion type was secondarily to adverse 
and progressive plaque development or in contrast, was primarily endogenous mechanism to 
enhance cytoprotection and prevent plaque morphology from deteriorating further. Systemic 
HO-1 expression induced by CoP PIX injection effectively increased HO~ 1 protein expression levels 
5-fold. Histomorphological analysis showed that atherosclerotic lesion progression into vulnerable 
plaques was attenuated, as suggested by a significant reduction of necrotic core formation and 
intraplaque lipid deposition, whereas cap thickness and the amount of intra lesional VSMCs were 
increased. These findings are indicative of stabilization of these rupture~prone lesions by the 
induction of systemic HO~ 1 expression. Based on these results, we postulate that HO~ 1 expression 
not only is involved in the inhibition of atherosclerotic plaque formation (chapter 2) but may also 
stabilize the vulnerable, rupture prone, lesion type. 
The molecular pathways underlying these effects still remain subject of investigation. Recently an 
interesting report byWatari and colleagues [35] postulated that silencing of the transcriptional factor 
Bach1, which normally inhibits H0-1 expression, upregulated H01 in the vasculature coinciding 
with the inhibition of atherogenesis in ApoE knockout mice. These investigators propose that the 
inhibition of Bach1 may provide a promising therapeutic option for local vascular enhancement of 
HO~ 1 activity and site specific inhibition of atherosclerosis. Conditional modulation of Bachl/HO~ 1 
enables the exploration of local and more focussed H0-1 upregulation without administering toxic 
pro-oxidants (such as hemin) or the possible adverse side effects of pharmacological H0-1 inducers 
(like CoPPIX). 
One of the interesting perspectives would be to study the effects ofBach1 deletion in our vulnerable 
plaque model to see whether the effects ofH0-1 expression on plaque destabilization are mediated 
by this transcription factor. 
After allogeneic organ transplantation, three main types of rejection may occur; including a 
hyperacute, an acute and a chronic rejection response. Hyperacute rejection is due to preformed 
lgG antibodies in the recipient that react to HLA antigens in the transplanted organ.Acute rejection 
occurs most frequently in the first 6 months after transplantation and is mainly mediated by 
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T-cells infiltrating into the allograft [34]. Most of the clinical used immunosuppressive drugs are 
active against this acute rejection phase; unfortunately these pharmacotherapy's have sign"1ficant 
deleterious sideeffects.Chronic rejection is the term used when allograftfunction slowly deteriorates 
overtime, and it is characterized by vascular neointimal proliferation and fibrosis. Chronic rejection 
characterized by development of transplant arteriosclerosis and interstitial fibrosis, is a major cause 
of long term organ transplant failure, particularly in heart transplant recipients since conventional 
immune suppressive agents fail to arrest neointima formation. 
Accumulating evidence suggests that in the context of allogeneic organ transplantation H0-1 
triggers cytoprotective responses that may sustain graft survival by reducing (peri-operative) 
oxidative tissue injury. In addition H0-1 was shown to mediate immunogenicity of the graft and to 
promote suppressive immune responses determining graft survival, suggesting that modulation 
H0-1/CO signaling might be a valuable therapeutic option adjacent to allograft transplantation 
[26,34, 37-43]. 
Insight in the exact molecular mechanism and cell and tissue specific effects of H0-1 signaling 
resulting in the allograft protection is eminent to develop novel and site/tissue specific therapies 
against chronic allograft rejection. 
In vivo models, demonstrated that prolonged graft survival in itself is not indicative of tolerance 
induction, as many procedures producing indefinite graft survival do not prevent chronic 
rejection [44].1n addition it was shown that blocking T-cell co-stimulation with CTLA4-Ig or CD40l 
monoclonal antibodies actually induced indefinite allograft survival. Furthermore, induction of 
H0-1 in allograft recipients treated with CD4 monoclonal antibody prevented chronic rejection [45]. 
It was also reported that xenografts were able to survive in the presence of anti-graft antibodies 
and complement, a situation which is referred to as 'accommodation: and that grafts surviving 
long-term in accommodated recipients show vascular expression of HO-1 ,in the context of a Th2 
dominant cytokine profile [46]. 
We gained interest in the effects of H0-1 expression specifically in DC regulated T -cell priming in 
the alia-immune response directed against vascular allografts. (chapter 4) 
In this study H0-1 deletion in DCs was shown to increase STAT1 phosphorylation and subsequent 
CIITA expression, leading to a rise in MHC class !I surface expression in DCs without modulation of 
MHC class 1 expression. These effects are associated with a preferential CD4+ T-ee!! alloimmune 
response in DC/T-cell co-cultures. In vivo ablation of H0-1 in DCs was shown to promote 
transplantation atherosclerosis and increased perivascular infiltration of CD4+ T-cell and lgG 
deposition in the vascular graft, suggestive of a chronic phase ofvasculopathy.These data suggest 
for the first time that H0-1 is an important regulator of dendrif1c cell-induced T-cell priming in the 
a!loimmune response. 
A key challenge in the future would beta translate these discoveries into new therapeutic modalities. 
Several studies attributed beneficial effects ofH0-1 in transplantation and atherosclerosis formation 
to the immune modulatory effects of the H0-1/CO signaling cascade. Even though these effects 
are well described we propose that in addition H0-1 signaling has an important role as a genetic 
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regulator of myeloid DC function and subsequent T-cell priming in the alia-immune response, 
influencing the long-term survival of transplanted grafts. 
Conditional! site-specific H0-1 (over) expression in DC would be an interesting target to further 
explore the effects of H0-1 gene expression in the T-cell mediated alloresponse 
Future research will have to find the answer whether these findings are applicable and beneficial in 
the context of human allogeneic organ transplantation.Previous studies have explored the effect of 
endogenous HO-1 expression in transplant organ recipients on graft survival 
In humans, the promoter region of H0-1 displays length polymorphism due to a variable number 
of GT repeats. Individuals exhibiting 29 or fewer GT repeats express higher levels of HO~I on cellular 
stress compared with individuals with 30 ormoreGT repeats. Previous work demonstrated a relation 
between HO-1 promoter length and graft survival [40,4749]. 
However, in a previous analysis of functional GT repeat polymorphism in the promoter of the HO-1 
gene, no associated with graft survival or the development of transplant atherosclerosis after heart 
transplantation was observed [Balk,Holweg 2004).lt was postulated that even though these results 
may indicate that the protective effects of HO~ 1 expression in cardiovascular allografting obtained 
in animal models are possibly not applicable in humans, investigators postulated that these results 
could in fact be influenced by inequalities in some baseline characteristics including statin use, 
as well as differences in HLA- mismatching between groups. We hypothesize in addition that the 
mechanism by which effects of HO-1 on the alloimmune response are exerted are complex and not 
only determined by promoter length. 
It was previously reported that signal transducer and activator of transcription (STAT) DNA binding 
sites located in the promoter region of HO-1 and activator protein (AP)~ 1 DNA binding sites in the 
distal enhancer element SX2 were necessary for optimal HO~ 1 gene activation after oxidative stress. 
Interestingly, a second 5' distal enhancer element, ABl, located 10 kb upstream from the H0~1 
promoter, was activated after hyperoxia but could not confer maximal hyperoxia-induced HO~ 1 
gene transcription. These results suggest that the 5' distal enhancer elements of the HO~ 1 gene act 
in concert with the promoter to regulate HO-1 gene induction. This is an example that highlights 
the complexity of HQ-1 gene transcription in response to cellular stress. We hypothesize that the 
role of HO~ 1 expression in DC regulated T-cell differentiation resembles this complexity and future 
research exploring HO~ 1 gene induction and function in the context of the alloimmune response 
will be necessary. 
In chapter 5 the effects of HO~ 1 in the regulation of the dendritic cell induced T~cell differentiation 
response was explored in depth. A well described in vivo model of DC sensitization based on 
intratracheal transfer of ovalbumin (OVA)~pulsed DCs [50] was utilized, to investigate the possibility 
that HO-1 expression in dendritic cells may be involved in the regulation and differentiation ofTh2 
helper cells. Previously Heme oxygenase-1 expression has been shown to exert anti-inflammatory 
effects in animal models of asthma [51-54]. These observed effects are suggested to be due to cell 
specific H0-1/CO triggered signaling cascades [55]. 
Jiscusslon and fut~.<re perspectives 
We were able to show that antigen presentation by H0~1 deficient OVA~pulsed DCs to naTve OTII 
specificT-cells abolished the Th2-response as compared to control mice sensitized with OVA-pulsed 
wild type DCs.These findings were characterized by a decrease in the production of the Th2 specific 
cytokines IL4, lLS, ll 10, IL 13, without affecting production of the typical Th1 cytokine lNF- in vitro. 
The obtained results seemed mainly independent of DC maturation, as flow cytometric analysis 
revealed that expression levels of the maturation markers CD40, COSO, and CD86 remained 
unaffected after H0-1 deletion. 
fn vivo, in a murine Th2-dependent asthma model, H0-1 knockout DCs failed to induce the typical 
Th2 mediated bronchoinflammatory response. H0-1 null De treated mice displayed a lack of 
peribronchial and perivascular infiltration of eosinophilic inflammatory cells, absence of goblet cell 
hyperplasia,and a substantial decrease of total cell number and eosinophils in the broncho-alveolar 
lavage fluid (SAL) fluid as compared to controls. These new findings for the first time attribute the 
immune- modulatory effects of H0-1 on inflammatory airway disease to its expression in the 
predominant antigen presenting cell, the DC. 
ln order to extend the molecular basis for these effects of H0-1 knockdown in DC on inflammation 
we focused on the transcription factor forkhead box-P3 expression (FOXP3). This transcription 
factor has been reported earlier to be crucial for CD4+CD25+ Treg cell development and function 
[56].lnduction of CD4+CD25+ Treg cells inhibited the infiltration of eosinophils in the airway[S7]. 
However, in our study the lungs of mice treated with H0-1 knockout DC displayed decreased 
levels of FOXP3 mRNA expression as determined with qPCR analysis. Therefore, it seems that H0-1 
deletion in DC does not counteract the current findings in this murine Th2 model via induction of 
T-regulatoryT cells but ·mterferes directly with Th2-T cell d.1fferentiation. ln the future the effect of 
H0-1 expression on molecular pathways involved in Th1/Th2 differentiation in DC will be further 
explored to depth. Based on current reports, the Notch signaling pathway and particularly delta-like 
4 and jagged-1 expression are interesting targets for future research in this respect (58]. 
In chapter 6 we explored the effects of H0-1 expression on directional migration and polarization 
of vascular smooth muscle cells (VSMQ. 
Directed migration of vascular smooth muscle cells from the media is thought to play a key role in 
the pathogenesis of many vascular diseases including neointima formation after vascular injury [59]. 
This process is regulated by growth factors and chemo attractants and is dependent on multiple 
interactions with the extra cellular matrix. 
One laboratory was already able to show that H0-1 directly inhibits VSMC proliferation (and 
subsequent neointima formation) in the course of vascular injury in a pig balloon injury model. 
These effects of H0-1 on vascular smooth muscle cell growth were shown to be mediated by cell-
cycle arrest involving p21 °P1[27]. 
However, effects of H0-1 on the regulation ofVSMC migration remain unclear but could contribute 
to a more complete understanding of the inhibitory effects of H0-1 on neointma formation [60,61]. 
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GENERAL FUTURE PERSPECTIVES 
Increasing evidence demonstrates that H0-1 expression and the degradation products of heme 
catabolism are crucial in the cytoprotective response againstvarious types of cellularstress and exert 
inhibitory effects against inflammation,apoptosis and cellular proliferation. Consequently, the role 
of the HO system in diabetes, heart disease, hypertension, neurological disorders, transplantation, 
endotoxemia among other pathologies constitute a growing area of scientific research [68].1n this 
regard it is interesting that humans differ in their ability to up regulate H0-1 in response to stressful 
stimuli, attributable to variability in two distinct H0-1 promoter polymorphisms[69]. 
In our study several new beneficial effects of HO-1 expression in cardiovascular related disease 
models have been observed and described. 
These results contribute to our increasing knowledge of the molecular background of the heme 
oxygenase I carbon monoxide signalling system. 
In the near future accumulating insights in these molecular backgrounds of H0-1 signalling, 
associated with results of administration of exogenous CO, biliverdin or bilirubin in in vivo research 
models will be the driving force for the ongoing development of approaches that might hold great 
therapeutic potential in human. 
However, before the effects of H0-1 or its metabolites actually are assessed within clinical trials 
there are also some major concerns to overcome. 
One of the major challengesofthefeasibilityofthe clinical application ofHO-1 will be to identify the 
particular disease states that in particular will benefit from altered H0-1 activity or administration 
of one of its metabolites. Scott and Otterbein recently proposed a general valuable approach for 
the determination of therapeutic applicability of HO-1 in human, depending on the disease and 
abilities to induce tissue specific H0-1 expression [70]. 
It is important to note that all HO-1 metabolites have both a toxic and a therapeutic range. In 
addition most of the pharmacological inducers of H0-1 including hemin and heavy metals, may 
cause concomitantly adverse cellular effects. The key will be to find the right window of opportunity 
of these compounds. 
Another challenging part is formed by the observation that the beneficial effect of H0-1 may 
vary depending on the level and tissue specific site of expression. The use of e.g carbon monoxide 
releasing molecules (CORMs) in this respect is promising since it enables additional routes of CO 
administration compared with gas delivery by inhalation [70]. 
To bypass the need for pharmacologic inducing compounds and their possible adverse side effects, 
a" gene therapy" approach depends on the introduction of the H0-1 gene by viral vector mediated 
overexpression. However, it should be emphasized that expression of H0-1 at supra-physiological 
levels may have counter protective effects, so this approach should be explored extensively 
and would require additional strategies that enable control of the site and level of expression. 
The generation of inducible or tissue-specific vectors in this respect, will provide challenging 
opportunities for therapeutic applicability of H0-1 in the future. 
Taken together, the benefit from therapeutically use of H0-1 will be tremendous, and may hold 
great promise for the future treatment of cardiovascular diseases. 
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SAMENVATIING HOOFDSTUKKEN 
Heme-Oxygenase-1 (H0-1) katalyseert de reactie waarbij eiwitstructuren die een heem 
groep bevatten worden afgebroken,zoals hemoglobine.Tijdens deze reactie worden 
degradatie producten gevormd, te weten; carbon monoxide (CO), ijzer ( Fe2+) en biliverdine 
(dat uiteindelijk wordt geconverteerd in bilirubine). 
Jarenlang was er weinig wetenschappelijke interesse in deze degradatieproducten en 
werden ze beschouwd als potentieel cytotoxisch, totdat onderzoek aantoonde dat ze 
dankzij hun sterkte anti-oxidatieve eigenschappen een belangrijke functie hadden in het 
waarborgen van de cellulaire homeostase en verdediging tegen vrije zuurstof radicalen.Van 
grate waarde was de bevinding dat cabon monoxide niet aileen toxische eigenschappen 
heeft, door een competitieve binding aan te gaan met zuurstof aan hemoglobine, maar in 
lag ere concentratie functioneert als een belangrijke second messenger in verschillende 
intra~cellulaire signaal transductiesystemen. 
Thans zijn er vele publicaties die het belang van H0-1 en de anti-inflammatoire, anti-
apoptotische en anti~oxidatieve eigenschappen van de door HO-1 gegenereerde 
metabolieten onderschrijven. H0-1 kan in dit Iicht worden gezien als een cellu!aire 
chaperonne tegen schadelijke invloeden vanuit het millieu exterieur. De moleculaire 
basis van de door H0-1 gegenereerde cytoprotectieve effecten is echter nog niet volledig 
bekend. Het verkrijgen van inzicht in de functie van H0-1/CO als second messenger in 
celbeschermende signaaltransductie system en kan uiteindelijk lei den tot ontwikkeling van 
nieuwe therapeutische strategieen. 
In dit proefschrift is getracht het belang van H0-1 gen-expressie in verschillende 
cardiovasculair gerelateerde ziekte modellen aan te tonen. Voorts is het moleculaire 
mechanisme van de door H0-1 expressie of deletie gegenereerde effecten geexploreerd. 
Hart- en vaatziekten zijn nog steeds de belangrijkste doodsoorzaak in de westerse were!d. 
Progressie van atherosclerotische laesies in de vaatwand kan in sommige gevallen leiden tot 
ontwikkeling van een instabiele, vulnerabele plaque die makke!ijk kan scheuren. Ruptuur 
van deze plaque leidt tot acute thrombus formatie,coronair occlusie en plotse hartdood. 
In hoofdstuk 2 en 3 van dit proefschrift wordt het effect van H0-1 genexpressie en diens 
metabolieten op de ontwikkeling van vulnerabele atherosderotische plaque beschreven. 
Het is aangetoond met behulp van dierexperimenteel onderzoek dat inductie van H0-1 
genexpressie een inhiberend effect heeft op de vorming van atherosclerotische plaque en 
dat remming vanH0-1 genexpressie, bijvoorbeeld met de farmacologische HO~ 1 inhibitor 
Sa:-:-,env~tting r.oo~c:stul<;ker. 
Zinc Protoporphyrine JX,Iaesie vorming juist stimuleert. Een mogelijke verklaring voor 
het effect van H0-1 genexpressie op de vorming van atherosclerose is de reduct'1e van 
de oxidatieve stress op de vaatwand, onder meer door een verhoogde afbraak van 
nicotinamide adenine dinucleotide phosphate-oxidase (NADPH), een belangrijke bron 
reactieve zuurstofmoleculen in de vaatwand. Biliverdine en ferritine treden voorts opals 
sterke anti-oxidanten en hebben een Jimiterende invloed op de oxidatie van LDL. Naast 
vermindering van de oxidatieve stress op de vaatwand inhibeert H0-1 expressie de vorming 
van atherosclerose door activatie van immuun-modulerende signaaltransductie systemen. 
Uit een aantal studies komt naarvoren dat CO via cGMP/p38MAPKafhankelijke, 
immuunsysteem regulerende signaalcascades, de productie van pro-inflammatoire 
cytokines remt en het vrijkomen van anti-inflammatoire cytokines als IL-l 0 juist stimuleert. 
Daarnaast heeft CO een anti-apoptotische werking en is beschreven dat CO gladde spiercel 
proliferatie remt door inductie van p2lctP1• Op basis van deze bevindingen die eerder werden 
beschreven stelden we de hypothese dat H0-1, en in het bijzonder de H0-1 metaboliet CO, 
niet aileen een rem mend effect heeft op de vorming van de atherosclerotische plaque, maar 
eveneens invloed heeft op de ontwikkel'lng van een stabiele in een vulnerabele plaque. Jn 
samenwerking met prof. M.Soares van het Gulbenkian Institute in Portugal werd het effect 
van CO inhalatie op ontwikkeling van atherosclerotische laesies in ApoE -/- muizen die een 
zgn Western diet kregen gedurende 8 weken onderzocht. Deze studie die wordt beschreven 
in hoofdstuk2 toont dat continue CO inhalatie gestart op verschillende tijdstippen tijdens 
het experiment de vorming van atherosclerotische laesies met 32-54% verminderde 
wanneer werd vergeleken met een controle groep dieren.Opvallend was dat dit effect 
aanwezig was zelfs wanneer CO inhalatie werd gestart 4 weken na aanvang van het Western 
diet. Dit zou betekenen dat CO inhalatie niet aileen het ontstaan van atherosclerose 
inhibeert maar dat het ook effectief is wanneer zich al laesies hebben gevormd. Deze 
bevinding is interessant voor eventuele toekomstige therapeutische mogelijkheden 
in de strijd tegen atherosclerose. Klinische trials zullen in de toekomst een veilige 
concentratie met effectieve werking moeten aantonen. De voortgaande ontwikkeling 
van de CO-releasing molecules kan een van die veilige en effectieve toedieningsvormen 
vertegenwoordigen. 
In hoofdstuk3 wordt het effect van H0-1 op de ontwikkling van vulnerabele plaques 
beschreven. Er werd gebruik gemaakt van de AtheroExpress database in samenwerking 
met de afdeling Experimentele cardiologie van het UMC Utrecht. H0-1 eiwit expressie 
werd bepaald in menselijk atherectomie materiaal. H0-1 eiwitexpressie bleek sterk te 
correleren met het vulnerabele type laesie,dat werd gedefinieerd door een hoog lipide en 
macrofaag gehalte en lage hoeveelheid aan collageen en glad de spiercel. Dit type laesie 
toonde tevens een hoge expressie van interleukine-6 (IL-6) en interleukine-8 (IL-8) en matrix 
metalloproteinase (MMP) 9 en 2, in vergelijking met de stabiele plaque regie's. 
137 
138 
We stellen de hypothese dat de oxidatieve stress die gepaard gaat met de progressie 
van aherosclerose een van de oorzaken is voor de verhoogde H0-1 eiwitexpressie in de 
vulnerabele regionen van de atherosclerotische plaque. Het is hierbij mogelijk dat ertevens 
compensatoire endogene inductie van H0-1 expressie optreed ten einde cytoprotectieve 
effecten en daardoor verdere plaque destabilisatie te voorkomen. 
Om deze stelling te onderzoeken maakten we gebruik van een geed gevalideerd 
muismodel voor de ontwikkeling van vulnerabele atherosclerotische plaque, het cast model. 
Systemische H0-1 inductie werd bereikt door injectie met kobalt protoporphyrine (CoPPIX). 
Histomorfologische analyse toonde aan dater door systemische HO~ 1 inductie significant 
minder vulnerabele plaques werden gevormd. Gebaseerd op deze bevindingen stellen we 
dat H0~1 expressie niet aileen leidt tot een vermindering van het aantal atherosderotische 
plaques maar ook een belangrijke en beschermende rol vervult in het voorkomen van de 
progressie van een stabiele laesie in een vulnerabele plaque. 
Er is toenemend bewijs dat HO-1 expressie erg belangrijk is in het kader van orgaan 
transplantatie. H0-1 inductie leidt tot activatie van cytoprotectieve responsen die de 
overlevingsduur van een allograft kunnen verlengen,enerzijds door reductie van {peri-
operatieve) oxidatieve stress en anderzijds door het onderdrukken van de afstotingsrespons 
. Het is echter nog onbekend welke rol H0-1 expressie speelt in antigen presentatie van de 
dendritische eel binnen het kader van de allograft immuun respons. 
In hoofdstuk 4 worden de effecten van H0-1 genexpressie in een model voor allogene 
vaat-transplantatie beschreven. H0-1 deletie in dendritische eel len resulteerde in een 
toename van STAT1 phosphorylatie en verhoogde expressie van CliTA, met een verhoging 
van de MHC klasse II oppervlakte expressie tot gevolg. Dit effect bleek sa mente gaan met 
een dominante CD4+ T-cel alloimmuun respons in DCff-cel co-culturen.ln een in vivo 
model voor vascu!aire allograft transp!antatie bleek dat H0-1 deletie in DC het ontstaan 
van transplantatie atherosderose bespoedigde, dit bleek uit ondermeertoegenomen neo-
intimavorming, perivasculaire infiltratie van CD4+ T cellen en verhoogde lgG depositie in 
de allografts. Deze data ton en aan dat H0-1 belangrijk is voor de T eel priming in een allo-
immuun respons. 
Uitdaging voor de toekomst is het vertalen van deze bevindingen naar klinisch toepasbare 
strategieen. 
Uit recente pubticaties blijkt dat HO-1 expressie een inhiberend effect heeft op het 
optreden van bronchiale hyperreactiviteit. Hierbij is een voornamelijkTh2-gemedieerde 
immuunrepons belangrijk bij het ontstaan. Het remmende effect van H0-1 op het ontstaan 
van dergelijke hyperreactiviteit lijkt gerelateerd aan door H0-1 geactiveerde celspecifieke 
signaal cascades .Het basaal moleculaire mechanisme hiervan is echter nog onbekend. 
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In hoofdstuk 5 beschrijven we de bevindingen van het onderzoek naar het effect van H0-1 
expressie in dendritische eel len in het kader van Th1/Th2-ce! differentiatie bij bronchiale 
hyperreactiviteit. 
Antigen presentatie door H0-1 knockout DC faalde in het ontlokken van een Th2-T eel 
respons in een gevalideerd muismodel voor het ontstaan van bronchiale hyperreactiviteit. 
Dit kwam onder meer tot uiting in de histologie van de long waarin bij de met H0-1 
knockout DC behandelde muizen geen peribronchiale en perivasculaire infiltratie van 
eosinofielen kon worden aangetoond en goblet eel hyperplasie ontbrak.ln de broncho 
alveolaire lavage (BAL) vloeistof was het aanta! eosinofielen substantieellager dan bij de 
groep met wild type DC behandelde muizen. Een en ander werd verder onderschreven 
door een verlaagde productie van Th2 specifieke cytokines, terwijl de productie van Thl-
gerelateerde cytokines gelijk bleef. Deze resultaten bleken voorts onafhankelijk van de mate 
van maturatie van de DC gezien het feit dat H0-1 deletie geen effect had op de oppervlakte 
expressie van maturatie markers CD40, COSO en CD86. 
Om een mechanisme te vinden voor deze effecten werd onder meer gekeken naar 
de FOXP3 expressie, een marker voorT-regulatoire T cellen (Treg), in de long en van de 
onderzoeksgroepen.Op basis van deze bevindingen is het onwaarschijn!ijk dat H0-1 dele tie 
in DC leidt tot inductie van Treg.ln de toekomst zal worden onderzocht of er na H0-1 deletie 
in de DC veranderingen optreden in de Notch pathway signaal eiwitten delta-like 4 en 
jagged-1, welke wei Iicht verk!arend kunnen zijn voor het ontbreken van de Th2 immuun 
respons na H0-1 deletie in de DC. 
In hoofdstuk 6 wordt het effect van H0-1 expressie op migratie en polarisatie van gladde 
spiercellen onderzocht. We hebben op dit moment aanwijzingen gevonden voor een 
inhiberend effect van H0-1 overexpressie op de migratie van glad de spiercellen. Er wordt 
met behulp van fluorescentie microscopie een effect gezien op de polarisatie en MTOC 
orientatie van de migrerende spiercel, en uit western blot analyse blijkt dat dit effect 
mogelijk samengaat met veranderingen in GSK-3 activiteit. Verder hebben we gevonden 
dat HO-1 overexpressie leidt tot veranderingen van de focal adhesion kinase activiteit. 
In de toekomst za! met behulp van time-lapse microscopie worden onderzocht hoe de 
turnover van focal adhesions door de verandering van focal adhesion kinase activiteit wordt 
be'invloed. 
In hoofdstuk 7 staat de rol van H0-1 in de ontwikkeling van plaque neovascularisatie in 
atherosderose centraal. Uit analyse van '1n vitro matrigel-assay's b!ijkt dat overexpressie 
van H0-1 in HUVEC de nieuwvorming van bloedvaatjes stimuleert in vergelijking 
met overexpressie met een sham virus.lnhibitie van H0-1 genexpressie met siRNA 
had in overeenkomst hiermee een rem mend effect op de bloedvat nieuwvorming. 
Uchtmicroscopie toonde echter aan dat de nieuwgevormde bloedvaatjes na H0-1 
overexpressie een wat afw"ijkende vorm had den. Mogelijk wordt dit veroorzaakt door een 
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cytopatisch effect tengevolge van een hoge dosering virus partikels.Toekomstig onderzoek 
zal moeten aantonen wat d.1t betekent voor de functionaliteit van deze vaatjes. 
In een in vivo muismodel voor de ontwikkeling van vulnerabele plaque werd 
H0-1 systemisch tot overexpressie gebracht door injectie met CoPPIX. 
In de groep dieren waarin HO-1 op deze wijze werd ge·induceerd, bleek de mate van 
vaatnieuwvorming in de plaques toegenomen, hoewel dit niet leidde tot toename van het 
aantal bloedingen in de plaque. Een toename van plaque neovascularisatie is een kenmerk 
van ontwikkeling van vulnerabele laesies. Opmerkelijk hierbij is dat in hoofdstuk 3 al werd 
vermeld dat H0·1 inductie in dit model eveneens tot gevolg had dat gevormde vulnerabele 
laesies stabiliseerden na HO-1 inductie, wat bleek uit toename van het aantal VSMC's en 
toename van de relatieve fibrous cap-dikte. 
Uit onderzoek van anderen kwam al eerder naar voren dat tijdens een toestand van 
chronische ontsteking H0-1 expressie de infiltratie van leukocyten in het weefsel remt en 
weefsel herstel bevordert doorVEGF gedreven non-inflammatoire angiogenese na H0-1 
del etie in de DC te stimuleren. 
Onze hypothese is dat H0-1 overexpressie de intra plaque neovascularisatie bevordert als 
onderdeel van een algemeen cytoprotectieve respons. Toekomstig onderzoek zal moeten 
uitwijzen of dit inderdaad het geval is. 
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Dit proefschrift had natuurlijk nooit geschreven kunnen worden zonder de zeer waardevolle hu!p 
van velen waarvoor ik een ieder dan oak zeer erkentelijk ben. 
Zo wil ik allereerst mijn begeleider en tevens copromoter Eric Duckers bedanken voor de kans die 
ik heb gekregen, en voor de jarenlange begeleiding.lk heb vee! respect voor je visie,je harde werk 
en drive die je aan de dag legt om jouw idea!en te verwezenlijken.lk was je eerste Aio en achteraf 
hadden we sommige dingen misschien anders moeten aanpakken. De voor jou zo kenmerkende 
uitspraken "Ora est" en "Noblesse oblige" dreven mij soms tot wan hoop, maar als je bekijkt dat we 
5 jaar geleden begonnen met z'n vieren met het bestellen van centrifuges en pipetten vanuit een 
catalog us en aileen een lege kale labruimte hadden dan is er vanaf dat punt, tot nu, toch heel vee! 
bereikt.Je hebt nu een vo! en draaiend moleculair lab en 15 Aio's en ana listen, hoe dan ook,je hebt 
het wei waargemaakt. 
Caroline Cheng,zonder jouw hulp was het simpe!weg niet ge!ukt. Ik ben je daar heel erg dankbaar 
voor.Je hebt vee! talent, en niet aileen op het wetenschappelijke gebied.lk vind je een bijzonder 
persoon, en ik zou graag dat eerste boek van je willen lezen. Heel vee! geluk samen met David in 
jullie nieuwe huis. Er ligt een prachtige carriere voor je en ik denk dat we nog vee! van je zullen 
horen. 
Professor Maarten Simoons, uiteraard ook u hartelijk bedankt voor het vertrouwen en voor aile 
begeleiding. Dit is voor mij van groot belang geweest. Er moesten grenzen worden gesteld aan 
het werk waar we mee bezig waren a! was het soms moeilijk om te accepteren dat we niet aile 
puzzelstukjes binnen de gestelde tijd konden vinden. 
Professor Dirk-Jan Duncker, ik wil u bedanken voor de support en de leerzame discussies over in 
het bijzonder het allograft transp!antatie werk. Bedankt dat we gebruik mochten maken van aile 
faciliteiten van het muizenlab,zonder uw steun was het niet mogelijk geweest. 
Professor Miguel P.Soares, obrigado para tudo. Era impossfvel faze-to sem voce. 
Sua ajuda era muito importante. 
Sofia, Isabel e Sylvia, obrigado muito para seu trabalho duro. 
Professor Jon Laman, hartelijk bedankt voor aile leerzame discussies. Dankzij uw steun kwamen we 
steeds weer een stapje verder. Uw input voor het schrijven van het uiteindelijke proefschrift was 
erg belangrijk. 
Professor Gerard Pasterkamp, bedanktvoor de prettige samenwerking. 
Professor Bart Lambrecht ik wil u bedanken voor uw medewerking en wetenschappelijke visie op 
het geheel. Uw ideeen brachten ons steeds weer verder. 
Ham ida, thank you very much for your help with the experiments. All the best for the future and 
good luck in Gent. 
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Timo ten Hagen, hartelijk bedankt voor de wetenschappelijke input en voor het gebruik van aile 
faciliteiten. 
Elza, toen ik aan kwam zetten met een filmpje van 5 minuten van een vasculaire allograft 
transplantatie en vroeg of het mogelijk was om dit ook in Rotterdam te doen zei je meteen dat als 
iemand erg ens op de wereld hetvoorelkaar gekregen had,hetjou ookzou lukken.Erzijn een aantal 
"keesjes" overheen gegaan maar je had ge!ijk en het lukte. Ontzettend bedankt voor je inzet, tijd, 
expertise en geduld.Zonder jou was het een"mission impossible" geweest. 
lneke Hekking, uiteindelijk kwam u op het briljante idee om de tubing onder warm water op te 
rekken zodat het kaliberverschil tussen carotis en aorta overkomen kon worden. Dit bleek een 
gouden zet en tevens de doorbraak in het opzetten van het transplantatiemodel. Bedankt voor a! 
uw steun en vakkennis. 
Esther,je bent een gouden persoon, de spil van het lab, en je hebt me met vee! geduld de basics 
geleerd. Bij jou kon ik altijd wei even terecht voor wat opbeurende woorden of gewoon om even 
mn hartte luchten, als de antilichamen niet werkten, de per misluktwas,of de virussen niet precies 
deden wat ik eigenlijk van plan was. Het was altijd erg gezellig met je en ik wil je heel hartelijk 
bedanken voor je support. 
Desire,jij ook heel hartelijk bedankt voor aile hulp,je geduld en de gezellige etentjes. 
Dennie, een speciaal bedankje voor jou voor al je hulp bij de confocal en voor het invallen op de 
laatste operatiedagen tijdens mijn zwangerschapsverlof. 
lk hoop datje vlugje eigen dankwoord mag gaan schrijven. 
Heel erg vee! succes. 
Aile Aio's van het moleculaire lab, en Aio's van de afdeling Experimentele Cardiologie, heel vee! 
sterkte metjul!ie promoties, ik hoop datjullie nog vee! mooie resultaten behalen in de toekomst. 
Monique, bedankt dat er altijd iets te regelen vie! als een bestelling te laat kwam of niet was 
geleverd. 
Hendrik-Jan, het is allemaal wat anders gelopen dan het eerste plan was.Jk wens je vee! succes met 
wat je in de toekomst gaat doen. Die eerste prijs bij de NWC en het Th2 artikel zijn eigenlijk ook 
vanjou. 
Joost Rens, bedankt voor al jouw waardevolle hulp met de migratie experimenten. 
Mirjam,Thomas,Monique en Menno,bedanktvoor aile hulp die ikvanjullie kreeg bij de dendritische 
eel experimenten. 
Lieve lnge, we zijn al30 jaar vriendinnen, en ik hoop dat weer zeker nog 30 jaar bij mogen doen.lk 
vind het helemaal geweldig datje in januari je dochtertje Donna eindelijk in je armen kon sluiten. 
Wat een prachtige wending van het leven.lk hou van je en wens jullie aile geluk van de wereld met 
zn drietjes. 
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lieve Maryse, ookjij bent al bijna 30 jaar een vriendin. 
Het began teen wezes waren en ik herinner meschoenendozen val brieven,dagenlang rollerskaten, 
sa men op ponykamp. Teen wilde ik al dokter worden en dacht ik dat ik met artisjokken (want dat 
klonkwel heel erg als een medicijn) je hooikoorts klachten ken genezen.We waren val verwachting 
over wat de toekomst zou brengen. 
Teen die toekomst eenmaal daar was deelden we lief en leed over de perikelen in De Liefde en 
Het Leven. Er is niemand met wie ik daar over kan praten zeals met jou,je humor is messcherp en 
laat me altijd weer lachen. Je hebt een moeilijke tijd achter de rug en hebt je ongelooflijk sterk 
gehouden, iets waar ik veel bewondering voor heb.lk en er erg trots op datje me vandaag terzijde 
staat en mijn paranimfwilt zijn. 
Brigitte,m'n andere paranimf,dat geldt allemaal oak voor jou. Van Maastricht tot Groningen,je hebt 
ongelooflijk vee! doorzettingsvermogen en een hele positieve kijk op het Ieven. !k hoop datje inje 
huidige specialisatie heel ge!ukkig wordt. Dater nag maar veel gedanst mag worden! 
Marieke en Sjeng, hier is dan voor mij de gelegenheid om jullie te bedanken voor a lies wat ju!lie 
voor mij hebben gedaan. Jullie warmte was voor mij in die tijd erg belangrijk en ik zal dat nooit 
vergeten. 
E!!eke, veel succes met je opleiding tot radioloog, ik hoop dat ik je nog vaak zal zien.Veel geluk 
sa men met Bas. 
Gerard,je bent een heellieve cpa voorThijmen, bedankt ook voor de belangrijke steun afgelopen 
jaar teen hij in het ziekenhuis lag. Dater nog maar vee! succesvolle vierdaagsen mogen volgen! 
Lieve Elise, Ueve Arjan, mijn zus en mijn broer, ik hou heel veel van jullie en ben erg blij datjullie er 
vandaag bij zijn.lk ben erg trots op jullie. 
Mama, het ·,s n'1et altijd allemaal even gemakkel'ljk geweest maar we z'1jn ertoch gekomen. Bedankt 
voor a lies watje me gegeven hebt en altijd voor ens hebt gedaan. 
Papa,je bent al enige tijd erg ver weg maar je blijft m'n vader.lk hoop dater een tijd komt dater 
ondanks het verdriet uit het verfeden ruimte ontstaatvoor een toekomst. 
Dan<woord 
Lieve GeerHan,deze laatste regels zijn natuurlijk voor jou. 
Wat ben ik blij dat ik die ene oktobernacht toch nog even ben meegegaan naar het "Feest van 
Sinterklaas': 
"Gewoon, gezellig" ... en voor ik het wist zat ik bij je achter op de motor en reden we in voile vaart 
langs de (lerse) kust de toekomst tegemoet. Jk ben heel erg blij metjou. We hebben al veel mooie 
momenten beleefd samen, metals hoogtepunt de geboorte van onze prachtige zoon Thijmen. 
Jouw warmte, kracht en optimisme maken mij heel erg gelukkig. Bedankt voor al jouw steun. 
lkhebje lief 
Annemarie 
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